{"clause_number": "Clause 1", "title": "Introductory", "text": "Introductory. Corvus Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"), to issue and sell to the several Underwriters shares (\"Firm Securities\") of its common stock, par value $0.0001 per share (\"Securities\") and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/corvus-pharmaceuticals-inc-5070/contract/369433/#clause-id-798145", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Corvus Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"), to issue and sell to the several Underwriters shares (\"Firm Securities\") of its common stock, par value $0.0001 per share (\"Securities\") and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/corvus-pharmaceuticals-inc-5070/contract/369433/#clause-id-798145"}, {"variation_number": "Variation 2", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Parsley Energy,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\")</ins> agrees with <ins>Morgan Stanley & Co. LLC (the \"Representative\"), as representative of</ins> the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(the \"Underwriters\"),</ins> to issue and sell to the <del>several</del> Underwriters <ins>18,250,000</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of <del>its</del>  <ins>the Company's Class A</ins> common stock, par value <del>$0.0001</del>  <ins>$0.01</ins> per share <del>(\"Securities\") and</del>  <ins>(the \"Securities\") on the terms set forth in this agreement (this \"Agreement\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to <del>issue and</del> sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>2,737,500</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <ins>(the \"Optional Securities\")</ins> as set forth <ins>in Section 3</ins> below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <ins>Certain terms used in this Agreement are defined in Section 2(i) hereof.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/parsley-energy-inc-4677/contract/368039/#clause-id-795228"}, {"variation_number": "Variation 3", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Parsley Energy,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\")</ins> agrees with <ins>J.P. Morgan Securities LLC (the \"Representative\"), as representative of</ins> the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(the \"Underwriters\"),</ins> to issue and sell to the <del>several</del> Underwriters <ins>7,250,000</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of <del>its</del>  <ins>the Company's Class A</ins> common stock, par value <del>$0.0001</del>  <ins>$0.01</ins> per share <del>(\"Securities\") and</del>  <ins>(the \"Securities\"), on the terms set forth in this agreement (this \"Agreement\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to <del>issue and</del> sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>1,087,500</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <ins>(the \"Optional Securities\")</ins> as set forth <ins>in Section 3</ins> below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <ins>Certain terms used in this Agreement are defined in Section 2(i) hereof.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/parsley-energy-inc-4677/contract/360258/#clause-id-782654"}, {"variation_number": "Variation 4", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Parsley Energy,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\")</ins> agrees with <ins>Credit Suisse Securities (USA) LLC (the \"Representative\"), as representative of</ins> the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(the \"Underwriters\"),</ins> to issue and sell to the <del>several</del> Underwriters <ins>8,250,000</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of<del>its</del>  <ins>the Company's Class A</ins> common stock, par value <del>$0.0001</del>  <ins>$0.01</ins> per share <del>(\"Securities\") and</del>  <ins>(the \"Securities\") on the terms set forth in this agreement (this \"Agreement\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to <del>issue and</del> sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>1,237,500</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <ins>(the \"Optional Securities\")</ins> as set forth <ins>in Section 3</ins> below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <ins>Certain terms used in this Agreement are defined in Section 2(i) hereof.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/parsley-energy-inc-4677/contract/368058/#clause-id-795314"}, {"variation_number": "Variation 5", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Parsley Energy,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\")</ins> agrees with <ins>Credit Suisse Securities (USA) LLC (the \"Representative\"), as representative of</ins> the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(the \"Underwriters\"),</ins> to issue and sell to the <del>several</del> Underwriters <ins>36,000,000</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of <del>its</del>  <ins>the Company's Class A</ins> common stock, par value <del>$0.0001</del>  <ins>$0.01</ins> per share <del>(\"Securities\") and</del>  <ins>(the \"Securities\"), on the terms set forth in this agreement (this \"Agreement\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to <del>issue and</del> sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>5,400,000</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <ins>(the \"Optional Securities\")</ins> as set forth <ins>in Section 3</ins> below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <ins>Certain terms used in this Agreement are defined in Section 2(i) hereof.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/parsley-energy-inc-4677/contract/328284/#clause-id-708425"}, {"variation_number": "Variation 6", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>The RealReal,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(\"Company\")</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>[ ]</ins> shares <del>(\"Firm Securities\")</del> of its common <del>stock, par value $0.0001 per share (\"Securities\") and</del>  <ins>stock (the \"Firm Securities\"). The Company</ins>also <del>proposes</del>  <ins>agrees</ins> to <del>issue and</del> sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>[ ]</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <ins>(such additional shares of securities to be sold by the Company, \"Optional Securities\"),</ins> as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/therealreal-inc-8293/contract/62950/#clause-id-112438"}, {"variation_number": "Variation 7", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Endocyte,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\"),</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(the \"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>4,500,000</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.001</ins> per share <del>(\"Securities\")</del>  <ins>(the \"Securities\" ),</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>675,000</ins> additional shares <del>(\"Optional</del>  <ins>(the \"Optional</ins> Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/endocyte-inc-16054/contract/404276/#clause-id-864692"}, {"variation_number": "Variation 8", "text": "Introductory. <del>Corvus Pharmaceuticals, Inc.,</del>  <ins>Synergy Resources Corporation,</ins> a <del>Delaware</del>  <ins>Colorado</ins> corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>19,500,000</ins> shares (\"Firm Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.001</ins> per share <del>(\"Securities\")</del>  <ins>(\"Securities\"),</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>2,925,000</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/src-energy-inc-1221/contract/351347/#clause-id-763601"}, {"variation_number": "Variation 9", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Entasis Therapeutics Holdings</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\"),</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom Credit Suisse Securities (USA) LLC and <del>Cowen and Company, LLC</del>  <ins>BMO Capital Markets Corp.</ins> are acting as representatives <del>(\"Representatives\"),</del>  <ins>(the \"Representatives\"),</ins> to issue and sell to the several Underwriters <ins>[ ]</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.001</ins> per share <del>(\"Securities\") and</del>  <ins>(the \"Securities\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>[ ]</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <del>as set forth below.</del>  <ins>(the \"Optional Securities\").</ins> The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/entasis-therapeutics-holdings-inc-6071/contract/292373/#clause-id-618349"}, {"variation_number": "Variation 10", "text": "Introductory. <del>Corvus Pharmaceuticals, Inc.,</del>  <ins>Synergy Resources Corporation,</ins> a <del>Delaware</del>  <ins>Colorado</ins> corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>45,000,000</ins> shares (\"Firm Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.001</ins> per share <del>(\"Securities\")</del>  <ins>(\"Securities\"),</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>6,750,000</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/src-energy-inc-1221/contract/351358/#clause-id-763622"}, {"variation_number": "Variation 11", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>XenoPort,</ins> Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>12,000,000</ins> shares (\"Firm Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.001</ins> per share <del>(\"Securities\")</del>  <ins>(\"Common Stock\"),</ins> and also proposes to issue andsell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>1,800,000</ins> additional shares (\"Optional Securities\") of its <del>Securities</del>  <ins>Common Stock</ins> as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/xenoport-inc-19558/contract/403441/#clause-id-862023"}, {"variation_number": "Variation 12", "text": "Introductory. Corvus Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"), to issue and sell to the several Underwriters shares (\"Firm Securities\") of its common stock, par value $0.0001 per share (\"Securities\") and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/corvus-pharmaceuticals-inc-5070/contract/369433/#clause-id-798145"}, {"variation_number": "Variation 13", "text": "Introductory. <del>Corvus Pharmaceuticals, Inc., a Delaware</del>  <ins>Energen Corporation, an Alabama</ins> corporation (\"Company\"), agrees with the several Underwriters named in Schedule <del>A</del>  <ins>B</ins> hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(the \"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>15,800,000</ins> shares (\"Firm Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.01</ins> per share <del>(\"Securities\")</del>  <ins>(\"Securities\"),</ins> and also proposes to issue and sell to the <ins>several</ins> Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>2,370,000</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <ins>To the extent there are no additional Underwriters named in Schedule B other than you, the terms \"Representative\" and \"Underwriters\" as used herein shall mean Credit Suisse Securities (USA) LLC, as the sole Underwriter.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/energen-465/contract/375105/#clause-id-807293"}, {"variation_number": "Variation 14", "text": "Introductory. <del>Corvus Pharmaceuticals, Inc.,</del>  <ins>Synergy Resources Corporation,</ins> a <del>Delaware</del>  <ins>Colorado</ins> corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>14,000,000</ins> shares (\"Firm Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.001</ins> per share <del>(\"Securities\")</del>  <ins>(\"Securities\"),</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>2,100,000</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/src-energy-inc-1221/contract/350656/#clause-id-761980"}, {"variation_number": "Variation 15", "text": "Introductory. <del>Corvus Pharmaceuticals, Inc.,</del>  <ins>Performance Health Holdings Corp.,</ins> a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(\"Underwriters\")</ins> for whom Credit Suisse Securities (USA) LLC <ins>(\"Credit Suisse\")</ins> and <del>Cowen and Company,</del>  <ins>Jefferies</ins> LLC <ins>(\"Jefferies\")</ins> are acting as representatives <del>(\"Representatives\"),</del>  <ins>(in such capacity, the \"Representatives\")</ins> to issue and sell to the several Underwriters <ins>[\u00b7]</ins> shares (\"Firm Securities\") of its common stock, par value $0.0001 per share (\"Securities\") and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>[\u00b7]</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/performance-health-holdings-corp-21717/contract/369813/#clause-id-798717"}, {"variation_number": "Variation 16", "text": "Introductory. <del>Corvus</del>  <ins>Adamas</ins> Pharmaceuticals, Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\"),</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom Credit Suisse Securities (USA) LLC and <del>Cowen and Company, LLC</del>  <ins>Piper Jaffray & Co.</ins> are acting as representatives <del>(\"Representatives\"),</del>  <ins>(the \"Representatives\"),</ins> to issue and sell to the several Underwriters <ins>[\u00b7]</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of its common stock, <ins>$0.001</ins> par value <del>$0.0001</del> per share <del>(\"Securities\")</del>  <ins>(the \"Securities\")</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>[\u00b7]</ins> additional shares <del>(\"Optional</del>  <ins>(the \"Optional</ins> Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/adamas-pharmaceuticals-inc-2832/contract/406645/#clause-id-870756"}, {"variation_number": "Variation 17", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Upland Software,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\")</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom Credit Suisse Securities (USA) LLC and <del>Cowen and Company,</del>  <ins>Jefferies</ins> LLC are acting as representatives <del>(\"Representatives\"),</del>  <ins>(in such capacity, the \"Representatives\")</ins> to issue and sell to the several Underwriters <ins>3,300,000</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of its common stock, par value $0.0001 per share <del>(\"Securities\") and</del>  <ins>(the \"Securities\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to <del>issue and</del> sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>495,000</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <del>as set forth below.</del>  <ins>(\"Optional Securities\").</ins> The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/upland-software-inc-3936/contract/62079/#clause-id-109861"}, {"variation_number": "Variation 18", "text": "Introductory. <del>Corvus Pharmaceuticals, Inc.,</del>  <ins>AK Steel Holding Corporation,</ins> a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>65,000,000</ins> shares (\"Firm Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.01</ins> per share <del>(\"Securities\")</del>  <ins>(\"Securities\"),</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>9,750,000</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ak-steel-holding-corp-41/contract/386230/#clause-id-822413"}, {"variation_number": "Variation 19", "text": "Introductory. <del>Corvus Pharmaceuticals, Inc.,</del>  <ins>AK Steel Holding Corporation,</ins> a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>52,000,000</ins> shares (\"Firm Securities\") of its common stock, par value <del>$0.0001</del>  <ins>$0.01</ins> per share <del>(\"Securities\")</del>  <ins>(\"Securities\"),</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>7,800,000</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ak-steel-holding-corp-41/contract/390534/#clause-id-829730"}, {"variation_number": "Variation 20", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>MyoKardia,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\"),</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives <del>(\"Representatives\"),</del>  <ins>(the \"Representatives\"),</ins> to issue and sell to the several Underwriters <ins>[ l ]</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of its common stock, <ins>$0.0001</ins> par value <del>$0.0001</del> per share <del>(\"Securi</del><ins>(the \"Securities\")</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>[ l ]</ins> additional shares <del>(\"Optional</del>  <ins>(the \"Optional</ins> Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/myokardia-inc-4266/contract/356018/#clause-id-775516"}, {"variation_number": "Variation 21", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Upland Software,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\")</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom Credit Suisse Securities (USA) LLC <del>and Cowen and Company, LLC</del> are acting as <del>representatives (\"Representatives\"),</del>  <ins>representative (in such capacity, the \"Representative\")</ins> to issue and sell to the several Underwriters <ins>3,500,000</ins> shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of its common stock, parvalue $0.0001 per share <del>(\"Securities\") and</del>  <ins>(the \"Securities\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to <del>issue and</del> sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>525,000</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <del>as set forth below.</del>  <ins>(\"Optional Securities\").</ins> The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/upland-software-inc-3936/contract/125271/#clause-id-235274"}, {"variation_number": "Variation 22", "text": "Introductory. <del>Corvus</del>  <ins>Satsuma</ins> Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"),</del>  <ins>(\"Underwriters\")</ins> to issue and sell to the several Underwriters <ins>[\u2022]</ins> shares (\"Firm Securities\") of its common stock, par value $0.0001 per share <del>(\"Securities\") and</del>  <ins>(\"Securities\"). The Company</ins> also <del>proposes</del>  <ins>agrees</ins> to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>[\u2022]</ins> additional shares <del>(\"Optional Securities\")</del> of its Securities <ins>(\"Optional Securities\")</ins> as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/satsuma-pharmaceuticals-inc-9027/contract/74584/#clause-id-139603"}, {"variation_number": "Variation 23", "text": "Introductory. Corvus Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives (\"Representatives\"), to issue and sell to the several Underwriters shares (\"Firm Securities\") of its common stock, par value $0.0001 per share (\"Securities\") and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/corvus-pharmaceuticals-inc-5070/contract/369433/#clause-id-798145"}, {"variation_number": "Variation 24", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Cloud Peak Energy</ins> Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC <del>and Cowen and Company, LLC are</del>  <ins>is</ins> acting as <del>representatives (\"Representatives\"),</del>  <ins>representative (the \"Representative\")</ins> to issue and sell to the several Underwriters <ins>13,500,000</ins> shares (\"Firm Securities\") of its common stock, <ins>$0.01</ins> par value <del>$0.0001</del> per share <del>(\"Securities\")</del>  <ins>(\"Securities\"),</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>2,000,000</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cloud-peak-energy-inc-303/contract/325902/#clause-id-703122"}, {"variation_number": "Variation 25", "text": "Introductory. Corvus Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom Credit Suisse Securities (USA) LLC and <del>Cowen and Company,</del>  <ins>Jefferies</ins> LLC are acting as representatives (\"Representatives\"), to issue and sell to the several Underwriters <ins>7,058,824</ins> shares (\"Firm Securities\") of its common stock, par value $0.0001 per share (\"Securities\") and also proposes to issue and sell to the Underwriters, at the option ofthe Underwriters, an aggregate of not more than <ins>1,058,823</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/corvus-pharmaceuticals-inc-5070/contract/314631/#clause-id-677510"}, {"variation_number": "Variation 26", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Ellington Financial</ins> Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(\"Underwriters\")</ins> for whom Credit Suisse Securities (USA) LLC and <del>Cowen and Company,</del>  <ins>UBS Securities</ins> LLC are acting as representatives <del>(\"Representatives\"),</del>  <ins>(the \"Representatives\")</ins> to issue and sell to the several Underwriters <del>shares</del>  <ins>3,500,000</ins> (\"Firm Securities\") of its common stock, <ins>$0.001</ins> par value <del>$0.0001 per share (\"Securities\")</del><ins>(\"Securities\"),</ins> and also <del>proposes</del>  <ins>agrees</ins> to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>525,000</ins> additional <del>shares</del>  <ins>Securities</ins> (\"Optional <del>Securities\") of its Securities</del>  <ins>Securities\"),</ins> as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ellington-financial-inc-3328/contract/71600/#clause-id-132462"}, {"variation_number": "Variation 27", "text": "Introductory. <del>Corvus Pharmaceuticals,</del>  <ins>Achaogen,</ins> Inc., a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\"),</ins> agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as representatives <del>(\"Representatives\"),</del>  <ins>(the \"Representatives\"),</ins> to issue and sell to the several Underwriters shares <del>(\"Firm</del>  <ins>(the \"Firm</ins> Securities\") of its common stock, <ins>$0.001</ins> par value <del>$0.0001</del> per share <del>(\"Securities\")</del>  <ins>( the \"Securities\")</ins> and also proposes to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than additional shares <del>(\"Optional</del>  <ins>(the \"Optional</ins> Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/achaogen-inc-2688/contract/405614/#clause-id-868215"}]}
{"clause_number": "Clause 2", "title": "Introductory", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of $220,000,000 aggregate principal amount of 0.64000% Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), $210,000,000 aggregate principal amount of 1.06% Asset Backed Notes, Class A-2a (the \"Class A-2a Notes\"), $175,000,000 aggregate principal amount of LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34% Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and $90,000,000 aggregate principal amount of 1.59% Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables 2016-A Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of at least $41,666,666.68. The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of February 10, 2016 (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of February 10, 2016 (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in (Nissan 2016-A Underwriting Agreement) such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/338650/#clause-id-732907", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of $220,000,000 aggregate principal amount of 0.64000% Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), $210,000,000 aggregate principal amount of 1.06% Asset Backed Notes, Class A-2a (the \"Class A-2a Notes\"), $175,000,000 aggregate principal amount of LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34% Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and $90,000,000 aggregate principal amount of 1.59% Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables 2016-A Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of at least $41,666,666.68. The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of February 10, 2016 (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of February 10, 2016 (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in (Nissan 2016-A Underwriting Agreement) such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/338650/#clause-id-732907"}, {"variation_number": "Variation 2", "text": "Introductory. Nissan Motor Acceptance <del>Corporation,</del>  <ins>Company LLC,</ins> a <del>California corporation</del>  <ins>Delaware limited liability company</ins> (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables <del>Corporation II,</del>  <ins>Company II LLC,</ins> a Delaware <del>corporation</del>  <ins>limited liability company</ins> (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>Wells Fargo Securities, LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$220,000,000</del>  <ins>$270,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>3.688%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$443,300,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>4.50%</ins> Asset Backed Notes, Class <del>A-2a</del>  <ins>A-2</ins> (the \"Class <del>A-2a</del>  <ins>A-2</ins> Notes\"), <del>$175,000,000</del>  <ins>$443,300,000</ins> aggregate principal amount of <del>LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34%</del>  <ins>4.46%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$93,400,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>4.45%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2022-B</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$52,149,047.88.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>September 28, 2022</ins> (the \"Indenture\"), between the Trust and U.S. Bank <ins>Trust Company,</ins> National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>September 28, 2022</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>(NAROT 2022-B Underwriting Agreement) 1</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/254582/#clause-id-538163"}, {"variation_number": "Variation 3", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>Wells Fargo Securities, LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$</del><ins>$268,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>2.49668%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$438,000,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>2.56%</ins> Asset Backed Notes, Class <del>A-2a</del>  <ins>A-2</ins> (the \"Class <del>A-2a</del>  <ins>A-2</ins> Notes\"), <del>$175,000,000</del>  <ins>$438,000,000</ins> aggregate principal amount of <del>LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34%</del>  <ins>2.50%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$106,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>2.54%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2019-B</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$52,084,171.97.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>May 28, 2019</ins> (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>May 28, 2019</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>(Nissan 2019-B Underwriting Agreement)</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-2019-b-owner-trust-8718/contract/59216/#clause-id-103174"}, {"variation_number": "Variation 4", "text": "Introductory. Nissan Motor Acceptance <del>Corporation,</del>  <ins>Company LLC,</ins> a <del>California corporation</del>  <ins>Delaware limited liability company</ins> (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables <del>Corporation II,</del>  <ins>Company II LLC,</ins> a Delaware <del>corporation</del>  <ins>limited liability company</ins> (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>Mizuho Securities USA LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative,collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$220,000,000</del>  <ins>$180,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>0.49597%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$365,000,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>1.32%</ins> Asset Backed Notes, Class <del>A-2a</del>  <ins>A-2</ins> (the \"Class <del>A-2a</del>  <ins>A-2</ins> Notes\"), <del>$175,000,000</del>  <ins>$365,000,000</ins> aggregate principal amount of <del>LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34%</del>  <ins>1.86%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and $90,000,000 aggregate principal amount of <del>1.59%</del>  <ins>2.07%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2022-A</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$41,666,667.78.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of February <del>10, 2016</del>  <ins>23, 2022</ins> (the \"Indenture\"), between the Trust and U.S. Bank <ins>Trust Company,</ins> National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of February <del>10, 2016</del>  <ins>23, 2022</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>1 (NAROT 2022-A Underwriting Agreement)</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/222690/#clause-id-480946"}, {"variation_number": "Variation 5", "text": "Introductory. Nissan Motor Acceptance <del>Corporation,</del>  <ins>Company LLC,</ins> a <del>California corporation</del>  <ins>Delaware limited liability company</ins> (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables <del>Corporation II,</del>  <ins>Company II LLC,</ins> a Delaware <del>corporation</del>  <ins>limited liability company</ins> (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>MUFG Securities Americas Inc.</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$220,000,000</del>  <ins>$172,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>0.05908%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$356,500,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>0.16%</ins> Asset Backed Notes, Class <del>A-2a</del>  <ins>A-2</ins> (the \"Class <del>A-2a</del>  <ins>A-2</ins> Notes\"), <del>$175,000,000</del>  <ins>$356,500,000</ins> aggregate principal amount of <del>LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34%</del>  <ins>0.33%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$115,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>0.57%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2021-A</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$41,666,668.49.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>June 23, 2021</ins> (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>June 23, 2021</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/183731/#clause-id-381063"}, {"variation_number": "Variation 6", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>Wells Fargo Securities, LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$</del><ins>$162,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>0.97793%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$352,000,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>1.45%</ins> Asset Backed Notes, Class <del>A-2a</del>  <ins>A-2</ins> (the \"Class <del>A-2a</del>  <ins>A-2</ins> Notes\"), <del>$175,000,000</del>  <ins>$401,000,000</ins> aggregate principal amount of <del>LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34%</del>  <ins>1.38%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$85,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>1.70%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2020-A</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$47,137,850.19.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>April 29, 2020</ins> (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>April 29, 2020</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>(Nissan 2020-A Underwriting Agreement)</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/112487/#clause-id-209971"}, {"variation_number": "Variation 7", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$220,000,000</del>  <ins>$179,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>0.23000%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$243,000,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>0.60%</ins> Asset Backed Notes, Class <del>A-2a</del>  <ins>A-2</ins> (the \"Class <del>A-2a</del>  <ins>A-2</ins> Notes\"), <del>$175,000,000</del>  <ins>$343,000,000</ins> aggregate principal amount of <del>LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34%</del>  <ins>1.11%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$85,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>1.66%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2014-B</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of at least <del>$41,666,666.68.</del>  <ins>$35,416,666.65.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February</del>  <ins>December</ins> 10, <del>2016</del>  <ins>2014</ins> (the \"Indenture\"), between the Trust and <del>U.S. Bank</del>  <ins>Wells Fargo Bank,</ins> National Association <del>(\"U.S. Bank\"),</del>  <ins>(\"Wells Fargo\"),</ins> as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February</del>  <ins>December</ins> 10, <del>2016</del>  <ins>2014</ins> (the \"Trust Agreement\"), between the <del>Depositor,</del>  <ins>Depositor and</ins> Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner <del>Trustee\"), and U.S. Bank, as certificate registrar and paying agent.</del>  <ins>Trustee\").</ins> Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>(Nissan 2014-B Underwriting Agreement)</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/402956/#clause-id-860928"}, {"variation_number": "Variation 8", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>Mizuho Securities USA LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$22</del><ins>$275,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>1.95978%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$371,250,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>1.97%</ins> Asset Backed Notes, Class A-2a (the \"Class A-2a Notes\"), <del>$175,000,000</del>  <ins>$60,000,000</ins> aggregate principal amount of <del>LIBOR</del>  <ins>Benchmark</ins> + <del>0.35%</del>  <ins>0.24%</ins> Asset Backed Notes, Class A-2b (the \"Class A-2b <del>Notes,\"</del>  <ins>Notes\",</ins> and together with the Class A-2a Notes, the \"Class A-2 Notes\"), <del>$305,000,000</del>  <ins>$431,250,000</ins> aggregate principal amount of <del>1.34%</del>  <ins>1.93%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$112,500,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>1.95%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2019-C</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$52,083,876.49.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>October 23, 2019</ins> (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>October 23, 2019</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>(Nissan 2019-C Underwriting Agreement)</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-2019-c-owner-trust-9748/contract/79285/#clause-id-149837"}, {"variation_number": "Variation 9", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>SG Americas Securities, LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$</del><ins>$272,500,000</ins> aggregate principal amount of <del>0.64000% Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), $210,000,000 aggregate principal amount of 1.06%</del>  <ins>2.76%</ins> Asset Backed Notes, Class A-2a (the \"Class A-2a Notes\"), <del>$175,000,000</del>  <ins>$75,000,000</ins> aggregate principal amount of LIBOR + <del>0.35%</del>  <ins>0.10%</ins> Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), <del>$305,000,000</del>  <ins>$347,500,000</ins> aggregate principal amount of <del>1.34%</del>  <ins>3.06%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$80,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>3.16%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, <del>the Class A-1 Notes,</del> the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the <del>\"Notes\"),</del>  <ins>\"Underwritten Notes\"),</ins> of Nissan Auto Receivables <del>2016-A</del>  <ins>2018-B</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which <ins>Underwritten</ins> Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. <ins>Simultaneously with the issuance of the Underwritten Notes, the Trust will also issue $225,000,000 aggregate principal amount of 2.35000% Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\" and, collectively with the Underwritten Notes, the \"Notes\"), which will be retained by the Depositor or conveyed to affiliates of the Depositor.</ins> Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of at least <del>$41,666,666.68.</del>  <ins>$41,669,415.04.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>July 25, 2018</ins> (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>July 25, 2018</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in (Nissan <del>2016-A</del>  <ins>2018-B</ins> Underwriting Agreement) such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/286753/#clause-id-602917"}, {"variation_number": "Variation 10", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>Mizuho Securities USA LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$22</del><ins>$200,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>2.77000%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$310,000,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>3.07%</ins> Asset Backed Notes, Class A-2a (the \"Class A-2a Notes\"), <del>$175,000,000</del>  <ins>$50,000,000</ins> aggregate principal amount of LIBOR + <del>0.35%</del>  <ins>0.17%</ins> Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), <del>$305,000,000</del>  <ins>$360,000,000</ins> aggregate principal amount of <del>1.34%</del>  <ins>3.22%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$80,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>3.27%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2018-C</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$59,308,919.50.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>December 12, 2018</ins> (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>December 12, 2018</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>(Nissan 2018-C Underwriting Agreement)</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/277335/#clause-id-580815"}, {"variation_number": "Variation 11", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with <del>Merrill Lynch, Pierce, Fenner & Smith Incorporated</del>  <ins>Mizuho Securities USA LLC</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$22</del><ins>$254,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>0.21995%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$420,000,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>0.47%</ins> Asset Backed Notes, Class A-2a (the \"Class A-2a Notes\"), <del>$175,000,000</del>  <ins>$50,000,000</ins> aggregate principal amount of <del>LIBOR</del>  <ins>Benchmark</ins> + <del>0.35%</del>  <ins>0.18%</ins> Asset Backed Notes, Class A-2b (the \"Class A-2b <del>Notes,\"</del>  <ins>Notes\",</ins> and together with the Class A-2a Notes, the \"Class A-2 Notes\"), <del>$305,000,000</del>  <ins>$470,000,000</ins> aggregate principal amount of <del>1.34%</del>  <ins>0.55%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$106,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>0.71%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2020-B</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of <del>at least $41,666,666.68.</del>  <ins>$ 61,260,676.66.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of <del>February 10, 2016</del>  <ins>June 30, 2020</ins> (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of <del>February 10, 2016</del>  <ins>June 30, 2020</ins> (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. <ins>(Nissan 2020-B Underwriting Agreement)</ins> Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/122578/#clause-id-230530"}, {"variation_number": "Variation 12", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of $220,000,000 aggregate principal amount of 0.64000% Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), $210,000,000 aggregate principal amount of 1.06% Asset Backed Notes, Class A-2a (the \"Class A-2a Notes\"), $175,000,000 aggregate principal amount of LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34% Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and $90,000,000 aggregate principal amount of 1.59% Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables 2016-A Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of at least $41,666,666.68. The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of February 10, 2016 (the \"Indenture\"), between the Trust and U.S. Bank National Association (\"U.S. Bank\"), as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of February 10, 2016 (the \"Trust Agreement\"), between the Depositor, Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in (Nissan 2016-A Underwriting Agreement) such capacity, the \"Owner Trustee\"), and U.S. Bank, as certificate registrar and paying agent. Each Note will represent an obligation of, and each Certificate will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural includes the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/338650/#clause-id-732907"}, {"variation_number": "Variation 13", "text": "Introductory. Nissan Motor Acceptance Corporation, a California corporation (\"NMAC\" or \"Servicer\"), and Nissan Auto Receivables Corporation II, a Delaware corporation (the \"Depositor\" or \"Seller\"), hereby confirm their agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$220,000,000</del>  <ins>$219,000,000</ins> aggregate principal amount of <del>0.64000%</del>  <ins>0.19000%</ins> Asset Backed Notes, Class A-1 (the \"Class A-1 Notes\"), <del>$210,000,000</del>  <ins>$330,000,000</ins> aggregate principal amount of <del>1.06%</del>  <ins>0.42%</ins> Asset Backed Notes, Class <del>A-2a</del>  <ins>A-2</ins> (the \"Class <del>A-2a</del>  <ins>A-2</ins> Notes\"), <del>$175,000,000</del>  <ins>$351,000,000</ins> aggregate principal amount of <del>LIBOR + 0.35% Asset Backed Notes, Class A-2b (the \"Class A-2b Notes,\" and together with the Class A-2a Notes, the \"Class A-2 Notes\"), $305,000,000 aggregate principal amount of 1.34%</del>  <ins>0.72%</ins> Asset Backed Notes, Class A-3 (the \"Class A-3 Notes\") and <del>$90,000,000</del>  <ins>$100,000,000</ins> aggregate principal amount of <del>1.59%</del>  <ins>1.34%</ins> Asset Backed Notes, Class A-4 (the \"Class A-4 Notes\") (collectively, the Class A-1 Notes, the Class A-2 Notes, the Class A-3 Notes, and the Class A-4 Notes are referred to herein as the \"Notes\"), of Nissan Auto Receivables <del>2016-A</del>  <ins>2014-A</ins> Owner Trust, a Delaware statutory trust (the \"Trust\" or \"Issuer\"), which Notes the Depositor proposes to sell to the Underwriters under the terms and conditions herein. Simultaneously with the issuance of the Notes, the Depositor will cause the Trust to issue Asset Backed Certificates (the \"Certificates\") with an original certificate balance of at least <del>$41,666,666.68.</del>  <ins>$41,666,666.67.</ins> The Notes and the Certificates shall collectively be referred to herein as the \"Securities.\" The Notes will be issued pursuant to an indenture, dated as of February <del>10, 2016</del>  <ins>19, 2014</ins> (the \"Indenture\"), between the Trust and <del>U.S. Bank National Association (\"U.S. Bank\"),</del>  <ins>Citibank, N.A. (\"Citibank\"),</ins> as indenture trustee (the \"Indenture Trustee\"). The Certificates will be issued pursuant to an amended and restated trust agreement, dated as of February <del>10, 2016</del>  <ins>19, 2014</ins> (the \"Trust Agreement\"), between the <del>Depositor,</del>  <ins>Depositor and</ins> Wilmington Trust, National Association (\"Wilmington Trust\"), as owner trustee (in <del>(Nissan 2016-A Underwriting Agreement)</del> such capacity, the \"Owner <del>Trustee\"), and U.S. Bank, as certificate registrar and paying agent.</del>  <ins>Trustee\").</ins> Each Note will represent an obligation of, and each Certificate <ins>(Nissan 2014-A Underwriting Agreement)</ins> will represent an undivided interest in, the Trust. The Certificates will be subordinated to the Notes to the extent described in the Indenture and the Trust Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Sale and Servicing Agreement. With respect to all terms in this Agreement, the singular includes the plural and the plural <del>includes</del> the singular; words importing any gender include the other genders; references to \"writing\" include printing, typing, lithography and other means of reproducing words in a visible form; references to agreements and other contractual instruments include all subsequent amendments, amendments and restatements and supplements thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement; references to Persons include their permitted successors and assigns; references to laws include their amendments and supplements, the rules and regulations thereunder and any successors thereto; the term \"including\" means \"including without limitation;\" and the term \"or\" is not exclusive.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-auto-receivables-corp-ii-2220/contract/402707/#clause-id-860431"}]}
{"clause_number": "Clause 3", "title": "Introductory", "text": "Introductory. The stockholders of Evoqua Water Technologies Corp., a Delaware corporation (\"Company\"), listed in Schedule A hereto (the \"Selling Stockholders\") agree severally with the several Underwriters named in Schedule B hereto (collectively, the \"Underwriters\") to sell to the Underwriters an aggregate of outstanding shares of the Company's common stock, par value $0.01 per share (the \"Common Stock\") (such shares of Common Stock being hereinafter referred to as the \"Firm Securities\"). The Selling Stockholders also agree to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than additional outstanding shares (\"Optional Securities\") of the Company's Common Stock, as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/evoqua-water-technologies-corp-4756/contract/314321/#clause-id-676522", "variations": [{"variation_number": "Variation 1", "text": "Introductory. The stockholders of Evoqua Water Technologies Corp., a Delaware corporation (\"Company\"), listed in Schedule A hereto (the \"Selling Stockholders\") agree severally with the several Underwriters named in Schedule B hereto (collectively, the \"Underwriters\") to sell to the Underwriters an aggregate of outstanding shares of the Company's common stock, par value $0.01 per share (the \"Common Stock\") (such shares of Common Stock being hereinafter referred to as the \"Firm Securities\"). The Selling Stockholders also agree to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than additional outstanding shares (\"Optional Securities\") of the Company's Common Stock, as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/evoqua-water-technologies-corp-4756/contract/314321/#clause-id-676522"}, {"variation_number": "Variation 2", "text": "Introductory. The stockholders of <del>Evoqua Water Technologies Corp.,</del>  <ins>Magnolia Oil & Gas Corporation,</ins> a Delaware corporation <del>(\"Company\"),</del>  <ins>(the \"Company\")</ins> listed in Schedule A hereto (the \"Selling <del>Stockholders\")</del>  <ins>Stockholders\"),</ins> agree severally with the <del>several</del> Underwriters named in Schedule B hereto <del>(collectively, the \"Underwriters\")</del>  <ins>(\"Underwriters\")</ins> to sell to the Underwriters an aggregate of <ins>17,000,000</ins> outstanding shares <ins>(the \"Firm Securities\")</ins> of the Company's <del>common stock,</del>  <ins>Class A Common Stock,</ins> par value <del>$0.0</del><ins>$0.0001</ins> per share (the <del>\"Common Stock\") (such shares of Common Stock being hereinafter referred to as the \"Firm Securities\").</del>  <ins>\"Securities\").</ins> The Selling Stockholders also agree to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>2,550,000</ins> additional outstanding shares (\"Optional Securities\") of the <del>Company's Common Stock,</del>  <ins>Securities,</ins> as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/magnolia-oil-gas-corp-5794/contract/162069/#clause-id-328685"}, {"variation_number": "Variation 3", "text": "Introductory. The stockholders of <del>Evoqua Water Technologies Corp.,</del>  <ins>GMS Inc.,</ins> a Delaware corporation (\"Company\"), listed in Schedule A hereto (the \"Selling Stockholders\") agree severally with the several Underwriters named in Schedule B hereto (collectively, the \"Underwriters\") to sell to the <ins>several</ins> Underwriters an aggregate of <ins>[\u00b7]</ins> outstanding shares <ins>(the \"Firm Securities\")</ins> of the Company's common stock, par value $0.01 per share (the \"Common <del>Stock\") (such shares of Common Stock being hereinafter referred to</del><ins>Stock\"), and</ins> also agree to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>[\u00b7]</ins> additional <del>outstanding</del> shares <del>(\"Optional</del>  <ins>of Common Stock (the \"Optional</ins> Securities\") <del>of the Company's Common Stock,</del> as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/gms-inc-4717/contract/328387/#clause-id-708667"}, {"variation_number": "Variation 4", "text": "Introductory. The stockholders of Evoqua Water Technologies Corp., a Delaware corporation (\"Company\"), listed in Schedule A hereto (the \"Selling Stockholders\") agree severally with the several Underwriters named in Schedule B hereto (collectively, the \"Underwriters\") to sell to the Underwriters an aggregate of <ins>8,000,000</ins> outstanding shares of the Company's common stock, par value $0.01 per share (the \"Common Stock\") (such <ins>8,000,000</ins> shares of Common Stock being hereinafter referred to as the \"Firm Securities\").The Selling Stockholders also agree to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>1,200,000</ins> additional outstanding shares (\"Optional Securities\") of the Company's Common Stock, as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <ins>To the extent there are no additional Underwriters listed in Schedule B other than you, the term \"Underwriters\" as used herein shall mean you, as Underwriter, and the term Underwriters shall mean the singular as the context requires.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/evoqua-water-technologies-corp-4756/contract/124159/#clause-id-232898"}, {"variation_number": "Variation 5", "text": "Introductory. The stockholders of Evoqua Water Technologies Corp., a Delaware corporation (\"Company\"), listed in Schedule A hereto (the \"Selling Stockholders\") agree severally with the several Underwriters named in Schedule B hereto (collectively, the \"Underwriters\") to sell to the Underwriters an aggregate of <ins>12,000,000</ins> outstanding shares of the Company's common stock, par value $0.01 per share (the \"Common Stock\") (such <ins>12,000,000</ins> shares of Common Stock being hereinafter referred to as the \"Firm Securities\"). The Selling Stockholders also agree to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>1,800,000</ins> additional outstanding shares (\"Optional Securities\") of the Company's Common Stock, as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <ins>To the extent there are no additional Underwriters listed in Schedule B other than you, the term \"Underwriters\" as used herein shall mean you, as Underwriter, and the term Underwriters shall mean the singular as the context requires.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/evoqua-water-technologies-corp-4756/contract/141294/#clause-id-276705"}, {"variation_number": "Variation 6", "text": "Introductory. The stockholders of Evoqua Water Technologies Corp., a Delaware corporation (\"Company\"), listed in Schedule A hereto (the \"Selling Stockholders\") agree severally with the several Underwriters named in Schedule B hereto (collectively, the \"Underwriters\") to sell to the Underwriters an aggregate of <ins>13,000,000</ins> outstanding shares of the Company's common stock, par value $0.01 per share (the \"Common Stock\") (such <ins>13,000,000</ins> shares of Common Stock being hereinafter referred to as the \"Firm Securities\"). The Selling Stockholders also agree to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <ins>1,950,000</ins> additional outstanding shares (\"Optional Securities\") of the Company's Common Stock, as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/evoqua-water-technologies-corp-4756/contract/94466/#clause-id-178332"}]}
{"clause_number": "Clause 4", "title": "Introductory", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust 2021-C (the \"Trust\") to issue $221,000,000 principal amount of 0.11014% Class A-1 Asset Backed Notes (the \"Class A-1 Notes\"), $306,500,000 principal amount of 0.33% Class A-2 Asset Backed Notes (the \"Class A-2 Notes\"), $306,500,000 principal amount of 0.81% Class A-3 Asset Backed Notes (the \"Class A-3 Notes\"), $85,270,000 principal amount of 1.16% Class A-4 Asset Backed Notes (the \"Class A-4 Notes\" and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \"Class A Notes\") and $21,160,000 principal amount of 1.41% Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the \"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the \"Representatives\"), in the respective amounts listed on Schedule I hereto. The Notes will be issued pursuant to the Indenture to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and Citibank, N.A., as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\"). Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and the Servicer, or, if not defined therein, in the Indenture or the Trust Agreement dated as of October 8, 2021 (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). Prior to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately 12:30 p.m. (New York time) on October 19, 2021 (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus dated October 13, 2021 (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated October 13, 2021 (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on October 13, 2021. If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at least 48 hours prior to the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/203970/#clause-id-432835", "variations": [{"variation_number": "Variation 1", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust 2021-C (the \"Trust\") to issue $221,000,000 principal amount of 0.11014% Class A-1 Asset Backed Notes (the \"Class A-1 Notes\"), $306,500,000 principal amount of 0.33% Class A-2 Asset Backed Notes (the \"Class A-2 Notes\"), $306,500,000 principal amount of 0.81% Class A-3 Asset Backed Notes (the \"Class A-3 Notes\"), $85,270,000 principal amount of 1.16% Class A-4 Asset Backed Notes (the \"Class A-4 Notes\" and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \"Class A Notes\") and $21,160,000 principal amount of 1.41% Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the \"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the \"Representatives\"), in the respective amounts listed on Schedule I hereto. The Notes will be issued pursuant to the Indenture to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and Citibank, N.A., as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\"). Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and the Servicer, or, if not defined therein, in the Indenture or the Trust Agreement dated as of October 8, 2021 (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). Prior to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately 12:30 p.m. (New York time) on October 19, 2021 (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus dated October 13, 2021 (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated October 13, 2021 (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on October 13, 2021. If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at least 48 hours prior to the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/203970/#clause-id-432835"}, {"variation_number": "Variation 2", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust <del>2021-C</del>  <ins>2014-A</ins> (the \"Trust\") to issue <del>$221,000,000</del>  <ins>and sell $172,000,000</ins> principal amount of <del>0.11014%</del>  <ins>0.20%</ins> Class A-1 Asset Backed Notes (the \"Class A-1 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $334,000,000</ins> principal amount of <del>0.33%</del>  <ins>0.49%</ins> Class A-2 Asset Backed Notes (the \"Class A-2 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $328,000,000</ins> principal amount of <del>0.81%</del>  <ins>0.84%</ins> Class A-3 Asset Backed Notes (the \"Class A-3 <del>Notes\"), $85,270,000</del>  <ins>Notes\"); $166,000,000</ins> principal amount of <del>1.16%</del>  <ins>1.50%</ins> Class A-4 Asset Backed Notes (the \"Class A-4 <del>Notes\" and, together with</del>  <ins>Notes\", and collectively,</ins> the Class A-1 Notes, the Class A-2 <ins>Notes, the Class A-3</ins> Notes and the Class <del>A-3</del>  <ins>A-4</ins> Notes, the \"Class A <del>Notes\")</del>  <ins>Notes\");</ins> and <del>$21,160,000</del>  <ins>$23,017,000</ins> principal amount of <del>1.41%</del>  <ins>1.93%</ins> Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the <del>\"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes</del>  <ins>\"Notes\")</ins> to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the <del>\"Representatives\"), in the respective amounts listed on Schedule I hereto.</del>  <ins>\"Representatives\").</ins> The Notes will be issued pursuant to the Indenture to be dated as of <del>October</del>  <ins>February</ins> 1, <del>2021</del>  <ins>2014</ins> (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and <del>Citibank, N.A.,</del>  <ins>Deutsche Bank Trust Company Americas,</ins> as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). <del>The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\").</del> Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of <del>October</del>  <ins>February</ins> 1, <del>2021</del>  <ins>2014</ins> (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and <del>the Servicer,</del>  <ins>New Holland, as servicer,</ins> or, if not defined therein, in the Indenture or the Trust Agreement dated as of <del>October 8, 2021</del>  <ins>February 1, 2014</ins> (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). <del>Prior</del>  <ins>At or prior</ins> to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately 12:30 p.m. (New York time) on <del>October 19, 2021</del>  <ins>February 12, 2014</ins> (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus <ins>supplement</ins> dated <del>October 13, 2021</del>  <ins>February 6, 2014, as amended and supplemented by a supplement to such preliminary prospectus supplement dated February 12, 2014 (the \"Preliminary Prospectus Supplement\") to the base prospectus dated February 6, 2014 (the \"Base Prospectus\")</ins> (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated <del>October 13, 2021</del>  <ins>February 6, 2014</ins> (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on <del>October 13, 2021.</del>  <ins>February 6, 2014.</ins> If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of <del>a</del> material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at <del>least 48 hours prior to</del> the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/399303/#clause-id-851722"}, {"variation_number": "Variation 3", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust <del>2021-C</del>  <ins>2015-A</ins> (the \"Trust\") to issue <del>$221,000,000</del>  <ins>and sell $158,000,000</ins> principal amount of <del>0.11014%</del>  <ins>0.25%</ins> Class A-1 Asset Backed Notes (the \"Class A-1 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $268,000,000</ins> principal amount of <del>0.33%</del>  <ins>0.84%</ins> Class A-2 Asset Backed Notes (the \"Class A-2 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $244,000,000</ins> principal amount of <del>0.81%</del>  <ins>1.30%</ins> Class A-3 Asset Backed Notes (the \"Class A-3 <del>Notes\"), $85,270,000</del>  <ins>Notes\"); $112,000,000</ins> principal amount of <del>1.16%</del>  <ins>1.85%</ins> Class A-4 Asset Backed Notes (the \"Class A-4 <del>Notes\" and, together with</del>  <ins>Notes\", and collectively,</ins> the Class A-1 Notes, the Class A-2 <ins>Notes, the Class A-3</ins> Notes and the Class <del>A-3</del>  <ins>A-4</ins> Notes, the \"Class A <del>Notes\")</del>  <ins>Notes\");</ins> and <del>$21,160,000</del>  <ins>$18,000,000</ins> principal amount of <del>1.41%</del>  <ins>2.14%</ins> Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the <del>\"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes</del>  <ins>\"Notes\")</ins> to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the <del>\"Representatives\"), in the respective amounts listed on Schedule I hereto.</del>  <ins>\"Representatives\").</ins> The Notes will be issued pursuant to the Indenture to be dated as of <del>October</del>  <ins>February</ins> 1, <del>2021</del>  <ins>2015</ins> (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and <del>Citibank, N.A.,</del>  <ins>Deutsche Bank Trust Company Americas,</ins> as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). <del>The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\").</del> Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of <del>October</del>  <ins>February</ins> 1, <del>2021</del>  <ins>2015</ins> (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and <del>the Servicer,</del>  <ins>New Holland, as servicer,</ins> or, if not defined therein, in the Indenture or the Trust Agreement dated as of <del>October 8, 2021</del>  <ins>January 1, 2015</ins> (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). <del>Prior</del>  <ins>At or prior</ins> to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately <del>12:30</del>  <ins>2:33</ins> p.m. (New York time) on <del>October 19, 2021</del>  <ins>February 25, 2015</ins> (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus <ins>supplement</ins> dated <del>October 13, 2021</del>  <ins>February 19, 2015 (the \"Preliminary Prospectus Supplement\") to the base prospectus dated February 19, 2015 (the \"Base Prospectus\")</ins> (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated <del>October 13, 2021</del>  <ins>February 19, 2015</ins> (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on <del>October 13, 2021.</del>  <ins>February 19, 2015.</ins> If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of <del>a</del> material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at <del>least 48 hours prior to</del> the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/400079/#clause-id-854443"}, {"variation_number": "Variation 4", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust <del>2021-C</del>  <ins>2014-B</ins> (the \"Trust\") to issue <del>$221,000,000</del>  <ins>and sell $188,000,000</ins> principal amount of <del>0.11014%</del>  <ins>0.19%</ins> Class A-1 Asset Backed Notes (the \"Class A-1 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $315,000,000</ins> principal amount of <del>0.33%</del>  <ins>0.48%</ins> Class A-2 Asset Backed Notes (the \"Class A-2 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $310,000,000</ins> principal amount of <del>0.81%</del>  <ins>0.91%</ins> Class A-3 Asset Backed Notes (the \"Class A-3 <del>Notes\"), $85,270,000</del>  <ins>Notes\"); $164,070,000</ins> principal amount of <del>1.16%</del>  <ins>1.61%</ins> Class A-4 Asset Backed Notes (the \"Class A-4 <del>Notes\" and, together with</del>  <ins>Notes\", and collectively,</ins> the Class A-1 Notes, the Class A-2 <ins>Notes, the Class A-3</ins> Notes and the Class <del>A-3</del>  <ins>A-4</ins> Notes, the \"Class A <del>Notes\")</del>  <ins>Notes\");</ins> and <del>$21,160,000</del>  <ins>$22,497,000</ins> principal amount of <del>1.41%</del>  <ins>1.93%</ins> Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the <del>\"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes</del>  <ins>\"Notes\")</ins> to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the <del>\"Representatives\"), in the respective amounts listed on Schedule I hereto.</del>  <ins>\"Representatives\").</ins> The Notes will be issued pursuant to the Indenture to be dated as of <del>October</del>  <ins>May</ins> 1, <del>2021</del>  <ins>2014</ins> (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and <del>Citibank, N.A.,</del>  <ins>Deutsche Bank Trust Company Americas,</ins> as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). <del>The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\").</del> Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of <del>October</del>  <ins>May</ins> 1, <del>2021</del>  <ins>2014</ins> (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and <del>the Servicer,</del>  <ins>New Holland, as servicer,</ins> or, if not defined therein, in the Indenture or the Trust Agreement dated as of <del>October 8, 2021</del>  <ins>May 1, 2014</ins> (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). <del>Prior</del>  <ins>At or prior</ins> to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately <del>12:30</del>  <ins>4:30</ins> p.m. (New York time) on <del>October 19, 2021</del>  <ins>June 3, 2014</ins> (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus <ins>supplement</ins> dated <del>October 13, 2021</del>  <ins>May 29, 2014 (the \"Preliminary Prospectus Supplement\") to the base prospectus dated May 29, 2014 (the \"Base Prospectus\")</ins> (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated <del>October 13, 2021</del>  <ins>May 29, 2014</ins> (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on <del>October 13, 2021.</del>  <ins>May 29, 2014.</ins> If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of <del>a</del> material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at <del>least 48 hours prior to</del> the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/399513/#clause-id-852370"}, {"variation_number": "Variation 5", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust <del>2021-C</del>  <ins>2014-C</ins> (the \"Trust\") to issue <del>$221,000,000</del>  <ins>and sell $219,000,000</ins> principal amount of <del>0.11014%</del>  <ins>0.20%</ins> Class A-1 Asset Backed Notes (the \"Class A-1 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $280,000,000</ins> principal amount of <del>0.33%</del>  <ins>0.63%</ins> Class A-2 Asset Backed Notes (the \"Class A-2 <del>Notes\"), $306,500,000</del>  <ins>Notes\"); $350,000,000</ins> principal amount of <del>0.81%</del>  <ins>1.05%</ins> Class A-3 Asset Backed Notes (the \"Class A-3 <del>Notes\"), $85,270,000</del>  <ins>Notes\"); $127,587,000</ins> principal amount of <del>1.16%</del>  <ins>1.65%</ins> Class A-4 Asset Backed Notes (the \"Class A-4 <del>Notes\" and, together with</del>  <ins>Notes\", and collectively,</ins> the Class A-1 Notes, the Class A-2 <ins>Notes, the Class A-3</ins> Notes and the Class <del>A-3</del>  <ins>A-4</ins> Notes, the \"Class A <del>Notes\")</del>  <ins>Notes\");</ins> and <del>$21,160,000</del>  <ins>$22,479,000</ins> principal amount of <del>1.41%</del>  <ins>1.95%</ins> Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the <del>\"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes</del>  <ins>\"Notes\")</ins> to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the <del>\"Representatives\"), in the respective amounts listed on Schedule I hereto.</del>  <ins>\"Representatives\").</ins> The Notes will be issued pursuant to the Indenture to be dated as of October 1, <del>2021</del>  <ins>2014</ins> (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and Citibank, N.A., as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). <del>The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of October 1, 2021 (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\").</del> Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of October 1, <del>2021</del>  <ins>2014</ins> (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and <del>the Servicer,</del>  <ins>New Holland, as servicer,</ins> or, if not defined therein, in the Indenture or the Trust Agreement dated as of October <del>8, 2021</del>  <ins>1, 2014</ins> (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). <del>Prior</del>  <ins>At or prior</ins> to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately <del>12:30</del>  <ins>12:26</ins> p.m. (New York time) on October <del>19, 2021</del>  <ins>16, 2014</ins> (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus <ins>supplement</ins> dated October <del>13, 2021</del>  <ins>8, 2014 (the \"Preliminary Prospectus Supplement\") to the base prospectus dated October 8, 2014 (the \"Base Prospectus\")</ins> (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated October <del>13, 2021</del>  <ins>8, 2014</ins> (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on October <del>13, 2021.</del>  <ins>8, 2014.</ins> If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of <del>a</del> material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at <del>least 48 hours prior to</del> the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/399335/#clause-id-851812"}, {"variation_number": "Variation 6", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust <del>2021-C</del>  <ins>2016-C</ins> (the \"Trust\") to issue <del>$221,000,000</del>  <ins>and sell $156,500,000</ins> principal amount of <del>0.11014%</del>  <ins>0.75%</ins> Class A-1 Asset Backed Notes (the \"Class A-1 Notes\"), <del>$306,500,000</del>  <ins>$290,000,000</ins> principal amount of <del>0.33%</del>  <ins>1.26%</ins> Class A-2 Asset Backed Notes (the \"Class A-2 Notes\"), <del>$306,500,000</del>  <ins>$213,930,000</ins> principal amount of <del>0.81%</del>  <ins>1.44%</ins> Class A-3 Asset Backed Notes (the \"Class A-3 Notes\"), <del>$85,270,000</del>  <ins>$75,000,000</ins> principal amount of <del>1.16%</del>  <ins>1.76%</ins> Class A-4 Asset Backed Notes (the \"Class A-4 <del>Notes\" and, together with</del>  <ins>Notes\", and collectively,</ins> the Class A-1 Notes, the Class A-2 <ins>Notes, the Class A-3</ins> Notes and the Class <del>A-3</del>  <ins>A-4</ins> Notes, the \"Class A Notes\") and <del>$21,160,000</del>  <ins>$16,930,000</ins> principal amount of <del>1.41%</del>  <ins>1.93%</ins> Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the <del>\"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes</del>  <ins>\"Notes\")</ins> to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the <del>\"Representatives\"), in the respective amounts listed on Schedule I hereto.</del>  <ins>\"Representatives\").</ins> The Notes will be issued pursuant to the Indenture to be dated as of <del>October</del>  <ins>September</ins> 1, <del>2021</del>  <ins>2016</ins> (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and Citibank, N.A., as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of <del>October</del>  <ins>September</ins> 1, <del>2021</del>  <ins>2016</ins> (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\"). Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of <del>October</del>  <ins>September</ins> 1, <del>2021</del>  <ins>2016</ins> (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and the Servicer, or, if not defined therein, in the Indenture or the Trust Agreement dated <del>as of October 8, 2021</del>  <ins>August 26, 2016</ins> (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). Prior to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately <del>12:30</del>  <ins>2:50</ins> p.m. (New York time) on <del>October 19, 2021</del>  <ins>September 13, 2016</ins> (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus dated <del>October 13, 2021</del>  <ins>September 7, 2016</ins> (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated <del>October 13, 2021</del>  <ins>September 7, 2016</ins> (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on <del>October 13, 2021.</del>  <ins>September 7, 2016.</ins> If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at least 48 hours prior to the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/337346/#clause-id-730102"}, {"variation_number": "Variation 7", "text": "Introductory. CNH Capital Receivables LLC, a Delaware limited liability company (the \"Seller\"), proposes to cause CNH Equipment Trust <del>2021-C</del>  <ins>2021-B</ins> (the \"Trust\") to issue <del>$221,000,000</del>  <ins>$163,000,000</ins> principal amount of <del>0.11014%</del>  <ins>0.14173%</ins> Class A-1 Asset Backed Notes (the \"Class A-1 Notes\"), <del>$306,500,000</del>  <ins>$273,000,000</ins> principal amount of <del>0.33%</del>  <ins>0.22%</ins> Class A-2 Asset Backed Notes (the \"Class A-2 Notes\"), <del>$306,500,000</del>  <ins>$313,000,000</ins> principal amount of <del>0.81%</del>  <ins>0.44%</ins> Class A-3 Asset Backed Notes (the \"Class A-3 Notes\"), <del>$</del><ins>$75,850,000</ins> principal amount of <del>1.16%</del>  <ins>0.70%</ins> Class A-4 Asset Backed Notes (the \"Class A-4 Notes\" and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \"Class A Notes\") and <del>$21,160,000</del>  <ins>$18,990,000</ins> principal amount of <del>1.41%</del>  <ins>0.90%</ins> Class B Asset Backed Notes (the \"Class B Notes\" and, together with the Class A Notes, the \"Notes\"). Pursuant to the terms hereof, the Seller agrees to sell the Class A Notes and the Class B Notes to the several underwriters named in Schedule I hereto (collectively, the \"Underwriters\"), for whom you are acting as representatives (the \"Representatives\"), in the respective amounts listed on Schedule I hereto. The Notes will be issued pursuant to the Indenture to be dated as of <del>October</del>  <ins>July</ins> 1, 2021 (as amended and supplemented from time to time, the \"Indenture\"), between the Trust and Citibank, N.A., as indenture trustee (the \"Indenture Trustee\"). The assets of the Trust include, among other things, a pool of fixed rate retail installment sale contracts and retail installment loans (the \"Receivables\") secured by new or used agricultural or construction equipment and the related security interests in the equipment financed thereby. The Receivables were sold to the Trust by the Seller. The Receivables are serviced for the Trust by New Holland Credit Company, LLC, a Delaware limited liability company (\"New Holland\"). The Trust will provide for the review of the Receivables for compliance with the representations and warranties made about them in certain circumstances under an asset representations review agreement to be dated as of <del>October</del>  <ins>July</ins> 1, 2021 (as amended and supplemented from time to time, the \"Asset Representations Review Agreement\"), among the Trust, New Holland, as servicer (the \"Servicer\"), and Clayton Fixed Income Services LLC, as asset representations reviewer (the \"Asset Representations Reviewer\"). Simultaneously with the issuance and sale of the Notes as contemplated in this Agreement, the Trust will issue to the Seller certificates representing fractional undivided equity interests in the Trust (the \"Certificates\"). The Notes and the Certificates are sometimes referred to herein as the \"Securities.\" Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Sale and Servicing Agreement to be dated as of <del>October</del>  <ins>July</ins> 1, 2021 (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Trust, the Seller and the Servicer, or, if not defined therein, in the Indenture or the Trust Agreement dated as of <del>October 8,</del>  <ins>July 9,</ins> 2021 (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Seller and Wilmington Trust Company, as trustee (the \"Trustee\"). Prior to the time when sales to purchasers of the Notes were first made to investors by the several Underwriters, which was approximately <del>12:30</del>  <ins>3:35</ins> p.m. (New York time) on <del>October 19,</del>  <ins>July 20,</ins> 2021 (the \"Time of Sale\"), the Seller had prepared the following information (collectively, the \"Time of Sale Information\"): the preliminary prospectus dated <del>October 13,</del>  <ins>July 15,</ins> 2021 (together, along with information referred to under the caption \"Annex A\u2014Static Pool Data\" therein, the \"Preliminary Prospectus\") and the free writing prospectus dated <del>October 13,</del>  <ins>July 15,</ins> 2021 (the \"Initial Free Writing Prospectus\") in the form filed with the Securities and Exchange Commission (the \"Commission\") on <del>October 13,</del>  <ins>July 15,</ins> 2021. If, subsequent to the Time of Sale and prior to the Closing Date (as defined below), such information included an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and as a result investors in the Notes may terminate their old \"Contracts of Sale\" (within the meaning of Rule 159 under the Securities Act of 1933, as amended (the \"Act\")) for any Notes and the Underwriters enter into new Contracts of Sale with investors in the Notes, then \"Time of Sale Information\" will refer to the information conveyed to investors at least 48 hours prior to the time of entry into the first such new Contract of Sale, in an amended Preliminary Prospectus approved by the Seller and the Representatives that corrects such material misstatements or omissions (a \"Corrected Prospectus\") and \"Time of Sale\" will refer to the time and date on which such new Contracts of Sale were entered into.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cnh-capital-receivables-llc-2159/contract/189368/#clause-id-397753"}]}
{"clause_number": "Clause 5", "title": "Introductory", "text": "Introductory. CAI International, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom B. Riley FBR, Inc. (\"FBR\") is acting as representative (the \"Representative\"), to issue and sell to the several Underwriters 1,600,000 shares (the \"Firm Securities\") of the 8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, liquidation preference $25.00 per share, of the Company (the \"Series A Preferred Stock\"), a new series of the Company's authorized preferred stock (the \"Preferred Stock\"). The Company also agrees to sell to the several Underwriters, at the option of the Underwriters, an aggregate of not more than 240,000 additional shares of Series A Preferred Stock (the \"Optional Securities\"). The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". This Underwriting Agreement (this \"Agreement\") confirms the agreement among the Company and the Underwriters concerning the purchase of the Offered Securities by the Underwriters. For purposes of this Agreement: \"430B Information\" means information included in a prospectus then deemed to be a part of the Registration Statement pursuant to Rule 430B(e) or retroactively deemed to be a part of the Registration Statement pursuant to Rule 430B(f). \"Act\" means the Securities Act of 1933, as amended. \"Applicable Time\" means 5:45 p.m. (Eastern time) on the date of this Agreement. \"Closing Date\" has the meaning defined in Section 3 hereof. \"Commission\" means the Securities and Exchange Commission. \"Effective Time\" of the Registration Statement relating to the Offered Securities means the time of the first contract of sale for the Offered Securities. \"Exchange Act\" means the Securities Exchange Act of 1934, as amended. 1 \"Final Prospectus\" means the Statutory Prospectus that discloses the public offering price, including any document incorporated by reference therein, other 430B Information and other final terms of the Offered Securities and otherwise satisfies Section 10(a) of the Act. \"General Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors, as evidenced by its being so specified in Schedule B to this Agreement. \"Issuer Free Writing Prospectus\" means any \"issuer free writing prospectus,\" as defined in Rule 433, relating to the Offered Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g). \"Limited Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is not a General Use Issuer Free Writing Prospectus. \"Rules and Regulations\" means the rules and regulations of the Commission. \"Securities Laws\" means, collectively, the Sarbanes-Oxley Act of 2002 (\"Sarbanes-Oxley\"), the Act, the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors of \"issuers\" (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board and, as applicable, the rules (\"Exchange Rules\") of the New York Stock Exchange (\"NYSE\"). \"Statutory Prospectus\" with reference to any particular time means the prospectus relating to the Offered Securities that is included in the Registration Statement immediately prior to that time, including any document incorporated by reference therein and all 430B Information with respect to the Registration Statement. For purposes of the foregoing definition, 430B Information shall be considered to be included in the Statutory Prospectus only as of the actual time that form of prospectus (including a prospectus supplement) is filed with the Commission pursuant to Rule 424(b) and not retroactively. Unless otherwise specified, a reference to a \"Rule\" is to the indicated rule under the Act.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cai-international-inc-3174/contract/311177/#clause-id-667964", "variations": [{"variation_number": "Variation 1", "text": "Introductory. CAI International, Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\"), for whom B. Riley FBR, Inc. (\"FBR\") is acting as representative (the \"Representative\"), to issue and sell to the several Underwriters 1,600,000 shares (the \"Firm Securities\") of the 8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, liquidation preference $25.00 per share, of the Company (the \"Series A Preferred Stock\"), a new series of the Company's authorized preferred stock (the \"Preferred Stock\"). The Company also agrees to sell to the several Underwriters, at the option of the Underwriters, an aggregate of not more than 240,000 additional shares of Series A Preferred Stock (the \"Optional Securities\"). The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". This Underwriting Agreement (this \"Agreement\") confirms the agreement among the Company and the Underwriters concerning the purchase of the Offered Securities by the Underwriters. For purposes of this Agreement: \"430B Information\" means information included in a prospectus then deemed to be a part of the Registration Statement pursuant to Rule 430B(e) or retroactively deemed to be a part of the Registration Statement pursuant to Rule 430B(f). \"Act\" means the Securities Act of 1933, as amended. \"Applicable Time\" means 5:45 p.m. (Eastern time) on the date of this Agreement. \"Closing Date\" has the meaning defined in Section 3 hereof. \"Commission\" means the Securities and Exchange Commission. \"Effective Time\" of the Registration Statement relating to the Offered Securities means the time of the first contract of sale for the Offered Securities. \"Exchange Act\" means the Securities Exchange Act of 1934, as amended. 1 \"Final Prospectus\" means the Statutory Prospectus that discloses the public offering price, including any document incorporated by reference therein, other 430B Information and other final terms of the Offered Securities and otherwise satisfies Section 10(a) of the Act. \"General Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors, as evidenced by its being so specified in Schedule B to this Agreement. \"Issuer Free Writing Prospectus\" means any \"issuer free writing prospectus,\" as defined in Rule 433, relating to the Offered Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g). \"Limited Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is not a General Use Issuer Free Writing Prospectus. \"Rules and Regulations\" means the rules and regulations of the Commission. \"Securities Laws\" means, collectively, the Sarbanes-Oxley Act of 2002 (\"Sarbanes-Oxley\"), the Act, the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors of \"issuers\" (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board and, as applicable, the rules (\"Exchange Rules\") of the New York Stock Exchange (\"NYSE\"). \"Statutory Prospectus\" with reference to any particular time means the prospectus relating to the Offered Securities that is included in the Registration Statement immediately prior to that time, including any document incorporated by reference therein and all 430B Information with respect to the Registration Statement. For purposes of the foregoing definition, 430B Information shall be considered to be included in the Statutory Prospectus only as of the actual time that form of prospectus (including a prospectus supplement) is filed with the Commission pursuant to Rule 424(b) and not retroactively. Unless otherwise specified, a reference to a \"Rule\" is to the indicated rule under the Act.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/cai-international-inc-3174/contract/311177/#clause-id-667964"}, {"variation_number": "Variation 2", "text": "Introductory. <del>CAI International,</del>  <ins>SOC Telemed,</ins> Inc., a Delaware corporation <del>(\"Company\"), agrees with</del>  <ins>(the \"Company\"), proposes, upon the terms and conditions set forth in this agreement (the \"Agreement\"), to issue and sell to Credit Suisse Securities (USA) LLC (\"Credit Suisse\") and</ins> the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom <del>B. Riley FBR, Inc. (\"FBR\")</del>  <ins>Credit Suisse</ins> is acting as representative <ins>(in such capacity, the \"Representative\") [\u25cf] shares of its Cla ss A Common Stock, par value $0.0001 per share</ins> (the <del>\"Representative\"),</del>  <ins>\"Securities\") (such shares of Securities being hereinafter referred</ins> to <del>issue and sell to</del>  <ins>as</ins> the <del>several Underwriters 1,600,000 shares (the</del> \"Firm <del>Securities\") of the 8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, liquidation preference $25.00 per share, of the Company (the \"Series A Preferred Stock\"), a new series of the Company's authorized preferred stock (the \"Preferred Stock\").</del>  <ins>Securities\").</ins> The Company also <del>agrees</del>  <ins>proposes</ins> to sell to the <del>several</del> Underwriters, at the option of the Underwriters, an aggregate of not more than <del>240,000</del>  <ins>[\u25cf]</ins> additional shares of <del>Series A Preferred Stock (the</del>  <ins>its Securities (collectively, such [\u25cf] shares of Securities being hereinafter referred to as the</ins> \"Optional <del>Securities\").</del>  <ins>Securities\"), as set forth below.</ins> The Firm Securities and the Optional Securities are herein collectively called the \"Offered <del>Securities\". This Underwriting Agreement (this \"Agreement\") confirms the agreement among the Company and the Underwriters concerning the purchase of the Offered Securities by the Underwriters.</del>  <ins>Securities.\"</ins> For purposes of this Agreement: <del>\"430B Information\"</del>  <ins>\"430A Information\", with respect to any registration statement,</ins> means information included in a prospectus <del>then deemed to be a part of the Registration Statement pursuant to Rule 430B(e) or</del>  <ins>and</ins> retroactively deemed to be a part of <ins>such registration statement pursuant to Rule 430A(b). 430A Information with respect to</ins> the Registration Statement <del>pursuant</del>  <ins>(as defined in Section 2) shall be considered</ins> to <ins>be included in such Registration Statement as of the time specified in</ins> Rule <del>430B(f).</del>  <ins>430A.</ins> \"Act\" means the Securities Act of 1933, as amended. <ins>Unless otherwise specified, a reference to a \"rule\" is to the indicated rule under the Act.</ins> \"Applicable Time\" means <del>5:45 p.m. (Eastern</del>  <ins>[\u25cf]:00 [A.M.][P.M.] (New York City</ins> time) on the date of this Agreement. \"Closing Date\" has the meaning defined in Section 3 hereof. \"Commission\" means the Securities and Exchange Commission. \"Effective Time\" <ins>means the date and time as</ins> of <ins>which</ins> the Registration Statement <del>relating</del>  <ins>(as defined herein) became, or is deemed</ins> to <ins>have become, effective in accordance with</ins> the <del>Offered Securities means the time of the first contract of sale for the Offered Securities.</del>  <ins>Rules and Regulations.</ins> \"Exchange Act\" means the Securities Exchange Act of 1934, as amended. <del>1</del> \"Final Prospectus\" means the <del>Statutory Prospectus</del>  <ins>final prospectus</ins> that discloses the public offering price, <del>including any document incorporated by reference therein,</del> other <del>430B</del>  <ins>430A</ins> Information and other final terms of the Offered <del>Securities and otherwise satisfies Section 10(a) of</del>  <ins>Securities, as filed with the Commission pursuant to Rule 424(b) under</ins> the Act. <del>\"General Use Issuer Free</del>  <ins>\"Free</ins> Writing Prospectus\" means <del>any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors, as evidenced by its being so specified in Schedule B to this Agreement. \"Issuer Free Writing Prospectus\" means any \"issuer</del>  <ins>a</ins> free writing <del>prospectus,\"</del>  <ins>prospectus,</ins> as defined in Rule <del>433, relating to the Offered Securities</del>  <ins>405. \"Preliminary Prospectus\" means each prospectus included</ins> in the <del>form filed or required to be</del>  <ins>Registration Statement (and any amendments thereto) before effectiveness, any prospectus</ins> filed with the Commission <del>or, if not required to be filed, in the form retained in the Company's records</del> pursuant to Rule <del>433(g). \"Limited Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus</del>  <ins>424(a) under the Act and the prospectus included in the Registration Statement at the time of its effectiveness</ins> that <del>is not a General Use Issuer Free Writing Prospectus.</del>  <ins>omits Rule 430A Information.</ins> \"Rules and Regulations\" means the rules and regulations of the Commission. \"Securities Laws\" means, collectively, the Sarbanes-Oxley Act of <del>2002</del>  <ins>2002, as amended, and all rules and regulations promulgated thereunder or implementing the provisions thereof</ins> (\"Sarbanes-Oxley\"), the Act, the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors of \"issuers\" (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board <del>and, as applicable,</del>  <ins>and</ins> the rules <del>(\"Exchange Rules\")</del> of <del>the New York Stock Exchange (\"NYSE\").</del>  <ins>The Nasdaq Global Select Market (the \"Exchange Rules\").</ins> \"Statutory Prospectus\" <del>with reference to any particular time</del> means <ins>(i)</ins> the <del>prospectus</del>  <ins>Preliminary Prospectus, dated [\u25cf], 2021,</ins> relating to the Offered Securities <ins>and (ii) the other information, if any, set forth on Schedule B hereto, considered together. \"Testing-the-Waters Communication\" means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Act or Rule 163B. \"Written Testing-the-Waters Communication\" means any Testing-the-Waters Communication</ins> that is <del>included in</del>  <ins>a written communication within</ins> the <del>Registration Statement immediately prior to that time, including any document incorporated by reference therein and all 430B Information with respect to the Registration Statement. For purposes</del>  <ins>meaning</ins> of <del>the foregoing definition, 430B Information shall be considered to be included in the Statutory Prospectus only as of the actual time that form of prospectus (including a prospectus supplement) is filed with the Commission pursuant to</del> Rule <del>424(b) and not retroactively. Unless otherwise specified, a reference to a \"Rule\" is to the indicated rule</del>  <ins>405</ins> under the Act.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/healthcare-merger-corp-9763/contract/180533/#clause-id-372227"}, {"variation_number": "Variation 3", "text": "Introductory. <del>CAI International,</del>  <ins>SOC Telemed,</ins> Inc., a Delaware corporation <del>(\"Company\"), agrees with</del>  <ins>(the \"Company\"), proposes, upon the terms and conditions set forth in this agreement (the \"Agreement\"), to issue and sell to Credit Suisse Securities (USA) LLC (\"Credit Suisse\") and</ins> the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom <del>B. Riley FBR, Inc. (\"FBR\")</del>  <ins>Credit Suisse</ins> is acting as representative <ins>(in such capacity, the \"Representative\") 8,000,000 shares of i ts Class A Common Stock, par value $0.0001 per share</ins> (the <del>\"Representative\"),</del>  <ins>\"Securities\") (such shares of Securities being hereinafter referred</ins> to <del>issue and sell to</del>  <ins>as</ins> the <del>several Underwriters 1,600,000 shares (the</del> \"Firm <del>Securities\") of the 8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, liquidation preference $25.00 per share, of the Company (the \"Series A Preferred Stock\"), a new series of the Company's authorized preferred stock (the \"Preferred Stock\").</del>  <ins>Securities\").</ins> The Company also <del>agrees</del>  <ins>proposes</ins> to sell to the <del>several</del> Underwriters, at the option of the Underwriters, an aggregate of not more than <del>240,000</del>  <ins>1,200,000</ins> additional shares of <del>Series A Preferred Stock (the</del>  <ins>its Securities (collectively, such 1,200,000 shares of Securities being hereinafter referred to as the</ins> \"Optional <del>Securities\").</del>  <ins>Securities\"), as set forth below.</ins> The Firm Securities and the Optional Securities are herein collectively called the \"Offered <del>Securities\". This Underwriting Agreement (this \"Agreement\") confirms the agreement among the Company and the Underwriters concerning the purchase of the Offered Securities by the Underwriters.</del>  <ins>Securities.\"</ins> For purposes of this Agreement: <del>\"430B Information\"</del>  <ins>\"430A Information\", with respect to any registration statement,</ins> means information included in a prospectus <del>then deemed to be a part of the Registration Statement pursuant to Rule 430B(e) or</del>  <ins>and</ins> retroactively deemed to be a part of <ins>such registration statement pursuant to Rule 430A(b). 430A Information with respect to</ins> the Registration Statement <del>pursuant</del>  <ins>(as defined in Section 2) shall be considered</ins> to <ins>be included in such Registration Statement as of the time specified in</ins> Rule <del>430B(f).</del>  <ins>430A.</ins> \"Act\" means the Securities Act of 1933, as amended. <ins>Unless otherwise specified, a reference to a \"rule\" is to the indicated rule under the Act.</ins> \"Applicable Time\" means <del>5:45 p.m. (Eastern</del>  <ins>6:00 P.M. (New York City</ins> time) on the date of this Agreement. \"Closing Date\" has the meaning defined in Section 3 hereof. \"Commission\" means the Securities and Exchange Commission. \"Effective Time\" <ins>means the date and time as</ins> of <ins>which</ins> the Registration Statement <del>relating</del>  <ins>(as defined herein) became, or is deemed</ins> to <ins>have become, effective in accordance with</ins> the <del>Offered Securities means the time of the first contract of sale for the Offered Securities.</del>  <ins>Rules and Regulations.</ins> \"Exchange Act\" means the Securities Exchange Act of 1934, as amended. <del>1</del> \"Final Prospectus\" means the <del>Statutory Prospectus</del>  <ins>final prospectus</ins> that discloses the public offering price, <del>including any document incorporated by reference therein,</del> other <del>430B</del>  <ins>430A</ins> Information and other final terms of the Offered <del>Securities and otherwise satisfies Section 10(a) of</del>  <ins>Securities, as filed with the Commission pursuant to Rule 424(b) under</ins> the Act. <del>\"General Use Issuer Free</del>  <ins>\"Free</ins> Writing Prospectus\" means <del>any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors, as evidenced by its being so specified in Schedule B to this Agreement. \"Issuer Free Writing Prospectus\" means any \"issuer</del>  <ins>a</ins> free writing <del>prospectus,\"</del>  <ins>prospectus,</ins> as defined in Rule <del>433, relating to the Offered Securities</del>  <ins>405. \"Preliminary Prospectus\" means each prospectus included</ins> in the <del>form filed or required to be</del>  <ins>Registration Statement (and any amendments thereto) before effectiveness, any prospectus</ins> filed with the Commission <del>or, if not required to be filed, in the form retained in the Company's records</del> pursuant to Rule <del>433(g). \"Limited Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus</del>  <ins>424(a) under the Act and the prospectus included in the Registration Statement at the time of its effectiveness</ins> that <del>is not a General Use Issuer Free Writing Prospectus.</del>  <ins>omits Rule 430A Information.</ins> \"Rules and Regulations\" means the rules and regulations of the Commission. \"Securities Laws\" means, collectively, the Sarbanes-Oxley Act of <del>2002</del>  <ins>2002, as amended, and all rules and regulations promulgated thereunder or implementing the provisions thereof</ins> (\"Sarbanes-Oxley\"), the Act, the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors of \"issuers\" (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board <del>and, as applicable,</del>  <ins>and</ins> the rules <del>(\"Exchange Rules\")</del> of <del>the New York Stock Exchange (\"NYSE\").</del>  <ins>The Nasdaq Global Select Market (the \"Exchange Rules\").</ins> \"Statutory Prospectus\" <del>with reference to any particular time</del> means <ins>(i)</ins> the <del>prospectus</del>  <ins>Preliminary Prospectus, dated May 24, 2021,</ins> relating to the Offered Securities <ins>and (ii) the other information, if any, set forth on Schedule B hereto, considered together. \"Testing-the-Waters Communication\" means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Act or Rule 163B. \"Written Testing-the-Waters Communication\" means any Testing-the-Waters Communication</ins> that is <del>included in</del>  <ins>a written communication within</ins> the <del>Registration Statement immediately prior to that time, including any document incorporated by reference therein and all 430B Information with respect to the Registration Statement. For purposes</del>  <ins>meaning</ins> of <del>the foregoing definition, 430B Information shall be considered to be included in the Statutory Prospectus only as of the actual time that form of prospectus (including a prospectus supplement) is filed with the Commission pursuant to</del> Rule <del>424(b) and not retroactively. Unless otherwise specified, a reference to a \"Rule\" is to the indicated rule</del>  <ins>405</ins> under the Act.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/healthcare-merger-corp-9763/contract/181294/#clause-id-374156"}, {"variation_number": "Variation 4", "text": "Introductory. <del>CAI International, Inc.,</del>  <ins>HireRight Holdings Corporation,</ins> a Delaware corporation <del>(\"Company\"), agrees with</del>  <ins>(the \"Company\") or its successor or parent entity following a corporate conversion or any substantially similar transaction as described under the caption \"Corporate Conversion\" in the Registration Statement and the final prospectus relating to the Public Offering (as defined below), proposes, upon the terms and conditions set forth in this agreement (the \"Agreement\"), to issue and sell to Cr edit Suisse Securities (USA) LLC (\"Credit Suisse\"), Goldman Sachs & Co. LLC (\"Goldman Sachs\") and</ins> the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(the \"Underwriters\"),</ins> for whom <del>B. Riley FBR, Inc. (\"FBR\") is</del>  <ins>Credit Suisse and Goldman Sachs are</ins> acting as <del>representative</del>  <ins>representatives (in such capacity, the \"Representatives\") [ o\u0300 ] shares of its common stock, par value $0.001 per share</ins> (the <del>\"Representative\"),</del>  <ins>\"Securities\", such [ o\u0300 ] shares of Securities being hereinafter referred</ins> to <del>issue and sell to</del>  <ins>as</ins> the <del>several Underwriters 1,600,000 shares (the</del> \"Firm <del>Securities\") of the 8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, liquidation preference $25.00 per share, of the Company (the \"Series A Preferred Stock\"), a new series of the Company's authorized preferred stock (the \"Preferred Stock\").</del>  <ins>Securities\").</ins> The Company also <del>agrees</del>  <ins>proposes</ins> to sell to the <del>several</del> Underwriters, at the option of the Underwriters, an aggregate of not more than <del>240,000</del>  <ins>[ o\u0300 ]</ins> additional shares of <del>Series A Preferred Stock</del>  <ins>its Securities</ins> (the \"Optional <del>Securities\").</del>  <ins>Securities\"), as set forth below.</ins> The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <del>This Underwriting Agreement (this \"Agreement\") confirms the agreement among the Company and the Underwriters concerning the purchase of the Offered Securities by the Underwriters.</del> For purposes of this <del>Agreement: \"430B Information\"</del>  <ins>Agreement:\"430A Information\", with respect to any registration statement,</ins> means information included in a prospectus <del>then deemed to be a part of the Registration Statement pursuant to Rule 430B(e) or</del>  <ins>and</ins> retroactively deemed to be a part of <ins>such registration statement pursuant to Rule 430A(b). 430A Information with respect to</ins> the Registration Statement <del>pursuant</del>  <ins>(as defined in Section 2) shall be considered</ins> to <ins>be included in such Registration Statement as of the time specified in</ins> Rule <del>430B(f). \"Act\"</del>  <ins>430A.\"Act\"</ins> means the Securities Act of 1933, as <del>amended. \"Applicable</del>  <ins>amended.\"Applicable</ins> Time\" means <del>5:45 p.m. (Eastern</del>  <ins>[ o\u0300 ]:00 pm (New York City</ins> time) on the date of this <del>Agreement. \"Closing</del>  <ins>Agreement.\"Closing</ins> Date\" has the meaning defined in Section 3 <del>hereof. \"Commission\"</del>  <ins>hereof.\"Commission\"</ins> means the Securities and Exchange <del>Commission. \"Effective</del>  <ins>Commission.\"Effective</ins> Time\" <ins>means the date and time as</ins> of <del>the</del>  <ins>which such</ins> Registration Statement <del>relating</del>  <ins>was declared effective by the Commission became, or is deemed</ins> to <ins>have become, effective in accordance with</ins> the <del>Offered Securities means the time of the first contract of sale for the Offered Securities.</del>  <ins>Rules and Regulations.</ins> \"Exchange Act\" means the Securities Exchange Act of 1934, as <del>amended. 1</del>  <ins>amended.1</ins> \"Final Prospectus\" means the <del>Statutory Prospectus</del>  <ins>final prospectus</ins> that discloses the public offering price, <del>including any document incorporated by reference therein,</del> other <del>430B</del>  <ins>430A</ins> Information and other final terms of the Offered <del>Securities and otherwise satisfies Section 10(a) of</del>  <ins>Securities, as filed with</ins> the <del>Act. \"General</del>  <ins>Commission pursuant to Rule 424(b) under the Act.\"General</ins> Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors, as evidenced by its being so specified in Schedule B to this <del>Agreement. \"Issuer</del>  <ins>Agreement.\"Issuer</ins> Free Writing Prospectus\" means any \"issuer free writing prospectus,\" as defined in Rule 433, relating to the Offered Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule <del>433(g). \"Limited</del>  <ins>433(g).\"Limited</ins> Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is not a General Use Issuer Free Writing <del>Prospectus.</del>  <ins>Prospectus.\"Preliminary Prospectus\" means each prospectus used prior to the effectiveness of the Registration Statement and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430A Information.</ins> \"Rules and Regulations\" means the rules and regulations of the Commission. \"Securities Laws\" means, collectively, the Sarbanes-Oxley Act of <del>2002</del>  <ins>2002, as amended and all rules and regulations promulgated thereunder or implementing the provisions thereof</ins> (\"Sarbanes-Oxley\"), the Act, the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors of \"issuers\" (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board and, as applicable, the rules <del>(\"Exchange Rules\")</del> of <del>the</del>  <ins>The</ins> New York Stock Exchange <del>(\"NYSE\"). \"Statutory Prospectus\"</del>  <ins>(the \"Exchange Rules\").\"Testing-the-Waters Communication\" means any oral or written communication</ins> with <del>reference to</del>  <ins>potential investors undertaken in reliance on Section 5(d) of the Act or Rule 163B.\"Written Testing-the-Waters Communication\" means</ins> any <del>particular time means the prospectus relating to the Offered Securities</del>  <ins>Testing-the-Waters Communication</ins> that is <del>included in</del>  <ins>a written communication within</ins> the <del>Registration Statement immediately prior to that time, including any document incorporated by reference therein and all 430B Information with respect to</del>  <ins>meaning of Rule 405 under</ins> the <del>Registration Statement. For purposes of the foregoing definition, 430B Information shall be considered to be included in the Statutory Prospectus only as of the actual time that form of prospectus (including a prospectus supplement) is filed with the Commission pursuant to Rule 424(b) and not retroactively. Unless</del>  <ins>Act.Unless</ins> otherwise specified, a reference to a <del>\"Rule\"</del>  <ins>\"rule\"</ins> is to the indicated rule under the Act.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/hireright-gis-group-holdings-llc-14046/contract/203887/#clause-id-432682"}, {"variation_number": "Variation 5", "text": "Introductory. <del>CAI International,</del>  <ins>United Rentals (North America),</ins> Inc., a Delaware corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto <del>(\"Underwriters\"),</del>  <ins>(\"Underwriters\")</ins> for whom <del>B. Riley FBR, Inc. (\"FBR\") is</del>  <ins>you are</ins> acting as representative (the <del>\"Representative\"),</del>  <ins>\"Representative\")</ins> to issue and sell to the several Underwriters <del>1,600,000 shares</del>  <ins>$800,000,000 principal amount of its 5.500% Senior Notes due 2025</ins> (the <del>\"Firm Securities\") of the 8.50% Series A Fixed-to-Floating R</del><ins>\"Notes\"). The Notes will be unconditionally guaranteed (each, a \"Guaranty\") on a senior basis by United Rentals, Inc., a Delaware corporation and parent</ins> of the Company <del>(the \"Series A Preferred Stock\"), a new series</del>  <ins>(\"Holdings\"), and each</ins> of the Company's <del>authorized preferred stock</del>  <ins>subsidiaries listed on Schedule B hereto</ins> (the <del>\"Preferred Stock\").</del>  <ins>\"Subsidiary Guarantors\" and, together with Holdings, the \"Guarantors\").</ins> The <ins>Notes will also be guaranteed by each subsequently organized domestic subsidiary of the</ins> Company <del>also agrees</del>  <ins>that becomes a guarantor pursuant</ins> to <ins>the Indenture (as hereinafter defined). The Notes will be issued under an indenture, dated as of March 26, 2015 (the \"Indenture\"), among the Company, the Guarantors and Wells Fargo Bank, National Association, as trustee (the \"Trustee\"). The Notes and the Guarantees are together referred to as the \"Offered Securities\". Substantially concurrently with the issuance of the Offered Securities, the Company will issue and</ins> sell to the several <del>Underwriters, at</del>  <ins>Underwriters $1,000,000,000 principal amount of its 4.625% Senior Secured Notes due 2023 (the \"Senior Secured Notes\"). This Agreement,</ins> the <del>option of the Underwriters, an aggregate of not more than 240,000 additional shares of Series A Preferred Stock (the \"Optional Securities\"). The Firm Securities</del>  <ins>Indenture</ins> and the <del>Optional</del>  <ins>Offered</ins> Securities are <ins>referred to</ins> herein <del>collectively called</del>  <ins>as</ins> the <del>\"Offered Securities\". This Underwriting Agreement (this \"Agreement\") confirms the agreement among the</del>  <ins>\"Operative Documents\". The</ins> Company and the <ins>Guarantors jointly and severally agree with the several</ins> Underwriters <del>concerning the purchase of the Offered Securities by the Underwriters.</del>  <ins>as follows:</ins> For purposes of this <del>Agreement:</del>  <ins>Underwriting Agreement (this \"Agreement\"):</ins> \"430B Information\" means information included in a prospectus then deemed to be a part of the Registration Statement pursuant to Rule 430B(e) or retroactively deemed to be a part of the Registration Statement pursuant to Rule 430B(f). <ins>\"430C Information\" means information included in a prospectus then deemed to be a part of the Registration Statement pursuant to Rule 430C.</ins> \"Act\" means the Securities Act of 1933, as amended. \"Applicable Time\" means <del>5:45</del>  <ins>3:00</ins> p.m. <del>(Eastern time)</del>  <ins>New York City time</ins> on the date of this Agreement. <del>\"Closing Date\" has the meaning defined in Section 3 hereof.</del> \"Commission\" means the Securities and Exchange Commission. \"Effective Time\" of the Registration Statement relating to the Offered Securities means the time of the first contract of sale for the Offered Securities. \"Exchange Act\" means the Securities Exchange Act of 1934, as amended. <del>1</del> \"Final Prospectus\" means the Statutory Prospectus that discloses the public offering price, <del>including any document incorporated by reference therein,</del> other 430B Information and other final terms of the Offered Securities and otherwise satisfies Section 10(a) of the Act. \"General Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors, as evidenced by its being so specified in Schedule <del>B</del>  <ins>C</ins> to this Agreement. \"Issuer Free Writing Prospectus\" means any \"issuer free writing prospectus,\" as defined in Rule 433, relating to the Offered Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g). \"Limited Use Issuer Free Writing Prospectus\" means any Issuer Free Writing Prospectus that is not a General Use Issuer Free Writing Prospectus. \"Rules and Regulations\" means the rules and regulations of the Commission. \"Securities Laws\" means, collectively, the Sarbanes-Oxley Act of 2002 (\"Sarbanes-Oxley\"), the Act, the Exchange Act, the <ins>Trust Indenture Act, the</ins> Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors of \"issuers\" (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board <del>and, as applicable,</del>  <ins>and</ins> the rules <del>(\"Exchange Rules\")</del> of the New York Stock Exchange <del>(\"NYSE\").</del>  <ins>(\"Exchange Rules\").</ins> \"Statutory Prospectus\" with reference to any particular time means the prospectus relating to the Offered Securities that is included in the Registration Statement immediately prior to that time, including <del>any document incorporated by reference therein</del>  <ins>all 430B Information</ins> and all <del>430B</del>  <ins>430C</ins> Information with respect to the Registration Statement. For purposes of the foregoing definition, 430B Information shall be considered to be included in the Statutory Prospectus only as of the actual time that form of prospectus (including a prospectus supplement) is filed with the Commission pursuant to Rule 424(b) and not retroactively. <ins>\"Trust Indenture Act\" means the Trust Indenture Act of 1939, as amended. 2</ins> Unless otherwise specified, a reference to a <del>\"Rule\"</del>  <ins>\"rule\"</ins> is to the indicated rule under the Act.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/united-rentals-north-america-inc-1762/contract/391474/#clause-id-831897"}]}
{"clause_number": "Clause 6", "title": "Introductory", "text": "Introductory. Avidity Biosciences, Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of [\u2022] shares of common stock, $0.0001 par value per share (the \"Common Stock\") of the Company. The aggregate of [\u2022] shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [\u2022] shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to \"subsidiaries\" of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/avidity-biosciences-inc-10583/contract/118698/#clause-id-221801", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Avidity Biosciences, Inc., a Delaware corporation (the \u201cCompany\u201d), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \u201cUnderwriters,\u201d or, each, an \u201cUnderwriter\u201d), an aggregate of [\u2022] shares of common stock, $0.0001 par value per share (the \u201cCommon Stock\u201d) of the Company. The aggregate of [\u2022] shares so proposed to be sold is hereinafter referred to as the \u201cFirm Stock\u201d. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [\u2022] shares of Common Stock (the \u201cOptional Stock\u201d). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \u201cStock\u201d. Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \u201cRepresentatives.\u201d In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to \u201csubsidiaries\u201d of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/avidity-biosciences-inc-10583/contract/118698/#clause-id-221801"}, {"variation_number": "Variation 2", "text": "Introductory. <del>Avidity Biosciences, Inc.,</del>  <ins>Angion Biomedica Corp.,</ins> a Delaware corporation (the \u201cCompany\u201d), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \u201cUnderwriters,\u201d or, each, an \u201cUnderwriter\u201d), an aggregate of <del>[\u2022]</del>  <ins>[\u00b7]</ins> shares of common stock, <del>$0.0001</del>  <ins>$0.01</ins> par value <del>per share</del> (the \u201cCommon Stock\u201d) of the Company. The aggregate of <del>[\u2022]</del>  <ins>[\u00b7]</ins> shares so proposed to be sold is hereinafter referred to as the \u201cFirm Stock\u201d. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>[\u2022]</del>  <ins>[\u00b7]</ins> shares of Common Stock (the \u201cOptional Stock\u201d). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \u201cStock\u201d. Cowen and Company, <del>LLC, SVB Leerink LLC, Credit Suisse Securities (USA)</del> LLC <ins>(\u201cCowen\u201d)</ins> and <del>Wells Fargo Securities, LLC</del>  <ins>Stifel, Nicolaus & Company, Incorporated</ins> are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \u201cRepresentatives.\u201d In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to \u201csubsidiaries\u201d of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/angion-biomedica-corp-11883/contract/150365/#clause-id-302652"}, {"variation_number": "Variation 3", "text": "Introductory. Avidity Biosciences, Inc., a Delaware corporation (the \u201cCompany\u201d), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \u201cUnderwriters,\u201d or, each, an \u201cUnderwriter\u201d), an aggregate of <del>[\u2022]</del>  <ins>12,000,000</ins> shares of common stock, $0.0001 par value per share (the \u201cCommon Stock\u201d) of the Company. The aggregate of <del>[\u2022]</del>  <ins>12,000,000</ins> shares so proposed to be sold is hereinafter referred to as the \u201cFirm Stock\u201d. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>[\u2022]</del>  <ins>1,800,000</ins> shares of Common Stock (the \u201cOptional Stock\u201d). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \u201cStock\u201d. Cowen and Company, LLC, <del>SVB Leerink LLC, Credit Suisse Securities (USA) LLC</del>  <ins>Evercore Group L.L.C.</ins> and Wells Fargo Securities, LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \u201cRepresentatives.\u201d In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to \u201csubsidiaries\u201d of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/avidity-biosciences-inc-10583/contract/263483/#clause-id-555550"}, {"variation_number": "Variation 4", "text": "Introductory. <del>Avidity</del>  <ins>Aura</ins> Biosciences, Inc., a Delaware corporation (the \u201cCompany\u201d), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \u201cUnderwriters,\u201d or, each, an \u201cUnderwriter\u201d), an aggregate of [\u2022] shares of common stock, <del>$0.0001</del>  <ins>$[\u2022]</ins> par value <del>per share</del> (the \u201cCommon Stock\u201d) of the Company. The aggregate of [\u2022] shares so proposed to be sold is hereinafter referred to as the \u201cFirm Stock\u201d. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [\u2022] shares of Common Stock (the \u201cOptional Stock\u201d). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \u201cStock\u201d. Cowen and Company, <del>LLC,</del>  <ins>LLC (\u201cCowen\u201d),</ins> SVB Leerink <del>LLC, Credit Suisse Securities (USA)</del> LLC <ins>(\u201cSVB Leerink\u201d)</ins> and <del>Wells Fargo Securities, LLC</del>  <ins>Evercore Group L.L.C. (\u201cEvercore\u201d)</ins> are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \u201cRepresentatives.\u201d In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to \u201csubsidiaries\u201d of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/aura-biosciences-inc-14060/contract/204456/#clause-id-434550"}, {"variation_number": "Variation 5", "text": "Introductory. <del>Avidity</del>  <ins>Aura</ins> Biosciences, Inc., a Delaware corporation (the \u201cCompany\u201d), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \u201cUnderwriters,\u201d or, each, an \u201cUnderwriter\u201d), an aggregate of <del>[\u2022]</del>  <ins>6,700,000</ins> shares of common stock, <del>$0.0001</del>  <ins>$0.00001</ins> par value per share (the \u201cCommon Stock\u201d) of the Company. The aggregate of <del>[\u2022]</del>  <ins>6,700,000</ins> shares so proposed to be sold is hereinafter referred to as the \u201cFirm Stock\u201d. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>[\u2022]</del>  <ins>1,005,000</ins> shares of Common Stock (the \u201cOptional Stock\u201d). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the <del>\u201cStock\u201d.</del>  <ins>\u201cStock.\u201d SVB Securities LLC (\u201cSVB Securities\u201d),</ins> Cowen and Company, <del>LLC, SVB Leerink LLC, Credit Suisse Securities (USA)</del> LLC <ins>(\u201cCowen\u201d)</ins> and <del>Wells Fargo Securities, LLC</del>  <ins>Evercore Group L.L.C. (\u201cEvercore\u201d)</ins> are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \u201cRepresentatives.\u201d In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to \u201csubsidiaries\u201d of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/aura-biosciences-inc-14060/contract/262286/#clause-id-552993"}]}
{"clause_number": "Clause 7", "title": "Introductory", "text": "Introductory. 908 Devices Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of [\u25cf] shares of common stock, $0.001 par value (the \"Common Stock\") of the Company. The aggregate of [\u25cf] shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [\u25cf] shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC and SVB Leerink LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, Cowen (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to 250,000 shares for sale to the Company's directors, officers, employees, individual stockholders, business associates and other persons with whom we have a relationship (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the public offering price. Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/908-devices-inc-11615/contract/142401/#clause-id-279858", "variations": [{"variation_number": "Variation 1", "text": "Introductory. 908 Devices Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of [\u25cf] shares of common stock, $0.001 par value (the \"Common Stock\") of the Company. The aggregate of [\u25cf] shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters, upon the terms andconditions set forth in Section 3 hereof, up to an additional [\u25cf] shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC and SVB Leerink LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, Cowen (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to 250,000 shares for sale to the Company's directors, officers, employees, individual stockholders, business associates and other persons with whom we have a relationship (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the public offering price. Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/908-devices-inc-11615/contract/142401/#clause-id-279858"}, {"variation_number": "Variation 2", "text": "Introductory. <del>908 Devices</del>  <ins>Praxis Precision Medicines,</ins> Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of [\u25cf] shares of common stock, <del>$0.001</del>  <ins>$0.0001</ins> par value (the \"Common Stock\") of the Company. The aggregate of [\u25cf] shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to theUnderwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [\u25cf] shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC <ins>(\"Cowen\"), Evercore Group L.L.C. (\"Evercore\"),</ins> and <del>SVB Leerink LLC</del>  <ins>Piper Sandler & Co. (\"Piper\")</ins> are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, <del>Cowen (the \"Designated Underwriter\") has</del>  <ins>the Underwriters have</ins> agreed to reserve out of the Firm Stock purchased by it under this Agreement up to <del>250,000</del>  <ins>[\u25cf]</ins> shares for sale to the Company's <ins>and its subsidiaries' officers,</ins> directors, <ins>employees, customers and friends of the Company's and its subsidiaries'</ins> officers, <del>employees, individual stockholders, business associates</del>  <ins>directors</ins> and <del>other persons with whom we have a relationship</del>  <ins>employees</ins> (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the <del>Designated Underwriter</del>  <ins>Underwriters</ins> pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the <del>Designated Underwriter pursuant to this Agreement</del>  <ins>Underwriters</ins> at the public offering price. Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/praxis-precision-medicines-inc-11215/contract/132522/#clause-id-255527"}, {"variation_number": "Variation 3", "text": "Introductory. <del>908 Devices</del>  <ins>Sutro Biopharma,</ins> Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of <del>[\u25cf]</del>  <ins>[\u2022]</ins> shares of common stock, $0.001 par value (the \"Common Stock\") of the Company. The aggregate of <del>[\u25cf]</del>  <ins>[\u2022]</ins> shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters,upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>[\u25cf]</del>  <ins>[\u2022]</ins> shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC and <del>SVB Leerink LLC</del>  <ins>Piper Jaffray & Co.</ins> are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, Cowen <ins>and Company, LLC</ins> (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to <del>250,000</del>  <ins>[\u2022]</ins> shares for sale to the Company's <ins>officers,</ins> directors, <ins>employees, customers [and business partners] and friends and family members of the Company's</ins> officers, <del>employees, individual stockholders, business associates</del>  <ins>directors</ins> and <del>other persons with whom we have a relationship</del>  <ins>employees</ins> (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the <del>public offering price.</del>  <ins>Offering Price set forth in Schedule C hereto.</ins> Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/sutro-biopharma-inc-8063/contract/288120/#clause-id-606238"}, {"variation_number": "Variation 4", "text": "Introductory. <del>908 Devices</del>  <ins>Aeglea BioTherapeutics,</ins> Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of <del>[\u25cf]</del>  <ins>[ ]</ins> shares of common stock, <del>$0.001</del>  <ins>$0.0001</ins> par value <ins>per share</ins> (the \"Common Stock\") of the Company. The aggregate of <del>[\u25cf]</del>  <ins>[ ]</ins> shares so proposed to be sold is hereinafter referred to as the \"Firm <del>Stock\".</del>  <ins>Stock.\"</ins> The Company alsoproposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>[\u25cf]</del>  <ins>[ ]</ins> shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the <del>\"Stock\". Cowen</del>  <ins>\"Stock.\" UBS Securities LLC (\"UBS\"), BMO Capital Markets Corp. (\"BMO\")</ins> and <del>Company, LLC and SVB Leerink</del>  <ins>Wells Fargo Securities,</ins> LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, <del>Cowen</del>  <ins>UBS Financial Services Inc.</ins> (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to <del>250,000</del>  <ins>[\u25cf]</ins> shares <ins>of Stock</ins> for sale to the Company's <ins>and its subsidiaries'</ins> directors, officers, <del>employees, individual stockholders, business associates</del>  <ins>employees</ins> and other <del>persons</del>  <ins>individuals associated</ins> with <del>whom we have a relationship</del>  <ins>the Company and its subsidiaries and members of their families</ins> (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the <del>public offering price.</del>  <ins>Offering Price set forth in Schedule B hereto.</ins> Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/aeglea-biotherapeutics-inc-5157/contract/370066/#clause-id-799112"}]}
{"clause_number": "Clause 8", "title": "Introductory", "text": "Introductory. Phillips 66, a Delaware corporation (the \"Company\"), and Phillips 66 Company, a Delaware corporation (the \"Guarantor\"), propose that the Company will issue and sell from time to time certain of its unsecured debt securities that will be fully and unconditionally guaranteed by the Guarantor registered under the registration statement referred to in Section 2(a) (such securities, including the guarantee relating thereto by the Guarantor (the \"Guarantee\"), being hereinafter called the \"Registered Securities\"). The Registered Securities will be issued under the Indenture, dated as of March 12, 2012 (the \"Indenture\"), among the Company, the Guarantor and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\"), in one or more series, which series may vary as to interest rates, maturities, redemption provisions, selling prices and other terms, with all such terms for any particular series of the Registered Securities being determined at the time of sale. Particular series of the Registered Securities will be sold pursuant to a Terms Agreement referred to in Section 3, for resale in accordance with terms of offering determined at the time of sale. The Registered Securities involved in any such offering are hereinafter referred to as the \"Offered Securities\". The firm or firms which agree to purchase the Offered Securities, as set forth in a Terms Agreement referred to in Section 3 hereof, are hereinafter referred to as the \"Underwriters\" of such securities, and the representative or representatives of the Underwriters, if any, specified in a Terms Agreement referred to in Section 3 are hereinafter referred to as the \"Representatives\"; provided, however, that if the Terms Agreement does not specify any representative of the Underwriters, the term \"Representatives\", as used in this Agreement (other than in Sections 2(b), 2(c), 2(f) and 6 and the second sentence of Section 3), shall mean the Underwriters.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/phillips-66-1047/contract/313270/#clause-id-673713", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Phillips 66, a Delaware corporation (the \"Company\"), and Phillips 66 Company, a Delaware corporation (the \"Guarantor\"), propose that the Company will issue and sell from time to time certain of its unsecured debt securities that will be fully and unconditionally guaranteed by the Guarantor registered under the registration statement referred to in Section 2(a) (such securities, including the guarantee relating thereto by the Guarantor (the \"Guarantee\"), being hereinafter called the \"RegisteredSecurities\"). The Registered Securities will be issued under the Indenture, dated as of March 12, 2012 (the \"Indenture\"), among the Company, the Guarantor and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\"), in one or more series, which series may vary as to interest rates, maturities, redemption provisions, selling prices and other terms, with all such terms for any particular series of the Registered Securities being determined at the time of sale. Particular series of the Registered Securities will be sold pursuant to a Terms Agreement referred to in Section 3, for resale in accordance with terms of offering determined at the time of sale. The Registered Securities involved in any such offering are hereinafter referred to as the \"Offered Securities\". The firm or firms which agree to purchase the Offered Securities, as set forth in a Terms Agreement referred to in Section 3 hereof, are hereinafter referred to as the \"Underwriters\" of such securities, and the representative or representatives of the Underwriters, if any, specified in a Terms Agreement referred to in Section 3 are hereinafter referred to as the \"Representatives\"; provided, however, that if the Terms Agreement does not specify any representative of the Underwriters, the term \"Representatives\", as used in this Agreement (other than in Sections 2(b), 2(c), 2(f) and 6 and the second sentence of Section 3), shall mean the Underwriters.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/phillips-66-1047/contract/313270/#clause-id-673713"}, {"variation_number": "Variation 2", "text": "Introductory. Phillips <del>66,</del>  <ins>66 Company,</ins> a Delaware corporation (the \"Company\"), and Phillips <del>66 Company,</del>  <ins>66,</ins> a Delaware corporation (the \"Guarantor\"), propose that the Company will issue and sell from time to time certain of its unsecured debt securities that will be fully and unconditionally guaranteed by the Guarantor registered under the registration statement referred to in Section 2(a) (such securities, including the guarantee relating thereto by the Guarantor (the \"Guarantee\"), being hereinafter calledthe \"Registered Securities\"). The Registered Securities will be issued under the Indenture, dated as of <del>March 12, 2012</del>  <ins>May 5, 2022</ins> (the \"Indenture\"), among the Company, the Guarantor and <del>The</del>  <ins>U.S.</ins> Bank <del>of New York Mellon</del> Trust Company, <del>N.A.,</del>  <ins>National Association,</ins> as trustee (the \"Trustee\"), in one or more series, which series may vary as to interest rates, maturities, redemption provisions, selling prices and other terms, with all such terms for any particular series of the Registered Securities being determined at the time of sale. Particular series of the Registered Securities will be sold pursuant to a Terms Agreement referred to in Section 3, for resale in accordance with terms of offering determined at the time of sale. The Registered Securities involved in any such offering are hereinafter referred to as the \"Offered Securities\". The firm or firms which agree to purchase the Offered Securities, as set forth in a Terms Agreement referred to in Section <del>3 hereof,</del>  <ins>3,</ins> are hereinafter referred to as the \"Underwriters\" of such securities, and the representative or representatives of the Underwriters, if any, specified in a Terms Agreement referred to in Section 3 are hereinafter referred to as the \"Representatives\"; provided, however, that if the Terms Agreement does not specify any representative of the Underwriters, the term \"Representatives\", as used in this Agreement (other than in Sections 2(b), 2(c), 2(f) and 6 and the second sentence of Section 3), shall mean the Underwriters. <ins>The Offered Securities are being issued and sold in connection with the merger (the \"Merger\") of Dynamo Merger Sub LLC, a Delaware limited liability company (the \"Merger Sub\"), with and into DCP Midstream, LP, a Delaware limited partnership (the \"Partnership\"), with the Partnership surviving the Merger, pursuant to a Agreement and Plan of Merger, dated as of January 5, 2023 (as may be amended and supplemented from time to time, the \"Merger Agreement\"), by and among the Guarantor, Phillips 66 Project Development Inc., the Merger Sub, the Partnership, DCP Midstream GP, LP and DCP Midstream GP, LLC. Subject to the terms of the Indenture, the Company will be required to redeem the Offered Securities of each series then outstanding at a special mandatory redemption price equal to 101% of the principal amount of the Offered Securities to be redeemed plus accrued and unpaid interest to the date of redemption upon the first occurrence of any of the following events: (a) the closing of the Merger does not occur on or prior to 11:59 p.m., New York City Time, on December 31, 2023 (the \"Special Mandatory Redemption End Date\"), (b) the Merger Agreement is terminated prior to the Special Mandatory Redemption End Date without the closing of the Merger or (c) the Company notifies the trustee of the Offered Securities in writing that in the Guarantor's reasonable judgment the Merger will not be consummated on or prior to the Special Mandatory Redemption End Date. The Company intends to use the net proceeds of the Offered Securities, together with borrowings under its $1.5 billion delayed draw term loan credit agreement, by and among the Company, the Guarantor, the lenders party thereto and Mizuho Bank, Ltd., as administrative agent, and cash on hand, to finance the merger consideration payable in the Merger. Prior to closing of the Merger, the Company may use the net proceeds of the Offered Securities for general corporate purposes.</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/phillips-66-1047/contract/285520/#clause-id-600135"}, {"variation_number": "Variation 3", "text": "Introductory. <del>Phillips 66,</del>  <ins>ConocoPhillips,</ins> a Delaware corporation (the \"Company\"), and <del>Phillips 66</del>  <ins>ConocoPhillips</ins> Company, a Delaware corporation <ins>and a wholly owned subsidiary of the Company</ins> (the <del>\"Guarantor\"),</del>  <ins>\"Issuer\"),</ins> propose that the <del>Company</del>  <ins>Issuer</ins> will issue and sell from time to time certain of its unsecured debt securities <del>that will be</del> fully and unconditionally guaranteed by the <del>Guarantor</del>  <ins>Company</ins> registered under the registration statement referred to in Section 2(a) (such securities, including theguarantee relating thereto by the <del>Guarantor</del>  <ins>Company</ins> (the \"Guarantee\"), being hereinafter called the \"Registered Securities\"). The Registered Securities will be issued under <del>the Indenture,</del>  <ins>an indenture,</ins> dated as <del>of March 12, 2012</del>  <ins>May 18, 2015</ins> (the \"Indenture\"), among the <del>Company,</del>  <ins>Issuer,</ins> the <del>Guarantor</del>  <ins>Company</ins> and <del>The Bank of New York Mellon Trust Company, N.A.,</del>  <ins>Wells Fargo Bank, National Association,</ins> as trustee (the \"Trustee\"), in one or more series, which series may vary as to interest rates, maturities, redemption provisions, selling prices and other terms, with all such terms for any particular series of the Registered Securities being determined at the time of sale. Particular series of the Registered Securities will be sold pursuant to a Terms Agreement referred to in Section 3, for resale in accordance with terms of offering determined at the time of sale. The Registered Securities involved in any such offering are hereinafter referred to as the \"Offered Securities\". The firm or firms which agree to purchase the Offered Securities, as set forth in a Terms Agreement referred to in Section 3 hereof, are hereinafter referred to as the \"Underwriters\" of such securities, and the representative or representatives of the Underwriters, if any, specified in a Terms Agreement referred to in Section 3 are hereinafter referred to as the \"Representatives\"; provided, however, that if the Terms Agreement does not specify any representative of the Underwriters, the term \"Representatives\", as used in this Agreement (other than in Sections 2(b), 2(c), 2(f) and 6 and the second sentence of Section 3), shall mean the Underwriters.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/conocophillips-332/contract/340086/#clause-id-736106"}, {"variation_number": "Variation 4", "text": "Introductory. <del>Phillips 66,</del>  <ins>ConocoPhillips,</ins> a Delaware corporation (the \"Company\"), and <del>Phillips 66</del>  <ins>ConocoPhillips</ins> Company, a Delaware corporation <ins>and a wholly owned subsidiary of the Company</ins> (the <del>\"Guarantor\"),</del>  <ins>\"Issuer\"),</ins> propose that the <del>Company</del>  <ins>Issuer</ins> will issue and sell from time to time certain of its unsecured debt securities <del>that will be</del> fully and unconditionally guaranteed by the <del>Guarantor</del>  <ins>Company</ins> registered under the registration statement referred to in Section 2(a) (such securities, including theguarantee relating thereto by the <del>Guarantor</del>  <ins>Company</ins> (the \"Guarantee\"), being hereinafter called the \"Registered Securities\"). The Registered Securities will be issued under <del>the Indenture,</del>  <ins>an indenture,</ins> dated as of <del>March 12, 2012</del>  <ins>the Closing Date (as defined below)</ins> (the \"Indenture\"), among the <del>Company,</del>  <ins>Issuer,</ins> the <del>Guarantor</del>  <ins>Company</ins> and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\"), in one or more series, which series may vary as to interest rates, maturities, redemption provisions, selling prices and other terms, with all such terms for any particular series of the Registered Securities being determined at the time of sale. Particular series of the Registered Securities will be sold pursuant to a Terms Agreement referred to in Section 3, for resale in accordance with terms of offering determined at the time of sale. The Registered Securities involved in any such offering are hereinafter referred to as the \"Offered Securities\". The firm or firms which agree to purchase the Offered Securities, as set forth in a Terms Agreement referred to in Section 3 hereof, are hereinafter referred to as the \"Underwriters\" of such securities, and the representative or representatives of the Underwriters, if any, specified in a Terms Agreement referred to in Section 3 are hereinafter referred to as the \"Representatives\"; provided, however, that if the Terms Agreement does not specify any representative of the Underwriters, the term \"Representatives\", as used in this Agreement (other than in Sections 2(b), 2(c), 2(f) and 6 and the second sentence of Section 3), shall mean the Underwriters.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/conocophillips-332/contract/397337/#clause-id-846649"}]}
{"clause_number": "Clause 9", "title": "Introductory", "text": "Introductory. <del>Identiv, Inc., a Delaware corporation</del>  <ins>The selling stockholders named in Schedule B hereto</ins> (the <del>\"Company\"), proposes</del>  <ins>\"Selling stockholders\") propose</ins> to sell, pursuant to the terms of this Agreement, to Cowen and Company, LLC (the <del>\"Underwriter\" or \"Cowen\")</del>  <ins>\"Underwriter\"),</ins> an aggregate of 2,000,000 shares of Common Stock, <del>$0.001</del>  <ins>$0.01</ins> par value (the \"Common Stock\") of <del>the Company.</del>  <ins>Turning Point Brands, Inc., a Delaware corporation (the \"Company\").</ins> The aggregate of 2,000,000 shares so proposed to besold is hereinafter referred to as the \"Firm Stock\". <del>The Company</del>  <ins>Certain of the Selling stockholders listed in Schedule B hereto</ins> also <del>proposes</del>  <ins>propose</ins> to sell to the Underwriter, upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>300,000</del>  <ins>215,000</ins> shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/standard-diversified-inc-7698/contract/107929/#clause-id-200444", "variations": []}
{"clause_number": "Clause 10", "title": "Introductory", "text": "Introductory. 908 Devices Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of [\u25cf] shares of common stock, $0.001 par value (the \"Common Stock\") of the Company. The aggregate of [\u25cf] shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [\u25cf] shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC and SVB Leerink LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, Cowen (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to 250,000 shares for sale to the Company's directors, officers, employees, individual stockholders, business associates and other persons with whom we have a relationship (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the public offering price. Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/908-devices-inc-11615/contract/142401/#clause-id-279858", "variations": [{"variation_number": "Variation 1", "text": "Introductory. 908 Devices Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of [\u25cf] shares of common stock, $0.001 par value (the \"Common Stock\") of the Company. The aggregate of [\u25cf] shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters, upon the terms andconditions set forth in Section 3 hereof, up to an additional [\u25cf] shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC and SVB Leerink LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, Cowen (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to 250,000 shares for sale to the Company's directors, officers, employees, individual stockholders, business associates and other persons with whom we have a relationship (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the public offering price. Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/908-devices-inc-11615/contract/142401/#clause-id-279858"}, {"variation_number": "Variation 2", "text": "Introductory. <del>908 Devices</del>  <ins>Praxis Precision Medicines,</ins> Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of [\u25cf] shares of common stock, <del>$0.001</del>  <ins>$0.0001</ins> par value (the \"Common Stock\") of the Company. The aggregate of [\u25cf] shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to theUnderwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [\u25cf] shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC <ins>(\"Cowen\"), Evercore Group L.L.C. (\"Evercore\"),</ins> and <del>SVB Leerink LLC</del>  <ins>Piper Sandler & Co. (\"Piper\")</ins> are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, <del>Cowen (the \"Designated Underwriter\") has</del>  <ins>the Underwriters have</ins> agreed to reserve out of the Firm Stock purchased by it under this Agreement up to <del>250,000</del>  <ins>[\u25cf]</ins> shares for sale to the Company's <ins>and its subsidiaries' officers,</ins> directors, <ins>employees, customers and friends of the Company's and its subsidiaries'</ins> officers, <del>employees, individual stockholders, business associates</del>  <ins>directors</ins> and <del>other persons with whom we have a relationship</del>  <ins>employees</ins> (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the <del>Designated Underwriter</del>  <ins>Underwriters</ins> pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the <del>Designated Underwriter pursuant to this Agreement</del>  <ins>Underwriters</ins> at the public offering price. Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/praxis-precision-medicines-inc-11215/contract/132522/#clause-id-255527"}, {"variation_number": "Variation 3", "text": "Introductory. <del>908 Devices</del>  <ins>Sutro Biopharma,</ins> Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of <del>[\u25cf]</del>  <ins>[\u2022]</ins> shares of common stock, $0.001 par value (the \"Common Stock\") of the Company. The aggregate of <del>[\u25cf]</del>  <ins>[\u2022]</ins> shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters,upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>[\u25cf]</del>  <ins>[\u2022]</ins> shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC and <del>SVB Leerink LLC</del>  <ins>Piper Jaffray & Co.</ins> are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, Cowen <ins>and Company, LLC</ins> (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to <del>250,000</del>  <ins>[\u2022]</ins> shares for sale to the Company's <ins>officers,</ins> directors, <ins>employees, customers [and business partners] and friends and family members of the Company's</ins> officers, <del>employees, individual stockholders, business associates</del>  <ins>directors</ins> and <del>other persons with whom we have a relationship</del>  <ins>employees</ins> (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the <del>public offering price.</del>  <ins>Offering Price set forth in Schedule C hereto.</ins> Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/sutro-biopharma-inc-8063/contract/288120/#clause-id-606238"}, {"variation_number": "Variation 4", "text": "Introductory. <del>908 Devices</del>  <ins>Aeglea BioTherapeutics,</ins> Inc., a Delaware corporation (the \"Company\"), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of <del>[\u25cf]</del>  <ins>[ ]</ins> shares of common stock, <del>$0.001</del>  <ins>$0.0001</ins> par value <ins>per share</ins> (the \"Common Stock\") of the Company. The aggregate of <del>[\u25cf]</del>  <ins>[ ]</ins> shares so proposed to be sold is hereinafter referred to as the \"Firm <del>Stock\".</del>  <ins>Stock.\"</ins> The Company alsoproposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>[\u25cf]</del>  <ins>[ ]</ins> shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the <del>\"Stock\". Cowen</del>  <ins>\"Stock.\" UBS Securities LLC (\"UBS\"), BMO Capital Markets Corp. (\"BMO\")</ins> and <del>Company, LLC and SVB Leerink</del>  <ins>Wells Fargo Securities,</ins> LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the \"Representatives.\" As part of the offering contemplated by this Agreement, <del>Cowen</del>  <ins>UBS Financial Services Inc.</ins> (the \"Designated Underwriter\") has agreed to reserve out of the Firm Stock purchased by it under this Agreement up to <del>250,000</del>  <ins>[\u25cf]</ins> shares <ins>of Stock</ins> for sale to the Company's <ins>and its subsidiaries'</ins> directors, officers, <del>employees, individual stockholders, business associates</del>  <ins>employees</ins> and other <del>persons</del>  <ins>individuals associated</ins> with <del>whom we have a relationship</del>  <ins>the Company and its subsidiaries and members of their families</ins> (collectively, \"Participants\"), as set forth in the Prospectus (as defined below) under the heading \"Underwriting\" (the \"Directed Share Program\"). The Firm Stock to be sold by the Designated Underwriter pursuant to the Directed Share Program (the \"Directed Shares\") will be sold by the Designated Underwriter pursuant to this Agreement at the <del>public offering price.</del>  <ins>Offering Price set forth in Schedule B hereto.</ins> Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/aeglea-biotherapeutics-inc-5157/contract/370066/#clause-id-799112"}]}
{"clause_number": "Clause 11", "title": "Introductory", "text": "Introductory. Nissan Master Owner Trust Receivables (the \"Trust\"), a Delaware statutory trust, hereby confirms its agreement with Barclays Capital Inc. (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of $550,000,000 aggregate principal amount LIBOR + 0.40% Class A-1 Notes (the \"Class A-1 Notes\") and $350,000,000 aggregate principal amount of 1.44% Class A-2 Notes(the \"Class A-2 Notes\" and, together with the Class A-1 Notes, the \"Notes\") of the Trust, which Notes the Trust proposes to sell to the Underwriters under the terms and conditions herein. The Notes will be issued pursuant to the Amended and Restated Indenture, dated as of October 15, 2003 (as amended, modified and supplemented, the \"Indenture\"), between the Trust and U.S. Bank National Association, as indenture trustee (the \"Indenture Trustee\") and the Annex of Definitions attached to the Amended and Restated Transfer and Servicing Agreement, dated as of October 15, 2003 (as amended, modified and supplemented, the \"Transfer and Servicing Agreement\"), among Nissan Wholesale Receivables Corporation II (the \"Depositor\"), the Trust and Nissan Motor Acceptance Corporation (\"NMAC\"). Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Indenture.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-wholesale-receivables-corp-ii-2503/contract/400817/#clause-id-856630", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Nissan Master Owner Trust Receivables (the \"Trust\"), a Delaware statutory trust, hereby confirms its agreement with Barclays Capital Inc. (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of $550,000,000 aggregate principal amount LIBOR + 0.40% Class A-1 Notes (the \"Class A-1 Notes\") and $350,000,000 aggregate principal amount of 1.44% Class A-2Notes (the \"Class A-2 Notes\" and, together with the Class A-1 Notes, the \"Notes\") of the Trust, which Notes the Trust proposes to sell to the Underwriters under the terms and conditions herein. The Notes will be issued pursuant to the Amended and Restated Indenture, dated as of October 15, 2003 (as amended, modified and supplemented, the \"Indenture\"), between the Trust and U.S. Bank National Association, as indenture trustee (the \"Indenture Trustee\") and the Annex of Definitions attached to the Amended and Restated Transfer and Servicing Agreement, dated as of October 15, 2003 (as amended, modified and supplemented, the \"Transfer and Servicing Agreement\"), among Nissan Wholesale Receivables Corporation II (the \"Depositor\"), the Trust and Nissan Motor Acceptance Corporation (\"NMAC\"). Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Indenture.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-wholesale-receivables-corp-ii-2503/contract/400817/#clause-id-856630"}, {"variation_number": "Variation 2", "text": "Introductory. Nissan Master Owner Trust Receivables (the \"Trust\"), a Delaware statutory trust, hereby confirms its agreement with <del>Barclays Capital Inc.</del>  <ins>Merrill Lynch, Pierce, Fenner & Smith Incorporated</ins> (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$550,000,000 aggregate principal amount LIBOR + 0.40% Class A-1 Notes (the \"Class A-1 Notes\") and $350,000,000</del><ins>$1,000,000,000</ins> aggregate principal amount of <del>1.44% Class A-2</del>  <ins>one-month LIBOR + 0.56% Nissan Master Owner Trust Receivables, Series 2019-A</ins> Notes (the <del>\"Class A-2 Notes\" and, together with the Class A-1 Notes, the</del> \"Notes\") of the Trust, which Notes the Trust proposes to sell to the Underwriters under the terms and conditions herein. The Notes will be issued pursuant to the Amended and Restated Indenture, dated as of October 15, 2003 (as amended, modified and supplemented, the <del>\"Indenture\"),</del>  <ins>\"Base Indenture\"),</ins> between the Trust and U.S. Bank National Association, as indenture trustee (the \"Indenture <del>Trustee\")</del>  <ins>Trustee\"), the Series 2019-A Indenture Supplement, dated as of March 13, 2019 (the \"Indenture Supplement\" and, together with the Base Indenture, the \"Indenture\"), between the Trust and the Indenture Trustee,</ins> and the Annex of Definitions attached to the Amended and Restated Transfer and Servicing Agreement, dated as of October 15, 2003 (as amended, modified and supplemented, the \"Transfer and Servicing Agreement\"), among Nissan Wholesale Receivables Corporation II (the \"Depositor\"), the Trust and Nissan Motor Acceptance Corporation (\"NMAC\"). Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Indenture.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-master-owner-trust-receivables-2504/contract/48319/#clause-id-80487"}, {"variation_number": "Variation 3", "text": "Introductory. Nissan Master Owner Trust Receivables (the \"Trust\"), a Delaware statutory trust, hereby confirms its agreement with <del>Barclays Capital</del>  <ins>BofA Securities,</ins> Inc. (the \"Representative\") and the several underwriters named in Schedule 1 hereto (together with the Representative, collectively, the \"Underwriters\") with respect to the purchase by the Underwriters of <del>$550,000,000 aggregate principal amount LIBOR + 0.40% Class A-1 Notes (the \"Class A-1 Notes\") and $350,000,000</del>  <ins>$1,000,000,000</ins> aggregateprincipal amount of <del>1.44% Class A-2</del>  <ins>Benchmark + 0.43% Nissan Master Owner Trust Receivables, Series 2019-B</ins> Notes (the <del>\"Class A-2 Notes\" and, together with the Class A-1 Notes, the</del> \"Notes\") of the Trust, which Notes the Trust proposes to sell to the Underwriters under the terms and conditions herein. The Notes will be issued pursuant to the Amended and Restated Indenture, dated as of October 15, 2003 (as amended, modified and supplemented, the <del>\"Indenture\"),</del>  <ins>\"Base Indenture\"),</ins> between the Trust and U.S. Bank National Association, as indenture trustee (the \"Indenture <del>Trustee\")</del>  <ins>Trustee\"), the Series 2019-B Indenture Supplement, dated as of November 25, 2019 (the \"Indenture Supplement\" and, together with the Base Indenture, the \"Indenture\"), between the Trust and the Indenture Trustee,</ins> and the Annex of Definitions attached to the Amended and Restated Transfer and Servicing Agreement, dated as of October 15, 2003 (as amended, modified and supplemented, the \"Transfer and Servicing Agreement\"), among Nissan Wholesale Receivables Corporation II (the \"Depositor\"), the Trust and Nissan Motor Acceptance Corporation (\"NMAC\"). Capitalized terms used herein and not otherwise defined herein shall have the meanings given them in the Indenture.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nissan-master-owner-trust-receivables-2504/contract/79706/#clause-id-150697"}]}
{"clause_number": "Clause 12", "title": "Introductory", "text": "Introductory. Mercedes-Benz Retail Receivables LLC, a Delaware limited liability company (the \"Depositor\"), proposes to cause Mercedes-Benz Auto Receivables Trust 2022-1 (the \"Issuer\") to issue $393,170,000 principal amount of Class A\u20101 0.00% Asset Backed Notes (the \"Class A\u20101 Notes\"), $693,000,000 principal amount of Class A\u20102 5.26% Asset Backed Notes (the \"Class A\u20102 Notes\"), $657,000,000 principal amount of Class A\u20103 5.21% Asset Backed Notes (the \"Class A\u20103 Notes\") and $124,000,000 principal amount of ClassA\u20104 5.25% Asset Backed Notes (the \"Class A\u20104 Notes\" and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \"Notes\") and to sell the Class A-2 Notes, the Class A-3 Notes and the Class A-4 Notes (together the \"Offered Notes\") to the several underwriters named in Schedule I hereto (the \"Underwriters\"), for whom you are acting as representatives (the \"Representatives\"). The assets of the Issuer will include, among other things, a pool of fixed-rate motor vehicle installment sales contracts and installment loans (the \"Receivables\") secured by new and pre-owned Mercedes-Benz and smart automobiles, including, without limitation, rights to receive certain payments with respect to such Receivables received after the close of business on September 30, 2022, and security interests in the vehicles financed by the Receivables (the \"Financed Vehicles\"), and any proceeds from claims on certain related insurance policies thereof. The Receivables will be transferred to the Issuer by the Depositor. The Receivables will be serviced for the Issuer by Mercedes-Benz Financial Services USA LLC, a Delaware limited liability company (the \"Servicer\" or \"MBFS\"). The Notes will be issued pursuant to the Indenture to be dated as of November 1, 2022 (as amended and supplemented from time to time, the \"Indenture\"), between the Issuer and U.S. Bank Trust Company, National Association, a national banking association (the \"Indenture Trustee\"). Simultaneously with the issuance of the Notes and sale of the Offered Notes as contemplated herein, the Issuer will issue Asset Backed Certificates (the \"Certificates\"), each such Certificate representing a fractional undivided beneficial interest in the Issuer, to the Depositor. Upon the occurrence of certain events described in the Indenture, an asset representations review may be performed by the Asset Representations Reviewer (as defined below) under an Asset Representations Review Agreement (the \"Asset Representations Review Agreement\") to be dated as of November 1, 2022 among Clayton Fixed Income Services LLC, a Delaware limited liability company, as asset representations reviewer (the \"Asset Representations Reviewer\"), the Issuer and MBFS USA, as Administrator and Servicer. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in Appendix A to the Sale and Servicing Agreement to be dated as of November 1, 2022 (as amended and supplemented from time to time, the \"Sale and Servicing Agreement\"), among the Issuer, the Depositor, the Seller and the Servicer or, if not defined therein, in the Indenture or the Trust Agreement to be dated as of November 1, 2022 (as amended and supplemented from time to time, the \"Trust Agreement\"), between the Depositor and Wilmington Trust, National Association, as owner trustee under the Trust Agreement (the \"Owner Trustee\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/mercedes-benz-auto-receivables-trust-2022-1-15712/contract/261228/#clause-id-551052", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Mercedes-Benz Retail Receivables LLC, a Delaware limited liability company (the \u201cDepositor\u201d),           proposes to cause Mercedes-Benz Auto Receivables Trust 2022-1 (the \u201cIssuer\u201d) to issue $393,170,000 principal amount of Class A\u20101 0.00% Asset Backed Notes (the \u201cClass A\u20101 Notes\u201d), $693,000,000 principal amount of Class A\u20102 5.26%           Asset Backed Notes (the \u201cClass A\u20102 Notes\u201d), $657,000,000 principal amount of Class A\u20103 5.21% Asset Backed Notes (the \u201cClass A\u20103 Notes\u201d) and $124,000,000 principal amount of Class A\u20104 5.25% Asset Backed Notes (the \u201cClass A\u20104 Notes\u201d           and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \u201cNotes\u201d) and to sell the Class A-2 Notes, the Class A-3 Notes and the Class A-4 Notes (together the \u201cOffered Notes\u201d) to the several           underwriters named in Schedule I hereto (the \u201cUnderwriters\u201d), for whom you are acting as representatives (the \u201cRepresentatives\u201d). The assets of the Issuer will include, among other things, a pool of fixed-rate motor vehicle           installment sales contracts and installment loans (the \u201cReceivables\u201d) secured by new and pre-owned Mercedes-Benz and smart automobiles, including, without limitation, rights to receive certain payments with respect to such Receivables           received after the close of business on September 30, 2022, and security interests in the vehicles financed by the Receivables (the \u201cFinanced Vehicles\u201d), and any proceeds from claims on certain related insurance policies thereof. The           Receivables will be transferred to the Issuer by the Depositor. The Receivables will be serviced for the Issuer by Mercedes-Benz Financial Services USA LLC, a Delaware limited liability company (the \u201cServicer\u201d or \u201cMBFS\u201d). The           Notes will be issued pursuant to the Indenture to be dated as of November 1, 2022 (as amended and supplemented from time to time, the \u201cIndenture\u201d), between the Issuer and U.S. Bank Trust Company, National Association, a national banking           association (the \u201cIndenture Trustee\u201d). Simultaneously with the issuance of the Notes and sale of the Offered Notes as contemplated herein, the Issuer will issue Asset Backed Certificates (the \u201cCertificates\u201d), each such         Certificate representing a fractional undivided beneficial interest in the Issuer, to the Depositor. Upon the occurrence of certain events described in the Indenture, an asset representations review may be performed by the Asset Representations Reviewer (as defined below) under an Asset         Representations Review Agreement (the \u201cAsset Representations Review Agreement\u201d) to be dated as of November 1, 2022 among Clayton Fixed Income Services LLC, a Delaware limited liability company, as asset representations reviewer (the \u201cAsset         Representations Reviewer\u201d), the Issuer and MBFS USA, as Administrator and Servicer. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in Appendix A to the Sale and Servicing Agreement to be dated as of November 1, 2022 (as amended and         supplemented from time to time, the \u201cSale and Servicing Agreement\u201d), among the Issuer, the Depositor, the Seller and the Servicer or, if not defined therein, in the Indenture or the Trust Agreement to be dated as of November 1, 2022 (as         amended and supplemented from time to time, the \u201cTrust Agreement\u201d), between the Depositor and Wilmington Trust, National Association, as owner trustee under the Trust Agreement (the \u201cOwner Trustee\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/mercedes-benz-auto-receivables-trust-2022-1-15712/contract/261228/#clause-id-551052"}, {"variation_number": "Variation 2", "text": "Introductory. <del>Mercedes-Benz</del>  <ins>Daimler</ins> Retail Receivables LLC, a Delaware limited liability company (the \u201cDepositor\u201d), proposes to cause Mercedes-Benz Auto Receivables Trust <del>2022-1</del>  <ins>2020-1</ins> (the \u201cIssuer\u201d) to issue <del>$393,170,000</del>  <ins>$278,000,000</ins> principal amount of Class A\u20101 <del>0.00%</del>  <ins>0.26275%</ins> Asset Backed Notes (the \u201cClass A\u20101 Notes\u201d), <del>$693,000,000</del>  <ins>$351,600,000</ins> principal amount of Class A\u20102 <del>5.26%</del>  <ins>0.46%</ins> Asset Backed Notes (the \u201cClass A\u20102 Notes\u201d), <del>$657,000,000</del>  <ins>$351,600,000</ins> principal amount of Class A\u20103 <del>5.21%</del>  <ins>0.55%</ins> Asset Backed Notes (the \u201cClass A\u20103 Notes\u201d) and <del>$124,000,000</del>  <ins>$80,020,000</ins> principal amount of Class A\u20104 <del>5.25%</del>  <ins>0.77%</ins> Asset Backed Notes (the \u201cClass A\u20104 Notes\u201d and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \u201cNotes\u201d) and to sell the <del>Class A-2 Notes, the Class A-3</del> Notes <del>and the Class A-4 Notes (together the \u201cOffered Notes\u201d)</del> to the several underwriters named in Schedule I hereto (the \u201cUnderwriters\u201d), for whom you are acting as representatives (the \u201cRepresentatives\u201d). The assets of the Issuer will include, among other things, a pool of fixed-rate motor vehicle installment sales contracts and installment loans (the \u201cReceivables\u201d) secured by new and pre-owned Mercedes-Benz and smart automobiles, including, without limitation, rights to receive certain payments with respect to such Receivables received after the close of business on <del>September</del>  <ins>April</ins> 30, <del>2022,</del>  <ins>2020,</ins> and security interests in the vehicles financed by the Receivables (the \u201cFinanced Vehicles\u201d), and any proceeds from claims on certain related insurance policies thereof. The Receivables will be transferred to the Issuer by the Depositor. The Receivables will be serviced for the Issuer by Mercedes-Benz Financial Services USA LLC, a Delaware limited liability company (the \u201cServicer\u201d or \u201cMBFS\u201d). The Notes will be issued pursuant to the Indenture to be dated as of <del>November</del>  <ins>June</ins> 1, <del>2022</del>  <ins>2020</ins> (as amended and supplemented from time to time, the \u201cIndenture\u201d), between the Issuer and U.S. Bank <del>Trust Company,</del> National Association, a national banking association (the \u201cIndenture Trustee\u201d). Simultaneously with the issuance <del>of the Notes</del> and sale of the <del>Offered</del> Notes as contemplated herein, the Issuer will issue Asset Backed Certificates (the \u201cCertificates\u201d), each such Certificate representing a fractional undivided beneficial interest in the Issuer, to the Depositor. Upon the occurrence of certain events described in the Indenture, an asset representations review may be performed by the Asset Representations Reviewer (as defined below) under an Asset Representations Review Agreement (the \u201cAsset Representations Review Agreement\u201d) to be dated as of <del>November</del>  <ins>June</ins> 1, <del>2022</del>  <ins>2020</ins> among Clayton Fixed Income Services LLC, a Delaware limited liability company, as asset representations reviewer (the \u201cAsset Representations Reviewer\u201d), the Issuer and MBFS USA, as Administrator and Servicer. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in Appendix A to the Sale and Servicing Agreement to be dated as of <del>November</del>  <ins>June</ins> 1, <del>2022</del>  <ins>2020</ins> (as amended and supplemented from time to time, the \u201cSale and Servicing Agreement\u201d), among the Issuer, the Depositor, the Seller and the Servicer or, if not defined therein, in the Indenture or the Trust Agreement to be dated as of <del>November</del>  <ins>June</ins> 1, <del>2022</del>  <ins>2020</ins> (as amended and supplemented from time to time, the \u201cTrust Agreement\u201d), between the Depositor and Wilmington Trust, National Association, as owner trustee under the Trust Agreement (the \u201cOwner Trustee\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/mercedes-benz-auto-receivables-trust-2020-1-10311/contract/121933/#clause-id-228941"}, {"variation_number": "Variation 3", "text": "Introductory. Mercedes-Benz Retail Receivables LLC, a Delaware limited liability company (the \u201cDepositor\u201d), proposes to cause Mercedes-Benz Auto Receivables Trust <del>2022-1</del>  <ins>2023-1</ins> (the \u201cIssuer\u201d) to issue <del>$393,170,000</del>  <ins>$435,500,000</ins> principal amount of Class A\u20101 0.00% Asset Backed Notes (the \u201cClass A\u20101 Notes\u201d), <del>$693,000,000</del>  <ins>$657,500,000</ins> principal amount of Class A\u20102 <del>5.26%</del>  <ins>5.09%</ins> Asset Backed Notes (the \u201cClass A\u20102 Notes\u201d), <del>$657,000,000</del>  <ins>$657,500,000</ins> principal amount of Class A\u20103 <del>5.21%</del>  <ins>4.51%</ins> Asset Backed Notes (the \u201cClass A\u20103 Notes\u201d) and <del>$124,000,000</del>  <ins>$118,600,000</ins> principal amount of Class A\u20104 <del>5.25%</del>  <ins>4.31%</ins> Asset Backed Notes (the \u201cClass A\u20104 Notes\u201d and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \u201cNotes\u201d) and to sell the Class A-2 Notes, the Class A-3 Notes and the Class A-4 Notes (together the \u201cOffered Notes\u201d) to the several underwriters named in Schedule I hereto (the \u201cUnderwriters\u201d), for whom you are acting as representatives (the \u201cRepresentatives\u201d). The assets of the Issuer will include, among other things, a pool of fixed-rate motor vehicle installment sales contracts and installment loans (the \u201cReceivables\u201d) secured by new and pre-owned Mercedes-Benz and smart automobiles, including, without limitation, rights to receive certain payments with respect to such Receivables received after the close of business on <del>September</del>  <ins>November</ins> 30, 2022, and security interests in the vehicles financed by the Receivables (the \u201cFinanced Vehicles\u201d), and any proceeds from claims on certain related insurance policies thereof. The Receivables will be transferred to the Issuer by the Depositor. The Receivables will be serviced for the Issuer by Mercedes-Benz Financial Services USA LLC, a Delaware limited liability company (the \u201cServicer\u201d or \u201cMBFS\u201d). The Notes will be issued pursuant to the Indenture to be dated as of <del>November</del>  <ins>January</ins> 1, <del>2022</del>  <ins>2023</ins> (as amended and supplemented from time to time, the \u201cIndenture\u201d), between the Issuer and U.S. Bank Trust Company, National Association, a national banking association (the \u201cIndenture Trustee\u201d). Simultaneously with the issuance of the Notes and sale of the Offered Notes as contemplated herein, the Issuer will issue Asset Backed Certificates (the \u201cCertificates\u201d), each such Certificate representing a fractional undivided beneficial interest in the Issuer, to the Depositor. Upon the occurrence of certain events described in the Indenture, an asset representations review may be performed by the Asset Representations Reviewer (as defined below) under an Asset Representations Review Agreement (the \u201cAsset Representations Review Agreement\u201d) to be dated as of <del>November</del>  <ins>January</ins> 1, <del>2022</del>  <ins>2023</ins> among Clayton Fixed Income Services LLC, a Delaware limited liability company, as asset representations reviewer (the \u201cAsset Representations Reviewer\u201d), the Issuer and MBFS USA, as Administrator and Servicer. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in Appendix A to the Sale and Servicing Agreement to be dated as of <del>November</del>  <ins>January</ins> 1, <del>2022</del>  <ins>2023</ins> (as amended and supplemented from time to time, the \u201cSale and Servicing Agreement\u201d), among the Issuer, the Depositor, the Seller and the Servicer or, if not defined therein, in the Indenture or the Trust Agreement to be dated as of <del>November</del>  <ins>January</ins> 1, <del>2022</del>  <ins>2023</ins> (as amended and supplemented from time to time, the \u201cTrust Agreement\u201d), between the Depositor and Wilmington Trust, National Association, as owner trustee under the Trust Agreement (the \u201cOwner Trustee\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/mercedes-benz-auto-receivables-trust-2023-1-15840/contract/266187/#clause-id-561663"}, {"variation_number": "Variation 4", "text": "Introductory. Mercedes-Benz Retail Receivables LLC, a Delaware limited liability company (the \u201cDepositor\u201d), proposes to cause Mercedes-Benz Auto Receivables Trust 2022-1 (the \u201cIssuer\u201d) to issue $393,170,000 principal amount of Class A\u20101 0.00% Asset Backed Notes (the \u201cClass A\u20101 Notes\u201d), $693,000,000 principal amount of Class A\u20102 5.26% Asset Backed Notes (the \u201cClass A\u20102 Notes\u201d), $657,000,000 principal amount of Class A\u20103 5.21% Asset Backed Notes (the \u201cClass A\u20103 Notes\u201d) and $124,000,000 principal amount of ClassA\u20104 5.25% Asset Backed Notes (the \u201cClass A\u20104 Notes\u201d and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \u201cNotes\u201d) and to sell the Class A-2 Notes, the Class A-3 Notes and the Class A-4 Notes (together the \u201cOffered Notes\u201d) to the several underwriters named in Schedule I hereto (the \u201cUnderwriters\u201d), for whom you are acting as representatives (the \u201cRepresentatives\u201d). The assets of the Issuer will include, among other things, a pool of fixed-rate motor vehicle installment sales contracts and installment loans (the \u201cReceivables\u201d) secured by new and pre-owned Mercedes-Benz and smart automobiles, including, without limitation, rights to receive certain payments with respect to such Receivables received after the close of business on September 30, 2022, and security interests in the vehicles financed by the Receivables (the \u201cFinanced Vehicles\u201d), and any proceeds from claims on certain related insurance policies thereof. The Receivables will be transferred to the Issuer by the Depositor. The Receivables will be serviced for the Issuer by Mercedes-Benz Financial Services USA LLC, a Delaware limited liability company (the \u201cServicer\u201d or \u201cMBFS\u201d). The Notes will be issued pursuant to the Indenture to be dated as of November 1, 2022 (as amended and supplemented from time to time, the \u201cIndenture\u201d), between the Issuer and U.S. Bank Trust Company, National Association, a national banking association (the \u201cIndenture Trustee\u201d). Simultaneously with the issuance of the Notes and sale of the Offered Notes as contemplated herein, the Issuer will issue Asset Backed Certificates (the \u201cCertificates\u201d), each such Certificate representing a fractional undivided beneficial interest in the Issuer, to the Depositor. Upon the occurrence of certain events described in the Indenture, an asset representations review may be performed by the Asset Representations Reviewer (as defined below) under an Asset Representations Review Agreement (the \u201cAsset Representations Review Agreement\u201d) to be dated as of November 1, 2022 among Clayton Fixed Income Services LLC, a Delaware limited liability company, as asset representations reviewer (the \u201cAsset Representations Reviewer\u201d), the Issuer and MBFS USA, as Administrator and Servicer. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in Appendix A to the Sale and Servicing Agreement to be dated as of November 1, 2022 (as amended and supplemented from time to time, the \u201cSale and Servicing Agreement\u201d), among the Issuer, the Depositor, the Seller and the Servicer or, if not defined therein, in the Indenture or the Trust Agreement to be dated as of November 1, 2022 (as amended and supplemented from time to time, the \u201cTrust Agreement\u201d), between the Depositor and Wilmington Trust, National Association, as owner trustee under the Trust Agreement (the \u201cOwner Trustee\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/mercedes-benz-auto-receivables-trust-2022-1-15712/contract/260971/#clause-id-550553"}, {"variation_number": "Variation 5", "text": "Introductory. <del>Mercedes-Benz</del>  <ins>Daimler</ins> Retail Receivables LLC, a Delaware limited liability company (the \u201cDepositor\u201d), proposes to cause Mercedes-Benz Auto Receivables Trust <del>2022-1</del>  <ins>2021-1</ins> (the \u201cIssuer\u201d) to issue <del>$393,170,000</del>  <ins>$332,500,000</ins> principal amount of Class A\u20101 0.00% Asset Backed Notes (the \u201cClass A\u20101 Notes\u201d), <del>$693,000,000</del>  <ins>$560,000,000</ins> principal amount of Class A\u20102 <del>5.26%</del>  <ins>0.21%</ins> Asset Backed Notes (the \u201cClass A\u20102 Notes\u201d), <del>$657,000,000</del>  <ins>$560,000,000</ins> principal amount of Class A\u20103 <del>5.21%</del>  <ins>0.46%</ins> Asset Backed Notes(the \u201cClass A\u20103 Notes\u201d) and <del>$124,000,000</del>  <ins>$130,000,000</ins> principal amount of Class A\u20104 <del>5.25%</del>  <ins>0.73%</ins> Asset Backed Notes (the \u201cClass A\u20104 Notes\u201d and, together with the Class A-1 Notes, the Class A-2 Notes and the Class A-3 Notes, the \u201cNotes\u201d) and to sell the Class A-2 Notes, the Class A-3 Notes and the Class A-4 Notes (together the \u201cOffered Notes\u201d) to the several underwriters named in Schedule I hereto (the \u201cUnderwriters\u201d), for whom you are acting as representatives (the \u201cRepresentatives\u201d). The assets of the Issuer will include, among other things, a pool of fixed-rate motor vehicle installment sales contracts and installment loans (the \u201cReceivables\u201d) secured by new and pre-owned Mercedes-Benz and smart automobiles, including, without limitation, rights to receive certain payments with respect to such Receivables received after the close of business on <del>September 30, 2022,</del>  <ins>July 31, 2021,</ins> and security interests in the vehicles financed by the Receivables (the \u201cFinanced Vehicles\u201d), and any proceeds from claims on certain related insurance policies thereof. The Receivables will be transferred to the Issuer by the Depositor. The Receivables will be serviced for the Issuer by Mercedes-Benz Financial Services USA LLC, a Delaware limited liability company (the \u201cServicer\u201d or \u201cMBFS\u201d). The Notes will be issued pursuant to the Indenture to be dated as of <del>November</del>  <ins>September</ins> 1, <del>2022</del>  <ins>2021</ins> (as amended and supplemented from time to time, the \u201cIndenture\u201d), between the Issuer and U.S. Bank <del>Trust Company,</del> National Association, a national banking association (the \u201cIndenture Trustee\u201d). Simultaneously with the issuance of the Notes and sale of the Offered Notes as contemplated herein, the Issuer will issue Asset Backed Certificates (the \u201cCertificates\u201d), each such Certificate representing a fractional undivided beneficial interest in the Issuer, to the Depositor. Upon the occurrence of certain events described in the Indenture, an asset representations review may be performed by the Asset Representations Reviewer (as defined below) under an Asset Representations Review Agreement (the \u201cAsset Representations Review Agreement\u201d) to be dated as of <del>November</del>  <ins>September</ins> 1, <del>2022</del>  <ins>2021</ins> among Clayton Fixed Income Services LLC, a Delaware limited liability company, as asset representations reviewer (the \u201cAsset Representations Reviewer\u201d), the Issuer and MBFS USA, as Administrator and Servicer. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in Appendix A to the Sale and Servicing Agreement to be dated as of <del>November</del>  <ins>September</ins> 1, <del>2022</del>  <ins>2021</ins> (as amended and supplemented from time to time, the \u201cSale and Servicing Agreement\u201d), among the Issuer, the Depositor, the Seller and the Servicer or, if not defined therein, in the Indenture or the Trust Agreement to be dated as of <del>November</del>  <ins>September</ins> 1, <del>2022</del>  <ins>2021</ins> (as amended and supplemented from time to time, the \u201cTrust Agreement\u201d), between the Depositor and Wilmington Trust, National Association, as owner trustee under the Trust Agreement (the \u201cOwner Trustee\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/mercedes-benz-auto-receivables-trust-2021-1-13933/contract/199121/#clause-id-419922"}]}
{"clause_number": "Clause 13", "title": "Introductory", "text": "Introductory. Apollo Gaming Holdings, L.P. (the \"Selling Stockholder\"), a stockholder of PlayAGS, Inc., a Nevada corporation (\"Company\") agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\") to sell to the several Underwriters <del>4,000,000</del>  <ins>8,208,076</ins> shares of the Company's common stock; par value $0.01 per share (the <del>\"Securities\" and, such shares of</del>  <ins>\"Securities\"). The</ins> Securities <del>being hereinafter referred to as</del>  <ins>are herein collectively called</ins> the \"Offered <del>Securities\").</del>  <ins>Securities\".</ins>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/playags-inc-4670/contract/260932/#clause-id-550425", "variations": []}
{"clause_number": "Clause 14", "title": "Introductory", "text": "Introductory. Pursuant to the terms and conditions of this Underwriting Agreement (this <del>\"Agreement\") Brigham Minerals, Inc., a Delaware corporation (the \"Company\"), agrees with Credit Suisse Securities (USA) LLC and Goldman Sachs & Co. LLC, as representatives (the \"Representatives\") of the several underwriters named in Schedule A hereto (the \"Underwriters\"), to issue and sell to the Underwriters 6,000,000 shares of its Class A common stock, par value $0.01 per share (\"Securities\") and</del>  <ins>\"Agreement\"),</ins> the selling stockholders listed on Schedule <del>B</del>  <ins>A</ins> hereto (the \"Selling Stockholders\") propose, severally and not jointly, to sell to <del>the several Underwriters</del>  <ins>Credit Suisse Securities (USA) LLC (the \"Underwriter\")</ins> an aggregate of <del>5,000,000 outstanding</del>  <ins>6,600,000</ins> shares of <del>Securities</del>  <ins>Class A common stock, par value $0.01 per share (\"Securities\") of Brigham Minerals, Inc., a Delaware corporation (the \"Company\"),</ins> (such <del>11,000,000</del>  <ins>6,600,000</ins> shares of Securities being hereinafter referred to as the \"Firm Securities\"). The Selling Stockholders have also agreed, severally and not jointly, to sell to the <del>Underwriters,</del>  <ins>Underwriter,</ins> at the option of the <del>Underwriters,</del>  <ins>Underwriter,</ins> an aggregate of not more than <del>1,650,000</del>  <ins>990,000</ins> additional shares of Securities (the \"Optional Securities\") as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\" and the proposed <del>issuance and</del> sale of the Offered Securities is referred to herein as the \"Offering\". A portion of the Offered Securities to be sold by the Selling Stockholders consists of Securities that are issuable upon redemption of units in Brigham Minerals Holdings, LLC, a Delaware limited liability company (\"Brigham LLC\"), pursuant to the First Amended and Restated Limited Liability Company Agreement of Brigham LLC, dated as of April 23, 2019, immediately prior to the Closing Date on which such Offered Securities are to be sold (any such redemption being hereinafter referred to as a \"Redemption Transaction\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/brigham-minerals-inc-6226/contract/121557/#clause-id-228158", "variations": []}
{"clause_number": "Clause 15", "title": "Introductory", "text": "Introductory. Express Scripts Holding Company, a Delaware corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") to issue and sell to the Underwriters $1,000,000,000 aggregate principal amount of its 3.000% Senior Notes due 2023 (the \"2023 Notes\"), $1,500,000,000 aggregate principal amount of its 3.400% Senior Notes due 2027 (the \"2027 Notes\") and $1,500,000,000 aggregate principal amount of its 4.800% Senior Notes due 2046 (the \"2046 Notes\" and, together with the 2023 Notes and the 2027 Notes, the \"Offered Securities\"). The Offered Securities will be unconditionally guaranteed (the \"Guarantees\") by the Guarantors (as defined below) and any other entity that becomes a guarantor of the Offered Securities following the Closing Date (as defined below), pursuant to the terms of the Indenture (as defined below). The Offered Securities shall be issued under an indenture, dated as of November 21, 2011 (the \"Base Indenture\"), and supplemented by supplemental indentures (each, a \"Supplemental Indenture\" and, collectively, the \"Supplemental Indentures\") to be dated as of the Closing Date, among the Company, each of the entities listed on Schedule B hereto (collectively, the \"Guarantors\") and Wells Fargo Bank, National Association, as Trustee (the Base Indenture, as supplemented by the Supplemental Indentures entered into on the Closing Date and as may be supplemented from time to time after the Closing Date, the \"Indenture\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/express-scripts-holding-co-8230/contract/355060/#clause-id-773328", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Express Scripts Holding Company, a Delaware corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") to issue and sell to the Underwriters $1,000,000,000 aggregate principal amount of its 3.000% Senior Notes due 2023 (the \"2023 Notes\"), $1,500,000,000 aggregate principal amount of its 3.400% Senior Notes due 2027 (the \"2027 Notes\") and $1,500,000,000 aggregate principal amount of its 4.800% Senior Notes due 2046 (the \"2046 Notes\" and,together with the 2023 Notes and the 2027 Notes, the \"Offered Securities\"). The Offered Securities will be unconditionally guaranteed (the \"Guarantees\") by the Guarantors (as defined below) and any other entity that becomes a guarantor of the Offered Securities following the Closing Date (as defined below), pursuant to the terms of the Indenture (as defined below). The Offered Securities shall be issued under an indenture, dated as of November 21, 2011 (the \"Base Indenture\"), and supplemented by supplemental indentures (each, a \"Supplemental Indenture\" and, collectively, the \"Supplemental Indentures\") to be dated as of the Closing Date, among the Company, each of the entities listed on Schedule B hereto (collectively, the \"Guarantors\") and Wells Fargo Bank, National Association, as Trustee (the Base Indenture, as supplemented by the Supplemental Indentures entered into on the Closing Date and as may be supplemented from time to time after the Closing Date, the \"Indenture\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/express-scripts-holding-co-8230/contract/355060/#clause-id-773328"}, {"variation_number": "Variation 2", "text": "Introductory. Express Scripts Holding Company, a Delaware corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") to issue and sell to the Underwriters <del>$1,000,000,000</del>  <ins>$500,000,000</ins> aggregate principal amount of its <del>3.000%</del>  <ins>3.300%</ins> Senior Notes due <del>2023</del>  <ins>2021</ins> (the <del>\"2023 Notes\"), $1,500,000,000 aggregate principal amount of its 3.400% Senior Notes due 2027 (the \"2027</del>  <ins>\"2021</ins> Notes\") and $1,500,000,000 aggregate principal amount of its <del>4.800%</del>  <ins>4.500%</ins> SeniorNotes due <del>2046</del>  <ins>2026</ins> (the <del>\"2046</del>  <ins>\"2026</ins> Notes\" and, together with the <del>2023 Notes and the 2027</del>  <ins>2021</ins> Notes, the \"Offered Securities\"). The Offered Securities will be unconditionally guaranteed (the \"Guarantees\") by the Guarantors (as defined below) and any other entity that becomes a guarantor of the Offered Securities following the Closing Date (as defined below), pursuant to the terms of the Indenture (as defined below). The Offered Securities shall be issued under an indenture, dated as of November 21, 2011 (the \"Base Indenture\"), and supplemented by supplemental indentures (each, a \"Supplemental Indenture\" and, collectively, the \"Supplemental Indentures\") to be dated as of the Closing Date, among the Company, each of the entities listed on Schedule B hereto (collectively, the \"Guarantors\") and Wells Fargo Bank, National Association, as Trustee (the Base Indenture, as supplemented by the Supplemental Indentures entered into on the Closing Date and as may be supplemented from time to time after the Closing Date, the \"Indenture\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/express-scripts-holding-co-8230/contract/358143/#clause-id-779368"}]}
{"clause_number": "Clause 16", "title": "Introductory", "text": "Introductory. Gulfport Energy Corporation, a Delaware corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") to issue and sell to the several Underwriters 29,000,000 shares of its common stock, par value $0.01 per share (\"Securities\") (such 29,000,000 shares of the Securities being hereinafter referred to as the \"Firm Securities\"). The Company also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 4,350,000 additional shares of its Securities (such 4,350,000 shares of the Securities being hereinafter referred to as the \"Optional Securities\") as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/gulfport-energy-corp-604/contract/382672/#clause-id-817606", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Gulfport Energy Corporation, a Delaware corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") to issue and sell to the several Underwriters 29,000,000 shares of its common stock, par value $0.01 per share (\"Securities\") (such 29,000,000 shares of the Securities being hereinafter referred to as the \"Firm Securities\"). The Company also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of notmore than 4,350,000 additional shares of its Securities (such 4,350,000 shares of the Securities being hereinafter referred to as the \"Optional Securities\") as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/gulfport-energy-corp-604/contract/382672/#clause-id-817606"}, {"variation_number": "Variation 2", "text": "Introductory. Gulfport Energy Corporation, a Delaware corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") to issue and sell to the several Underwriters <del>29,000,000</del>  <ins>14,700,000</ins> shares of its common stock, par value $0.01 per share (\"Securities\") (such <del>29,000,000</del>  <ins>14,700,000</ins> shares of the Securities being hereinafter referred to as the \"Firm Securities\"). The Company also agrees to issue and sell to the Underwriters, at the option of the Underwriters,an aggregate of not more than <del>4,350,000</del>  <ins>2,205,000</ins> additional shares of its Securities (such <del>4,350,000</del>  <ins>2,205,000</ins> shares of the Securities being hereinafter referred to as the \"Optional Securities\") as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/gulfport-energy-corp-604/contract/386999/#clause-id-823576"}]}
{"clause_number": "Clause 17", "title": "Introductory", "text": "Introductory. PPG Industries, Inc., a Pennsylvania corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\") to issue and sell to the several Underwriters \u20ac300,000,000 principal amount of its 1.875% Senior Notes due 2025 (the \"2025 Notes\") and \u20ac700,000,000 principal amount of its 2.750% Senior Notes due 2029 (the \"2029 Notes\" and, together with the 2025 Notes, the \"Securities\" or \"Offered Securities\"), all to be issued under an indenture, dated as of March 18, 2008 and as supplemented through the Closing Date (\"Indenture\"), between the Company and 1 The Bank of New York Trust Company, N.A., as Trustee. In connection with the issuance of the Offered Securities, the Company will enter into a paying agency agreement (the \"Paying Agency Agreement\"), to be dated May 25, 2022, among the Company and The Bank of New York Mellon, London Branch, as London Paying Agent.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ppg-industries-1066/contract/241242/#clause-id-510568", "variations": [{"variation_number": "Variation 1", "text": "Introductory. PPG Industries, Inc., a Pennsylvania corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\") to issue and sell to the several Underwriters \u20ac300,000,000 principal amount of its 1.875% Senior Notes due 2025 (the \"2025 Notes\") and \u20ac700,000,000 principal amount of its 2.750% Senior Notes due 2029 (the \"2029 Notes\" and, together with the 2025 Notes, the \"Securities\" or \"Offered Securities\"), all to be issued under an indenture, dated as of March 18,2008 and as supplemented through the Closing Date (\"Indenture\"), between the Company and 1 The Bank of New York Trust Company, N.A., as Trustee. In connection with the issuance of the Offered Securities, the Company will enter into a paying agency agreement (the \"Paying Agency Agreement\"), to be dated May 25, 2022, among the Company and The Bank of New York Mellon, London Branch, as London Paying Agent.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ppg-industries-1066/contract/241242/#clause-id-510568"}, {"variation_number": "Variation 2", "text": "Introductory. PPG Industries, Inc., a Pennsylvania corporation (\"Company\"), agrees with the several Underwriters named in Schedule A hereto (\"Underwriters\") to issue and sell to the several Underwriters \u20ac300,000,000 principal amount of its <del>1.875% Senior</del>  <ins>0.000% Notes due 2019 (the \"2019 Notes\") and \u20ac600,000,000 principal amount of its 0.875%</ins> Notes due 2025 (the \"2025 <del>Notes\") and \u20ac700,000,000 principal amount of its 2.750% Senior Notes due 2029 (the \"2029</del> Notes\" and, together with the <del>2025</del>  <ins>2019</ins> Notes, the\"Securities\" or \"Offered Securities\"), all to be issued under an indenture, dated as of March 18, 2008 and as supplemented through the Closing Date (\"Indenture\"), between the Company and <del>1</del> The Bank of New York Trust Company, N.A., as Trustee. In connection with the issuance of the Offered Securities, the Company will enter into a paying agency agreement (the \"Paying Agency Agreement\"), to be dated <del>May 25, 2022,</del>  <ins>November 3, 2016,</ins> among the Company and The Bank of New York <del>Mellon, London Branch,</del>  <ins>Mellon (London Branch),</ins> as London Paying Agent.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ppg-industries-1066/contract/379271/#clause-id-812995"}]}
{"clause_number": "Clause 18", "title": "Introductory", "text": "Introductory. Viveve Medical, Inc., a Delaware corporation (the \"Company\") proposes to sell, pursuant to the terms of this Underwriting Agreement (this \"Agreement\"), to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of 13,333,334 shares of Common Stock, $0.0001 par value (the \"Common Stock\") of the Company. The aggregate of 13,333,334 shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional 1,999,999 shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC (\"Cowen\") is acting as representative of the several Underwriters and in such capacity is hereinafter referred to as the \"Representative.\" To the extent that only one Underwriter is listed on Schedule A hereto, all references herein to the Representative and the Underwriters shall refer just to you.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/viveve-medical-inc-7513/contract/284881/#clause-id-598754", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Viveve Medical, Inc., a Delaware corporation (the \"Company\") proposes to sell, pursuant to the terms of this Underwriting Agreement (this \"Agreement\"), to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of 13,333,334 shares of Common Stock, $0.0001 par value (the \"Common Stock\") of the Company. The aggregate of 13,333,334 shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". The Company also proposes tosell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional 1,999,999 shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC (\"Cowen\") is acting as representative of the several Underwriters and in such capacity is hereinafter referred to as the \"Representative.\" To the extent that only one Underwriter is listed on Schedule A hereto, all references herein to the Representative and the Underwriters shall refer just to you.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/viveve-medical-inc-7513/contract/284881/#clause-id-598754"}, {"variation_number": "Variation 2", "text": "Introductory. Viveve Medical, Inc., a Delaware corporation (the \"Company\") proposes to sell, pursuant to the terms of this Underwriting Agreement (this \"Agreement\"), to the several underwriters named in Schedule A hereto (the \"Underwriters,\" or, each, an \"Underwriter\"), an aggregate of <del>13,333,334</del>  <ins>10,000,000</ins> shares of Common Stock, $0.0001 par value (the \"Common Stock\") of the Company. The aggregate of <del>13,333,334</del>  <ins>10,000,000</ins> shares so proposed to be sold is hereinafter referred to as the \"Firm Stock\". TheCompany also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional <del>1,999,999</del>  <ins>1,500,000</ins> shares of Common Stock (the \"Optional Stock\"). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \"Stock\". Cowen and Company, LLC (\"Cowen\") is acting as representative of the several Underwriters and in such capacity is hereinafter referred to as the \"Representative.\" To the extent that only one Underwriter is listed on Schedule A hereto, all references herein to the Representative and the Underwriters shall refer just to you.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/viveve-medical-inc-7513/contract/319051/#clause-id-688675"}]}
{"clause_number": "Clause 19", "title": "Introductory", "text": "Introductory. State Street Corporation, a Massachusetts corporation (the \"Company\"), agrees with the Underwriters listed in Schedule I hereto (the \"Underwriters\") to issue and sell to the Underwriters 21,724,217 shares (the \"Shares\") of its common stock, par value $1.00 per share (the \"Common Stock\"). The Shares are described in the Final Prospectus, which is referred to below. Capitalized terms used herein and not otherwise defined, but that are defined in the Statutory Prospectus (as defined in Section 2(a)), have the meaning specified in the Statutory Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/state-street-corp-1227/contract/198375/#clause-id-417736", "variations": [{"variation_number": "Variation 1", "text": "Introductory. State Street Corporation, a Massachusetts corporation (the \"Company\"), agrees with the Underwriters listed in Schedule I hereto (the \"Underwriters\") to issue and sell to the Underwriters 21,724,217 shares (the \"Shares\") of its common stock, par value $1.00 per share (the \"Common Stock\"). The Shares are described in the Final Prospectus, which is referred to below. Capitalized terms used herein and not otherwise defined, but that are defined in the Statutory Prospectus (as defined in Section2(a)), have the meaning specified in the Statutory Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/state-street-corp-1227/contract/198375/#clause-id-417736"}, {"variation_number": "Variation 2", "text": "Introductory. State Street Corporation, a Massachusetts corporation (the \"Company\"), agrees with the <del>Underwriters</del>  <ins>Underwriter</ins> listed in Schedule I hereto (the <del>\"Underwriters\")</del>  <ins>\"Underwriter\")</ins> to issue and sell to the <del>Underwriters 21,724,217</del>  <ins>Underwriter 13,244,271</ins> shares (the \"Shares\") of its common stock, par value $1.00 per share (the \"Common Stock\"). The Shares are described in the Final Prospectus, which is referred to below. Capitalized terms used herein and not otherwise defined, but that are defined inthe Statutory Prospectus (as defined in Section 2(a)), have the meaning specified in the Statutory Prospectus.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/state-street-corp-1227/contract/295124/#clause-id-625649"}]}
{"clause_number": "Clause 20", "title": "Introductory", "text": "Introductory. NVR, Inc., a Virginia corporation (the \"Company\"), agrees with Credit Suisse Securities (USA) LLC (\"Credit Suisse\"), as underwriter, to issue and sell to Credit Suisse $250,000,000 principal amount of its 3.000% Senior Notes due 2030 (the \"Offered Securities\") as set forth below, all to be issued under the seventh supplemental indenture, to be dated as of the Closing Date (the \"Seventh Supplemental Indenture\"), to the indenture dated as of April 14, 1998 and as supplemented to the Closing Date,between the Company and U.S. Bank Trust National Association, successor to The Bank of New York, as Trustee (the \"Base Indenture\" and, together with the Seventh Supplemental Indenture, the \"Indenture\"). The Company has previously issued $600,000,000 aggregate principal amount of its 3.000% Senior Notes due 2030 under the sixth supplemental indenture, dated as of May 4, 2020, to the Base Indenture (the \"Existing Securities\"). The Offered Securities constitute Additional Notes (as such term is defined in the Indenture) under the Indenture. Except as disclosed in the General Disclosure Package and the Final Prospectus (each, as defined below), the Offered Securities will have terms identical to those of the Existing Securities and, together with the Existing Securities, will be treated as a single class of securities for all purposes under the Indenture.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nvr-inc-979/contract/128236/#clause-id-243581", "variations": [{"variation_number": "Variation 1", "text": "Introductory. NVR, Inc., a Virginia corporation (the \"Company\"), agrees with Credit Suisse Securities (USA) LLC (\"Credit Suisse\"), as underwriter, to issue and sell to Credit Suisse $250,000,000 principal amount of its 3.000% Senior Notes due 2030 (the \"Offered Securities\") as set forth below, all to be issued under the seventh supplemental indenture, to be dated as of the Closing Date (the \"Seventh Supplemental Indenture\"), to the indenture dated as of April 14, 1998 and as supplemented to the Closing Date,between the Company and U.S. Bank Trust National Association, successor to The Bank of New York, as Trustee (the \"Base Indenture\" and, together with the Seventh Supplemental Indenture, the \"Indenture\"). The Company has previously issued $600,000,000 aggregate principal amount of its 3.000% Senior Notes due 2030 under the sixth supplemental indenture, dated as of May 4, 2020, to the Base Indenture (the \"Existing Securities\"). The Offered Securities constitute Additional Notes (as such term is defined in the Indenture) under the Indenture. Except as disclosed in the General Disclosure Package and the Final Prospectus (each, as defined below), the Offered Securities will have terms identical to those of the Existing Securities and, together with the Existing Securities, will be treated as a single class of securities for all purposes under the Indenture.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nvr-inc-979/contract/128236/#clause-id-243581"}, {"variation_number": "Variation 2", "text": "Introductory. NVR, Inc., a Virginia corporation (the \"Company\"), agrees with Credit Suisse Securities (USA) LLC (\"Credit Suisse\"), as underwriter, to issue and sell to Credit Suisse <del>$250,000,000</del>  <ins>$600,000,000</ins> principal amount of its 3.000% Senior Notes due 2030 (the \"Offered Securities\") as set forth below, all to be issued under the <del>seventh</del>  <ins>sixth</ins> supplemental indenture, to be dated as of the Closing Date (the <del>\"Seventh</del>  <ins>\"Sixth</ins> Supplemental Indenture\"), to the indenture dated as of April 14, 1998 and assupplemented to the Closing Date, between the Company and U.S. Bank Trust National Association, successor to The Bank of New York, as Trustee (the \"Base Indenture\" and, together with the <del>Seventh</del>  <ins>Sixth</ins> Supplemental Indenture, the \"Indenture\"). <del>The Company has previously issued $600,000,000 aggregate principal amount of its 3.000% Senior Notes due 2030 under the sixth supplemental indenture, dated as of May 4, 2020, to the Base Indenture (the \"Existing Securities\"). The Offered Securities constitute Additional Notes (as such term is defined in the Indenture) under the Indenture. Except as disclosed in the General Disclosure Package and the Final Prospectus (each, as defined below), the Offered Securities will have terms identical to those of the Existing Securities and, together with the Existing Securities, will be treated as a single class of securities for all purposes under the Indenture.</del>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nvr-inc-979/contract/114113/#clause-id-213119"}]}
{"clause_number": "Clause 21", "title": "Introductory", "text": "Introductory. Analog Devices, Inc., a Massachusetts corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") for whom J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are acting as Representatives (the \"Representatives\") to issue and sell to the several Underwriters $400,000,000 principal amount of its 2.950% Senior Notes due 2025 (the \"Securities\"). The Securities shall be issued under an indenture, dated as of June 3, 2013 (the \"Base Indenture\"), as supplemented by a supplemental indenture (the \"Supplemental Indenture\" and, together with the Base Indenture, the \"Indenture\") to be dated as of the Closing Date (as defined below) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/analog-devices-inc-97/contract/102644/#clause-id-193271", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Analog Devices, Inc., a Massachusetts corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") for whom J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are acting as Representatives (the \"Representatives\") to issue and sell to the several Underwriters $400,000,000 principal amount of its 2.950% Senior Notes due 2025 (the \"Securities\"). The Securities shall be issued under an indenture, dated as of June 3, 2013 (the \"BaseIndenture\"), as supplemented by a supplemental indenture (the \"Supplemental Indenture\" and, together with the Base Indenture, the \"Indenture\") to be dated as of the Closing Date (as defined below) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/analog-devices-inc-97/contract/102644/#clause-id-193271"}, {"variation_number": "Variation 2", "text": "Introductory. Analog Devices, Inc., a Massachusetts corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") for whom <del>J.P. Morgan</del>  <ins>SMBC Nikko</ins> Securities <del>LLC and Citigroup Global Markets</del>  <ins>America,</ins> Inc. <del>are</del>  <ins>is</ins> acting as <del>Representatives</del>  <ins>Representative</ins> (the <del>\"Representatives\")</del>  <ins>\"Representative\")</ins> to issue and sell to the several Underwriters <del>$400,000,000</del>  <ins>$300,000,000</ins> principal amount of its <del>2.950%</del>  <ins>4.250%</ins> Senior Notes due <del>2025</del>  <ins>October 1, 2032</ins> (the \"Securities\").The Securities shall be issued under an indenture, dated as of June 3, 2013 (the \"Base Indenture\"), as supplemented by a supplemental indenture (the \"Supplemental Indenture\" and, together with the Base Indenture, the \"Indenture\") to be dated as of the Closing Date (as defined below) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/analog-devices-inc-97/contract/254096/#clause-id-536910"}]}
{"clause_number": "Clause 22", "title": "Introductory", "text": "Introductory. Ra Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with Jefferies LLC (\"Jefferies\"), BMO Capital Markets Corp. (\"BMO\") and Stifel, Nicolaus & Company, Incorporated (\"Stifel\") and the several Underwriters named in Schedule A hereto (collectively, the \"Underwriters\"), for whom Jefferies, BMO and Stifel are acting as representatives (in such capacity, the \"Representatives\"), to issue and sell to the several Underwriters 4,000,000 shares (\"Firm Securities\") of its common stock, parvalue $0.001 per share (\"Securities\"), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 600,000 additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ra-pharmaceuticals-inc-3759/contract/72265/#clause-id-134000", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Ra Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with Jefferies LLC (\"Jefferies\"), BMO Capital Markets Corp. (\"BMO\") and Stifel, Nicolaus & Company, Incorporated (\"Stifel\") and the several Underwriters named in Schedule A hereto (collectively, the \"Underwriters\"), for whom Jefferies, BMO and Stifel are acting as representatives (in such capacity, the \"Representatives\"), to issue and sell to the several Underwriters 4,000,000 shares (\"Firm Securities\") of its common stock,par value $0.001 per share (\"Securities\"), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 600,000 additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ra-pharmaceuticals-inc-3759/contract/72265/#clause-id-134000"}, {"variation_number": "Variation 2", "text": "Introductory. Ra Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with Jefferies LLC (\"Jefferies\"), BMO Capital Markets Corp. (\"BMO\") and Stifel, Nicolaus & Company, Incorporated (\"Stifel\") and the several Underwriters named in Schedule A hereto (collectively, the \"Underwriters\"), for whom Jefferies, BMO and Stifel are acting as representatives (in such capacity, the \"Representatives\"), to issue and sell to the several Underwriters <del>4,000,000</del>  <ins>8,387,097</ins> shares (\"Firm Securities\") of its commonstock, par value $0.001 per share (\"Securities\"), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <del>600,000</del>  <ins>1,258,064</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ra-pharmaceuticals-inc-3759/contract/279601/#clause-id-586394"}]}
{"clause_number": "Clause 23", "title": "Introductory", "text": "Introductory. Nevada Power Company, a Nevada corporation (the \"Company\"), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule A attached hereto (collectively, the \"Underwriters\"), for whom BMO Capital Markets Corp., BNP Paribas Securities Corp., CIBC World Markets Corp., Citigroup Global Markets Inc. and SunTrust Robinson Humphrey, Inc. are acting as representatives (the \"Representatives\"), $500,000,000 principal amount of its 3.700% General andRefunding Mortgage Notes, Series CC, due 2029 (the \"Offered Securities\") to be issued under that certain General and Refunding Mortgage Indenture, dated as of May 1, 2001 (the \"Original Indenture\"), between the Company and The Bank of New York Mellon Trust Company, N.A. (successor in trust to The Bank of New York Mellon, formerly The Bank of New York), as trustee (the \"Trustee\"), as amended and supplemented by various instruments including an officer's certificate, to be dated the Closing Date (as defined herein) (the \"Officer's Certificate\"), establishing the terms of the Offered Securities, such Original Indenture, as so amended and supplemented, being hereinafter called the \"Indenture.\" On September 30, 2016, the Company filed with the Securities and Exchange Commission (the \"Commission\") a registration statement on Form S-3 (File No. 333-213897) for the registration of securities, including the Offered Securities, under the United States Securities Act of 1933, as amended (the \"Securities Act\"), and the offer and sale thereof from time to time in accordance with Rule 415 of the rules and regulations of the Commission thereunder (the \"Rules and Regulations) and for the qualification of the Indenture under the United States Trust Indenture Act of 1939, as amended (the \"Trust Indenture Act\"). As used herein, the term \"Registration Statement\" means, as of any particular time, such registration statement, including (a) any amendments thereto at such time, (b) the exhibits and schedules thereto at such time (if any) and (c) any prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act that, in accordance with Rule 430B under the Securities Act, is deemed to be a part thereof.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nevada-power-co-6883/contract/55598/#clause-id-95371", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Nevada Power Company, a Nevada corporation (the \"Company\"), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule A attached hereto (collectively, the \"Underwriters\"), for whom BMO Capital Markets Corp., BNP Paribas Securities Corp., CIBC World Markets Corp., Citigroup Global Markets Inc. and SunTrust Robinson Humphrey, Inc. are acting as representatives (the \"Representatives\"), $500,000,000 principal amount of its 3.700% Generaland Refunding Mortgage Notes, Series CC, due 2029 (the \"Offered Securities\") to be issued under that certain General and Refunding Mortgage Indenture, dated as of May 1, 2001 (the \"Original Indenture\"), between the Company and The Bank of New York Mellon Trust Company, N.A. (successor in trust to The Bank of New York Mellon, formerly The Bank of New York), as trustee (the \"Trustee\"), as amended and supplemented by various instruments including an officer's certificate, to be dated the Closing Date (as defined herein) (the \"Officer's Certificate\"), establishing the terms of the Offered Securities, such Original Indenture, as so amended and supplemented, being hereinafter called the \"Indenture.\" On September 30, 2016, the Company filed with the Securities and Exchange Commission (the \"Commission\") a registration statement on Form S-3 (File No. 333-213897) for the registration of securities, including the Offered Securities, under the United States Securities Act of 1933, as amended (the \"Securities Act\"), and the offer and sale thereof from time to time in accordance with Rule 415 of the rules and regulations of the Commission thereunder (the \"Rules and Regulations) and for the qualification of the Indenture under the United States Trust Indenture Act of 1939, as amended (the \"Trust Indenture Act\"). As used herein, the term \"Registration Statement\" means, as of any particular time, such registration statement, including (a) any amendments thereto at such time, (b) the exhibits and schedules thereto at such time (if any) and (c) any prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act that, in accordance with Rule 430B under the Securities Act, is deemed to be a part thereof.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nevada-power-co-6883/contract/55598/#clause-id-95371"}, {"variation_number": "Variation 2", "text": "Introductory. Nevada Power Company, a Nevada corporation (the \"Company\"), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule A attached hereto (collectively, the \"Underwriters\"), for whom <del>BMO Capital Markets Corp., BNP Paribas Securities Corp., CIBC World Markets Corp.,</del> Citigroup Global Markets <del>Inc.</del>  <ins>Inc., J.P. Morgan Securities LLC, TD Securities (USA) LLC</ins> and <del>SunTrust Robinson Humphrey,</del>  <ins>U.S. Bancorp Investments,</ins> Inc. are acting asrepresentatives (the \"Representatives\"), <del>$500,000,000</del>  <ins>$575,000,000</ins> principal amount of its <del>3.700%</del>  <ins>2.75%</ins> General and Refunding Mortgage Notes, Series <del>CC,</del>  <ins>BB,</ins> due <del>2029</del>  <ins>2020</ins> (the \"Offered Securities\") to be issued under that certain General and Refunding Mortgage Indenture, dated as of May 1, 2001 (the \"Original Indenture\"), between the Company and The Bank of New York Mellon Trust Company, N.A. (successor in trust to The Bank of New York Mellon, formerly The Bank of New York), as trustee (the \"Trustee\"), as amended and supplemented by various instruments including an officer's certificate, to be dated the Closing Date (as defined herein) (the \"Officer's Certificate\"), establishing the terms of the Offered Securities, such Original Indenture, as so amended and supplemented, being hereinafter called the \"Indenture.\" On September 30, 2016, the Company filed with the Securities and Exchange Commission (the \"Commission\") a registration statement on Form S-3 (File No. 333-213897) for the registration of securities, including the Offered Securities, under the United States Securities Act of 1933, as amended (the \"Securities Act\"), and the offer and sale thereof from time to time in accordance with Rule 415 of the rules and regulations of the Commission thereunder (the \"Rules and Regulations) and for the qualification of the Indenture under the United States Trust Indenture Act of 1939, as amended (the \"Trust Indenture Act\"). As used herein, the term \"Registration Statement\" means, as of any particular time, such registration statement, including (a) any amendments thereto at such time, (b) the exhibits and schedules thereto at such time (if any) and (c) any prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act that, in accordance with Rule 430B under the Securities Act, is deemed to be a part thereof.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/nevada-power-co-6883/contract/305394/#clause-id-653730"}]}
{"clause_number": "Clause 24", "title": "Introductory", "text": "Introductory. Analog Devices, Inc., a Massachusetts corporation (the \u201cCompany\u201d), agrees with the several Underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) for whom J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are acting as Representatives (the \u201cRepresentatives\u201d) to issue and sell to the several Underwriters $400,000,000 principal amount of its 2.950% Senior Notes due 2025 (the \u201cSecurities\u201d). The Securities shall be issued under an indenture, dated as of June 3, 2013 (the \u201cBase Indenture\u201d), as supplemented by a supplemental indenture (the \u201cSupplemental Indenture\u201d and, together with the Base Indenture, the \u201cIndenture\u201d) to be dated as of the Closing Date (as defined below) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the \u201cTrustee\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/analog-devices-inc-97/contract/102644/#clause-id-193271", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Analog Devices, Inc., a Massachusetts corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") for whom J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are acting as Representatives (the \"Representatives\") to issue and sell to the several Underwriters $400,000,000 principal amount of its 2.950% Senior Notes due 2025 (the \"Securities\"). The Securities shall be issued under an indenture, dated as of June 3, 2013 (the \"BaseIndenture\"), as supplemented by a supplemental indenture (the \"Supplemental Indenture\" and, together with the Base Indenture, the \"Indenture\") to be dated as of the Closing Date (as defined below) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/analog-devices-inc-97/contract/102644/#clause-id-193271"}, {"variation_number": "Variation 2", "text": "Introductory. Analog Devices, Inc., a Massachusetts corporation (the \"Company\"), agrees with the several Underwriters named in Schedule A hereto (the \"Underwriters\") for whom <del>J.P. Morgan</del>  <ins>SMBC Nikko</ins> Securities <del>LLC and Citigroup Global Markets</del>  <ins>America,</ins> Inc. <del>are</del>  <ins>is</ins> acting as <del>Representatives</del>  <ins>Representative</ins> (the <del>\"Representatives\")</del>  <ins>\"Representative\")</ins> to issue and sell to the several Underwriters <del>$400,000,000</del>  <ins>$300,000,000</ins> principal amount of its <del>2.950%</del>  <ins>4.250%</ins> Senior Notes due <del>2025</del>  <ins>October 1, 2032</ins> (the \"Securities\").The Securities shall be issued under an indenture, dated as of June 3, 2013 (the \"Base Indenture\"), as supplemented by a supplemental indenture (the \"Supplemental Indenture\" and, together with the Base Indenture, the \"Indenture\") to be dated as of the Closing Date (as defined below) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the \"Trustee\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/analog-devices-inc-97/contract/254096/#clause-id-536910"}]}
{"clause_number": "Clause 25", "title": "Introductory", "text": "Introductory. Ra Pharmaceuticals, Inc., a Delaware corporation (\u201cCompany\u201d), agrees with Jefferies LLC (\u201cJefferies\u201d), BMO Capital Markets Corp. (\u201cBMO\u201d) and Stifel, Nicolaus & Company, Incorporated (\u201cStifel\u201d) and the several Underwriters named in Schedule A hereto (collectively, the \u201cUnderwriters\u201d), for whom Jefferies, BMO and Stifel are acting as representatives (in such capacity, the \u201cRepresentatives\u201d), to issue and sell to the several Underwriters 4,000,000 shares (\u201cFirm Securities\u201d) of its common stock, parvalue $0.001 per share (\u201cSecurities\u201d), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 600,000 additional shares (\u201cOptional Securities\u201d) of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \u201cOffered Securities\u201d.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ra-pharmaceuticals-inc-3759/contract/72265/#clause-id-134000", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Ra Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with Jefferies LLC (\"Jefferies\"), BMO Capital Markets Corp. (\"BMO\") and Stifel, Nicolaus & Company, Incorporated (\"Stifel\") and the several Underwriters named in Schedule A hereto (collectively, the \"Underwriters\"), for whom Jefferies, BMO and Stifel are acting as representatives (in such capacity, the \"Representatives\"), to issue and sell to the several Underwriters 4,000,000 shares (\"Firm Securities\") of its common stock,par value $0.001 per share (\"Securities\"), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 600,000 additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ra-pharmaceuticals-inc-3759/contract/72265/#clause-id-134000"}, {"variation_number": "Variation 2", "text": "Introductory. Ra Pharmaceuticals, Inc., a Delaware corporation (\"Company\"), agrees with Jefferies LLC (\"Jefferies\"), BMO Capital Markets Corp. (\"BMO\") and Stifel, Nicolaus & Company, Incorporated (\"Stifel\") and the several Underwriters named in Schedule A hereto (collectively, the \"Underwriters\"), for whom Jefferies, BMO and Stifel are acting as representatives (in such capacity, the \"Representatives\"), to issue and sell to the several Underwriters <del>4,000,000</del>  <ins>8,387,097</ins> shares (\"Firm Securities\") of its commonstock, par value $0.001 per share (\"Securities\"), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <del>600,000</del>  <ins>1,258,064</ins> additional shares (\"Optional Securities\") of its Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\".", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ra-pharmaceuticals-inc-3759/contract/279601/#clause-id-586394"}]}
{"clause_number": "Clause 26", "title": "Introductory", "text": "Introductory. Wengen Alberta, Limited Partnership (the \u201cSelling Securityholder\u201d), a stockholder  of Laureate Education, Inc., a public benefit corporation organized under the laws of Delaware (the \u201cCompany\u201d), proposes to sell to the several Underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) for whom BMO Capital Markets Corp. is acting as representative (the \u201cRepresentative\u201d), 10,000,000 shares (the \u201cFirm Securities\u201d) of the Company\u2019s Class A common stock, par value $0.004 per share (the \u201cSecurities\u201d), and also proposes to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 1,500,000 additional shares (\u201cOptional Securities\u201d) of the Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \u201cOffered Securities\u201d. In the event that only one Underwriter is listed in Schedule A hereto, any references to the \u201cUnderwriters\u201d shall be deemed to refer to the sole Underwriter in the singular form listed in such Schedule A to this Underwriting Agreement (this \u201cAgreement\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/laureate-education-inc-7708/contract/68584/#clause-id-125953", "variations": [{"variation_number": "Variation 1", "text": "Introductory. Wengen Alberta, Limited Partnership (the \"Selling Securityholder\"), a stockholder of Laureate Education, Inc., a public benefit corporation organized under the laws of Delaware (the \"Company\"), proposes to sell to the several Underwriters named in Schedule A hereto (the \"Underwriters\") for whom BMO Capital Markets Corp. is acting as representative (the \"Representative\"), 10,000,000 shares (the \"Firm Securities\") of the Company's Class A common stock, par value $0.004 per share (the\"Securities\"), and also proposes to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 1,500,000 additional shares (\"Optional Securities\") of the Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". In the event that only one Underwriter is listed in Schedule A hereto, any references to the \"Underwriters\" shall be deemed to refer to the sole Underwriter in the singular form listed in such Schedule A to this Underwriting Agreement (this \"Agreement\").", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/laureate-education-inc-7708/contract/68584/#clause-id-125953"}, {"variation_number": "Variation 2", "text": "Introductory. Wengen Alberta, Limited Partnership (the \"Selling Securityholder\"), a stockholder of Laureate Education, Inc., a public benefit corporation organized under the laws of Delaware (the \"Company\"), proposes to sell to the several Underwriters named in Schedule A hereto (the \"Underwriters\") for whom <ins>Credit Suisse Securities (USA) LLC, Barclays Capital Inc. and</ins> BMO Capital Markets Corp. <del>is</del>  <ins>are</ins> acting as <del>representative</del>  <ins>representatives</ins> (the <del>\"Representative\"), 10,000,000</del>  <ins>\"Representatives\"), 12,250,000</ins>shares (the \"Firm Securities\") of the Company's Class A common stock, par value $0.004 per share (the \"Securities\"), and also proposes to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than <del>1,500,000</del>  <ins>1,837,500</ins> additional shares (\"Optional Securities\") of the Securities as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \"Offered Securities\". <del>In the event that only one Underwriter is listed in Schedule A hereto, any references to the \"Underwriters\" shall be deemed to refer to the sole Underwriter in the singular form listed in such Schedule A to this Underwriting Agreement (this \"Agreement\").</del>", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/laureate-education-inc-7708/contract/285175/#clause-id-599468"}]}
{"clause_number": "Clause 27", "title": "Introductory", "text": "Introductory. Brigham Minerals, Inc., a Delaware corporation (the \u201cCompany\u201d), agrees with Credit Suisse Securities (USA) LLC and Goldman Sachs & Co. LLC, as representatives (the \u201cRepresentatives\u201d) of the several underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d), to issue and sell to the Underwriters [ \u25cf ] shares of its Class A common stock, par value $0.01 per share (\u201cSecurities\u201d) (such [ \u25cf ] shares of Securities being hereinafter referred to as the \u201cFirm Securities\u201d). The Company also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than [ \u25cf ] additional shares of its Securities (the \u201cOptional Securities\u201d) as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \u201cOffered Securities.\u201d As part of the offering contemplated by this Agreement, UBS Securities LLC (the \u201cDesignated Underwriter\u201d) has agreed to reserve out of the Firm Securities purchased by it under this Agreement up to [ \u25cf ] shares for sale to the Company\u2019s directors, officers, employees and other parties associated with the Company (collectively, \u201cParticipants\u201d), as set forth in the Final Prospectus (as defined herein) under the heading \u201cUnderwriting\u201d (the \u201cDirected Share Program\u201d). The Firm Securities to be sold by UBS Financial Services Inc., a selected dealer affiliated with the Designated Underwriter, pursuant to the Directed Share Program (the \u201cDirected Shares\u201d) will be sold by UBS Financial Services Inc. pursuant to this Agreement at the public offering price. Any Directed Shares not subscribed for by the end of the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Final Prospectus. The Company is a Delaware corporation that was formed in contemplation of the proposed issuance and sale of the Offered Securities (the \u201cOffering\u201d). It is understood and agreed to by all parties that immediately prior to the initial closing of the Offering, the Company will enter into certain corporate reorganization transactions (the \u201cReorganization Transactions\u201d), pursuant to which the following transactions, among others, will occur (as further described under the headings \u201cCorporate Reorganization\u201d and \u201cUse of Proceeds\u201d in the General Disclosure Package (as defined below)):        (a)  Brigham Equity Holdings, LLC (\u201cBrigham Equity Holdings\u201d) will distribute all of its equity interests in Brigham Minerals Holdings, LLC (\u201cBrigham LLC\u201d), other than its interests in Brigham LLC attributable to certain unvested incentive units in Brigham Equity Holdings, to the Company, the Company\u2019s management team and other investors and certain entities affiliated with Warburg Pincus LLC, Yorktown Partners LLC and Pine Brook Road Advisors, LP (collectively, the \u201cExisting Owners\u201d) (which will result in the ownership in Brigham LLC of the Company\u2019s Existing Owners who hold unvested incentive units remaining consolidated in Brigham Equity Holdings);        (b)  all of the outstanding membership interests in Brigham LLC will be converted into a single class of common units in Brigham LLC (\u201cBrigham LLC Units\u201d);        (c)  the Company will issue and sell the Offered Securities to the Underwriters;        (d)  each holder of Brigham LLC Units following the restructuring (a \u201cBrigham Unit Holder\u201d) other than the Company and its Subsidiaries, will receive a number of shares of the Company\u2019s Class B common stock equal to the number of Brigham LLC Units held by such Brigham Unit Holder following the Offering; and        (e)  the Company will contribute the net proceeds of the Offering to Brigham LLC in exchange for an additional number of Brigham LLC Units such that the Company holds a total number of Brigham LLC Units equal to the number of shares of the Company\u2019s Class A common stock outstanding following the Offering.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/brigham-minerals-inc-6226/contract/54069/#clause-id-92101", "variations": []}
{"clause_number": "Clause 28", "title": "Introductory", "text": "Introductory. Aldeyra Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d) proposes to sell, pursuant to the terms of this Agreement, to the several Underwriters named in Schedule A hereto (the \u201cUnderwriters,\u201d or each, an \u201cUnderwriter\u201d), an aggregate of 2,222,222 shares of common stock, $0.001 par value (the \u201cCommon Stock\u201d) of the Company. The aggregate of 2,222,222 shares so proposed to be sold is hereinafter referred to as the \u201cFirm Stock\u201d. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional 333,333 shares of Common Stock (the \u201cOptional Stock\u201d). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \u201cStock\u201d.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/aldeyra-therapeutics-inc-2890/contract/324300/#clause-id-699203", "variations": []}
{"clause_number": "Clause 29", "title": "Introductory", "text": "Introductory. Aldeyra Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d) proposes to sell, pursuant to the terms of this Agreement, to the several Underwriters named in Schedule A hereto (the \u201cUnderwriters,\u201d or each, an \u201cUnderwriter\u201d), an aggregate of 2,222,222 shares of common stock, $0.001 par value (the \u201cCommon Stock\u201d) of the Company. The aggregate of 2,222,222 shares so proposed to be sold is hereinafter referred to as the \u201cFirm Stock\u201d. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional 333,333 shares of Common Stock (the \u201cOptional Stock\u201d). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the \u201cStock\u201d.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/aldeyra-therapeutics-inc-2890/contract/324300/#clause-id-699203", "variations": []}
{"clause_number": "Clause 30", "title": "Introductory", "text": "Introductory. American Tower Corporation, a Delaware corporation (the \u201cCompany\u201d), subject to the terms and conditions set forth herein, agrees with the several Underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) to issue and sell to the several Underwriters 5,250,000 shares of its 5.25% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the \u201cFirm Shares\u201d). The Company also proposes to issue and sell to the several Underwriters not more than an additional 750,000 shares of its5.25% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the \u201cAdditional Shares\u201d), if and to the extent that you, as Representatives, shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares granted to the Underwriters in Section 3 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the \u201cShares\u201d or the \u201cSecurities.\u201d The 5.25% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share, of the Company are hereinafter referred to as the \u201cPreferred Shares.\u201d The Preferred Shares will be convertible into a variable number of shares of common stock, par value $0.01 per share, of the Company. Such shares of common stock into which the Shares are convertible are hereinafter referred to as the \u201cConversion Shares\u201d and the shares of common stock, par value $0.01 per share, generally, of the Company are hereinafter referred to as \u201cCommon Stock.\u201d  The terms of the Preferred Shares will be set forth in a Certificate of Designations (the \u201cCertificate of Designations\u201d) to be filed by the Company with the Secretary of State of the State of Delaware.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/american-tower-corp-85/contract/400096/#clause-id-854622", "variations": []}
{"clause_number": "Clause 31", "title": "Introductory", "text": "Introductory. The Company agrees with the Manager to issue and sell from time to time through the Manager, as sales agent and/or principal, the shares of its common stock, $0.0001 par value (the \u201cCommon Stock\u201d), having an aggregate offering price of up to $97,168,693.51 (the \u201cShares\u201d) on the terms set forth herein.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/western-alliance-bancorporation-2457/contract/401517/#clause-id-858070", "variations": []}
{"clause_number": "Clause 32", "title": "Introductory", "text": "Introductory. Aon Corporation, a Delaware corporation (the \u201cCompany\u201d), agrees with the several Underwriters named in Exhibit A hereto (the \u201cUnderwriters\u201d) to issue and sell to the several Underwriters $1,000,000,000 principal amount of its 2.800% Senior Notes due 2030 (the \u201cNotes\u201d), to be issued under an indenture dated as of December 3, 2018 (the \u201cBase Indenture\u201d), as supplemented by the amended and restated indenture dated as of April 1, 2020 (the \u201cSupplemental Indenture\u201d) among the Company, the Guarantors(as defined below) and The Bank of New York Mellon Trust Company, N.A., as trustee (the \u201cTrustee\u201d), as further supplemented by an officers\u2019 certificate of the Company to be dated as of May 15, 2020 (together with the Base Indenture and the Supplemental Indenture, the \u201cIndenture\u201d). The Notes will be fully and unconditionally guaranteed as to the payment of principal and interest by Aon plc, a public limited company duly organized and existing under the laws of Ireland (\u201cAon plc\u201d), Aon plc, a public limited company duly organized and existing under the laws of England and Wales (\u201cAGL\u201d) and Aon Global Holdings plc, a public limited company duly organized and existing under the laws of England and Wales (\u201cAGH,\u201d and together with Aon plc and AGL, the \u201cGuarantors,\u201d and each, a \u201cGuarantor,\u201d and such guarantees, the \u201cGuarantees\u201d). \u201cAon plc\u201d refers to (i) for time periods prior to the completion of the Reorganization (as defined in the General Disclosure Package), AGL, and (ii) for time periods on or after the completion of the Reorganization, Aon plc, an Irish public limited company formerly known as Aon Limited. The Notes, together with the Guarantees, are referred to in this Agreement as the \u201cSecurities.\u201d  As part of the transactions described under the heading \u201cSummary\u2014Recent Developments\u2014Combination with Willis Towers Watson\u201d in the General Disclosure Package, AGL and Willis Towers Watson Public Limited Company (\u201cWTW\u201d) entered into a business combination agreement (the \u201cBusiness Combination Agreement\u201d) on March 9, 2020 with respect to a combination of the parties (the \u201cCombination\u201d). AGL and Aon plc entered into an     1             assignment agreement (the \u201cAssignment Agreement\u201d) on April 2, 2020 pursuant to which AGL assigned all of its rights and obligations under the Business Combination Agreement to Aon plc, and Aon plc assumed all such rights and obligations.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/aon-plc-105/contract/117911/#clause-id-219967", "variations": []}
{"clause_number": "Clause 33", "title": "Introductory", "text": "Introductory. Intellia Therapeutics, Inc., a Delaware corporation (\u201cCompany\u201d), agrees with Goldman Sachs & Co. LLC (\u201cGoldman Sachs\u201d), Jefferies LLC (\u201cJefferies\u201d) and SVB Leerink LLC (\u201cSVB Leerink\u201d) and the several Underwriters named in Schedule A hereto (collectively, the \u201cUnderwriters\u201d), for whom Goldman Sachs, Jefferies and SVB Leerink are acting as representatives (in such capacity, the \u201cRepresentatives\u201d), to issue and sell to the several Underwriters 4,794,521 shares (the \u201cFirm Securities\u201d) of its commonstock, par value $0.0001 per share (the \u201cSecurities\u201d), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, not more than 719,178 additional Securities (such 719,178 additional shares of the Securities, the \u201cOptional Securities\u201d), as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \u201cOffered Securities\u201d.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/intellia-therapeutics-inc-5324/contract/141042/#clause-id-275900", "variations": []}
{"clause_number": "Clause 34", "title": "Introductory", "text": "Introductory. The Company proposes to issue and sell from time to time its Unsecured Debt Securities (\u201cNotes\u201d) registered under the registration statement referred to in Section 2(a). The Notes will be issued under an Indenture, dated as of February 1, 2003, between the Company and The Bank of New York Mellon Trust Company, N.A., as successor to JPMorgan Chase Bank, as Trustee, as may be supplemented from time to time, (the \u201cIndenture\u201d). The Notes will be sold to the Purchasers (as defined below) for resale in accordance with the terms of the offering determined at the time of the sale. The Notes involved in any such offering are hereinafter referred to as the \u201cPurchased Notes,\u201d and the firm or firms, as the case may be, which agree to purchase the same are hereinafter referred to as the \u201cPurchasers\u201d of such Purchased Notes. The terms \u201cyou\u201d and \u201cyour\u201d refer to those Purchasers who sign the Purchase Agreement either on behalf of themselves only or on behalf of themselves and as representatives of the several Purchasers named in Schedule A thereto, as the case may be.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/boeing-191/contract/151329/#clause-id-305933", "variations": []}
{"clause_number": "Clause 35", "title": "Introductory", "text": "Introductory. Global Payments Inc., a Georgia corporation (the \u201cCompany\u201d), agrees with BofA Securities, Inc. and J.P. Morgan Securities LLC (together, the \u201cRepresentatives\u201d) and each of the several Underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) to issue and sell to the several Underwriters $1,100,000,000 principal amount of its 1.200% Senior Notes due 2026 (the \u201cOffered Securities\u201d) to be issued under the indenture, dated as of August 14, 2019 (the \u201cBase Indenture\u201d), as supplemented by a third supplemental indenture thereto, to be dated as of February 26, 2021 (the \u201cSupplemental Indenture\u201d and, together with the Base Indenture, the \u201cIndenture\u201d), in each case between the Company and U.S. Bank National Association, as Trustee (the \u201cTrustee\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/global-payments-inc-585/contract/156184/#clause-id-317461", "variations": []}
{"clause_number": "Clause 36", "title": "Introductory", "text": "Introductory. Ramaco Resources, Inc., a Delaware corporation (\u201cCompany\u201d) proposes to issue and sell to the several underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d), for whom B. Riley Securities, Inc. is acting as representative (the \u201cRepresentative\u201d), $30,000,000 aggregate principal amount of its 9.00% Senior Notes due 2026 (the \u201cFirm Securities\u201d), to be issued pursuant to the provisions of an Indenture to be dated as of the Closing Date (the \u201cBase Indenture\u201d) between the Company and Wilmington Savings Fund Society, FSB, as trustee (the \u201cTrustee\u201d), as supplemented by a First Supplemental Indenture to be dated as of the Closing Date between the Company and the Trustee (the \u201cFirst Supplemental Indenture\u201d and, together with the Base Indenture, the \u201cIndenture\u201d). The Company also proposes to issue and sell to the several Underwriters not more than an additional $4,500,000 aggregate principal amount of its 9.00% Senior Notes due 2026 (the \u201cOptional Securities\u201d), if and to the extent that the Representative shall have elected to exercise, on behalf of the Underwriters, the right to purchase Optional Securities pursuant to the option granted to the Underwriters in Section 3 hereof. The Firm Securities and the Optional Securities are hereinafter collectively referred to as the \u201cSecurities.\u201d     This Underwriting Agreement (this \u201cAgreement\u201d) confirms the agreement among the Company and the Underwriters concerning the purchase of the Securities by the Underwriters.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/ramaco-resources-inc-5670/contract/187489/#clause-id-391872", "variations": []}
{"clause_number": "Clause 37", "title": "Introductory", "text": "Introductory. Kosmos Energy Ltd., a Delaware corporation (the \u201cCompany\u201d) proposes to issue and sell to the several underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d), 37,500,000 common shares (the \u201cFirm Securities\u201d) of the Company\u2019s common stock, par value $0.01 per share (the \u201cSecurities\u201d), and also agrees to issue and sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than 5,625,000 additional common shares (\u201cOptional Securities\u201d) of the Company\u2019s Securities, asset forth below. The Firm Securities and the Optional Securities are herein collectively called the \u201cOffered Securities.\u201d In the event only one underwriter is listed in Schedule A hereto, any references in this Agreement to the \u201cUnderwriters\u201d shall be deemed to refer to the sole underwriter in the singular form listed in such Schedule A. Barclays Capital Inc. is acting as the representative (the \u201cRepresentative\u201d) of the Underwriters.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/kosmos-energy-ltd-3975/contract/203626/#clause-id-431572", "variations": []}
{"clause_number": "Clause 38", "title": "Introductory", "text": "Introductory. The Stockholders listed in Schedule A hereto (the \u201cSelling Stockholders\u201d), agree, subject to the terms and conditions stated herein, to sell an aggregate of 34,176,574 outstanding shares (such 34,176,574 outstanding shares being hereinafter referred to as the \u201cOffered Securities\u201d) of the common stock, par value $0.01 per share (the \u201cSecurities\u201d or \u201cCommon Stock\u201d) of The Mosaic Company, a Delaware corporation (the \u201cCompany\u201d), registered under the registration statement referred to in Section 2(a)(i) (the \u201cRegistered Securities\u201d), to you (the \u201cUnderwriter\u201d), in connection with the offering (the \u201cOffering\u201d) and sale of such Offered Securities, as set forth below. Subject to the sale of the Offered Securities by the Selling Stockholders to the Underwriter in compliance with the terms of this Agreement, the Underwriter has agreed to sell to the Company, and the Company has agreed herein to purchase from the Underwriter (the \u201cShare Repurchase\u201d), an aggregate of 8,544,144 shares of the Offered Securities (such 8,544,144 shares being hereinafter referred to as the \u201cRepurchase Shares\u201d) pursuant to Section 3 of this Agreement.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/the-mosaic-company-1297/contract/207809/#clause-id-442363", "variations": []}
{"clause_number": "Clause 39", "title": "Introductory", "text": "Introductory. Global Payments Inc., a Georgia corporation (the \u201cCompany\u201d), agrees with BofA Securities, Inc. and J.P. Morgan Securities LLC (collectively, the \u201cRepresentatives\u201d) and each of the several Underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) to issue and sell to the several Underwriters $500,000,000 principal amount of its 4.950% Senior Notes due 2027 (the \u201c2027 Notes\u201d), $500,000,000 principal amount of its 5.300% Senior Notes due 2029 (the \u201c2029 Notes\u201d), $750,000,000 principal amount ofits 5.400% Senior Notes due 2032 (the \u201c2032 Notes\u201d) and $750,000,000 principal amount of its 5.950% Senior Notes due 2052 (the \u201c2052 Notes\u201d and, together with the 2027 Notes, the 2029 Notes and the 2032 Notes, the \u201cOffered Securities\u201d) to be issued under the indenture, dated as of August 14, 2019 (the \u201cBase Indenture\u201d), as supplemented by a fifth supplemental indenture thereto, to be dated as of August 22, 2022 (the \u201cSupplemental Indenture\u201d and, together with the Base Indenture, the \u201cIndenture\u201d), in each case between the Company and U.S. Bank Trust Company, National Association (in the case of the Base Indenture, as successor to U.S. Bank National Association), as Trustee (the \u201cTrustee\u201d). The offering of the Offered Securities is being made in connection with the proposed merger of Falcon Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (\u201cFalcon Merger Sub\u201d) with and into EVO Payments, Inc., a Delaware corporation (\u201cEVO Payments\u201d), pursuant to an Agreement and Plan of Merger, dated as of August 1, 2022, by and among the Company, EVO Payments and Falcon Merger Sub (as amended, modified or supplemented in accordance with the terms thereof, the \u201cMerger Agreement\u201d). The term \u201cTransaction\u201d as used herein shall refer to the transactions contemplated by the Merger Agreement.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/global-payments-inc-585/contract/249999/#clause-id-528136", "variations": []}
{"clause_number": "Clause 40", "title": "Introductory", "text": "Introductory. Global Payments Inc., a Georgia corporation (the \u201cCompany\u201d), agrees with Merrill Lynch International, J.P. Morgan Securities plc and Barclays Bank PLC (collectively, the \u201cRepresentatives\u201d) and each of the several Underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) to issue and sell to the several Underwriters \u20ac800,000,000 principal amount of its 4.875% Senior Notes due 2031 (the \u201cOffered Securities\u201d) to be issued under the indenture, dated as of August 14, 2019 (the \u201cBase Indenture\u201d), between the Company and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as Trustee (the \u201cTrustee\u201d), as supplemented by a sixth supplemental indenture thereto, to be dated as of March 17, 2023 (the \u201cSupplemental Indenture\u201d and, together with the Base Indenture, the \u201cIndenture\u201d), among the Company, the Trustee, U.S. Bank Trust Company, National Association, as registrar and transfer agent (the \u201cTransfer Agent\u201d), and Elavon Financial Services DAC, UK Branch, as paying agent (the \u201cPaying Agent\u201d). The Offered Securities will be issued in book-entry form and registered in the name of a common depository or its nominee on behalf of Clearstream Banking, S.A., (\u201cClearstream\u201d) and Euroclear Bank SA/NV, as operator of the Euroclear System (\u201cEuroclear\u201d).", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/global-payments-inc-585/contract/273484/#clause-id-574144", "variations": []}
{"clause_number": "Clause 41", "title": "Introductory", "text": "Introductory. Riley Exploration-Permian, LLC, a Delaware limited liability company and following the Corporate Conversion (as defined below), a Delaware corporation (the \u201cCompany\u201d), agrees with SunTrust Robinson Humphrey, Inc. (\u201cSunTrust\u201d) and Seaport Global Securities LLC (\u201cSeaport Global\u201d and, collectively with SunTrust, the \u201cRepresentatives\u201d), as representatives of the several Underwriters named in Schedule A hereto (\u201cUnderwriters\u201d), following the completion of the Corporation Conversion to issue and sellto the several Underwriters [\u2022] shares of its common stock, par value $0.01 per share (the \u201cCommon Stock\u201d) (such [\u2022] shares of Common Stock being hereinafter referred to as the \u201cFirm Securities\u201d). The Company also agrees to sell to the Underwriters, at the option of the Underwriters, an aggregate of not more than [\u2022] additional shares of its Common Stock (the \u201cOptional Securities\u201d) as set forth below. The Firm Securities and the Optional Securities are herein collectively called the \u201cOffered Securities.\u201d  The Company hereby confirms its engagement of Seaport Global as, and Seaport Global hereby confirms its agreement with the Company to render services as, the \u201cqualified independent underwriter\u201d within the meaning of Rule 5121(f)(12) of the Financial Industry Regulatory Authority, Inc. (\u201cFINRA\u201d) with respect to the offering and sale of the Offered Securities. Seaport Global, solely in its capacity as the qualified independent underwriter and not otherwise, is referred to herein as the \u201cQIU.\u201d  It is understood and agreed to by all parties that prior to the delivery of the Firm Securities, Riley Exploration-Permian, LLC, a Delaware limited liability company (\u201cREP LLC\u201d), will effect a corporate conversion (the \u201cCorporate Conversion\u201d), pursuant to which the following actions, among others more fully set forth in the Registration Statement, the General Disclosure Package and the Final Prospectus (each as defined below) under the heading \u201cCorporate Conversion\u201d, will be effected in accordance with Delaware law:     1             (a) REP LLC will convert from a Delaware limited liability company into a Delaware corporation; and  (b) The holders of common units and Series A Preferred Units of REP LLC will receive an aggregate of [\u2022] shares of Common Stock based on the relative levels of ownership in REP LLC.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/riley-exploration-permian-llc-8508/contract/282080/#clause-id-592624", "variations": []}
{"clause_number": "Clause 42", "title": "Introductory", "text": "Introductory. Chesapeake Energy Corporation, an Oklahoma corporation (the \u201cCompany\u201d), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) $850,000,000 principal amount of its 7.00% Senior Notes due 2024 (the \u201c2024 Notes\u201d) and $400,000,000 principal amount of its 7.50% Senior Notes due 2026 (the \u201c2026 Notes\u201d and, together with the 2024 Notes, the \u201cOffered Securities\u201d). The Offered Securities will be unconditionally guaranteed on a senior unsecured basis (the \u201cGuarantees\u201d) by each subsidiary of the Company named in Schedule B hereto (collectively, the \u201cSubsidiary Guarantors\u201d), and subject to certain exceptions, by subsequently acquired domestic subsidiaries of the Company in accordance with the terms of the Indentures (as defined below). The 2024 Notes are to be issued under an indenture dated as of April 24, 2014 (the \u201cBase Indenture\u201d), among the Company, the Subsidiary Guarantors and Deutsche Bank Trust Company Americas, a New York banking corporation, as trustee (the \u201cTrustee\u201d), as previously supplemented and as supplemented by the eighth supplemental indenture, dated September 27, 2018, among the Company, the Subsidiary Guarantors and the Trustee (the \u201cEighth Supplemental Indenture\u201d and, together with the Base Indenture, the \u201c2024 Notes Indenture\u201d). The 2026 Notes are to be issued under the Base Indenture, as previously supplemented and as supplemented by the ninth supplemental indenture, dated September 27, 2018, among the Company, the Subsidiary Guarantors and the Trustee (the \u201cNinth Supplemental Indenture\u201d and, together with the Base Indenture, the \u201c2026 Notes Indenture\u201d). The Eighth Supplemental Indenture and the Ninth Supplemental Indenture are collectively referred to herein as the \u201cSupplemental Indentures.\u201d The 2024 Notes Indenture and the 2026 Notes Indenture are collectively referred to herein as the \u201cIndentures.\u201d References to the \u201cOffered Securities\u201d shall include the Guarantees, unless the context otherwise requires.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/chesapeake-energy-278/contract/294810/#clause-id-625072", "variations": []}
{"clause_number": "Clause 43", "title": "Introductory", "text": "Introductory. Taylor Morrison Home Corporation, a Delaware corporation (the \u201cCompany\u201d), agrees with the several underwriters named in Schedule A hereto (the \u201cUnderwriters\u201d) to issue and sell to the several Underwriters 17,706,924 shares of its Class A common stock, par value $0.00001 per share (the \u201cSecurities\u201d), and each of the stockholders listed in Schedule A hereto (each, a \u201cSelling Stockholder\u201d), severally and not jointly, agrees with the Underwriters to sell to the Underwriters the number of Securitiesset forth opposite its name on Schedule A hereto. The 17,706,924 shares of Securities to be sold by the Company and the 1,499,732 shares to be sold by the Selling Stockholders in the aggregate are hereinafter referred to collectively as the \u201cOffered Securities\u201d.", "found_in": "https://contracts.justia.comhttps://contracts.justia.com/companies/taylor-morrison-home-corp-4357/contract/313563/#clause-id-674352", "variations": []}
